<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ncit="http://purl.bioontology.org/ontology/NCIT#"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:linkedspls:uuid:990A861C-8128-4BEB-B3B9-1F189E42FDD0">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD62DBE9-A22C-4E69-889F-CBABF0174ADF">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34070-3 CONTRAINDICATIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34070-3 CONTRAINDICATIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905">
    <ao:body rdf:resource="urn:linkedspls:uuid:FDB20A03-F525-4339-8EEA-2CFD60F6E2CD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:FFDCD61D-7861-4B4F-AE17-4A15CD51BFA2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C553B1B6-192B-4B2C-A32D-72E7FBC6CC65"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-31 13:47:03 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-22 22:00:21 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:07CDF067-72A2-4DA6-AFEB-7D7F2DCB57DD</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:58EFF7E3-78B6-4587-A089-7F58793F2EBF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E3D25B8-C473-4C01-A52F-0E6E3FDDBEFD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B103237F-F633-4CA4-934C-2488AC33F8BF">
    <pav:lastSavedOn>2014-03-31 10:22:07 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C9688E86-8AE0-488E-BCCE-5552AF549D79"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0238086F-B61A-4EA7-8488-FCC3838FDB57"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:67CFB9CB-FD5B-4134-A50F-35E212088286"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-31 10:20:28 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4FE06C9D-AEEF-4C99-9805-AA0671345438"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:442430E7-389A-467E-BBB9-C440249A2205"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2C281AE-12B5-4CA9-8DEC-B53BBBA62366"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:764C28A6-ECBD-4FA5-A5A4-E81D3E2E88F3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hormone receptor positive breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2541641-9CF3-49C1-8121-194DE9983852">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>INDICATIONS AND USAGE (34067-9)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF1F10F0-D061-4FDE-925A-1B1B7243A890"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D07A471E-9AE7-4A93-BF39-B8A753C23859"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:33C9F7CE-B041-40EE-8E53-5C94B51B626C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:289239D5-3976-472F-9914-D5F5369EE441"/>
    <pav:createdOn>2014-03-31 09:05:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:78A1719D-0994-4541-ACAD-575FC841174F"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N77e4a82d60a742d2bc48f601890e4006">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05B32788-CE44-4C1C-974B-C8CF01591D5B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:05B32788-CE44-4C1C-974B-C8CF01591D5B"/>
    <pav:createdOn>2014-08-08 10:53:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <ao:exact>Elitek is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD) </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>[</ao:suffix>
    <domeo:uuid>05B32788-CE44-4C1C-974B-C8CF01591D5B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:867F97C5-1697-4CDE-BDAD-6B1188AE8969">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>This is referring mainly to the poor metabolizers. </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25AF9BA3-192F-4D8A-A295-8A7742CC5E06">
    <ao:body rdf:resource="urn:linkedspls:uuid:80E8B364-3435-40AE-9C30-BAB9083AC4D1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF3E7D6E-9DB0-4936-A18A-707ABCA6A729"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:C9B38BF8-70CA-43C9-A5FB-6920866EF383</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:24E6F1B0-21A6-49CB-814E-700D437D14D5"/>
    <pav:lastSavedOn>2014-03-22 18:13:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-13 04:36:02 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:60FBB145-D76F-422C-A632-269FA8998274"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F86084C3-9B07-43EE-A3DA-7A9BE7729213"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8195F57-B3E9-4619-9637-6684DBB32A9D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B73E5996-7642-4482-8767-64D56ECCF0D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC5E8713-E77E-4C1D-8205-DC59E3CD350E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E296F083-C6F9-4F83-B284-2E730777F02A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FEBA183F-845F-4961-A518-20B74CE0EDBC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B3C45053-B687-47A2-BC3B-6F24989DCD68">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9718231-5945-4B15-8C90-921DFE7E3D2C">
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A99DF291-EDBE-490B-A5F9-A395B25AB97A">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A99DF291-EDBE-490B-A5F9-A395B25AB97A"/>
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 00:35:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884">
    <ao:body rdf:resource="urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0D15111-C445-4596-9C63-C7EFADEB3394"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1694EBD6-F324-4F34-BF46-96811165F624"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17885E5A-0B08-4791-8E05-BD3606CC3AC3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:B44F6619-C144-4D12-B575-BA96FED0BC7B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-31 08:56:07 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 08:55:42 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:0C36300D-CA3C-4C26-A406-FC14CBBC2C74</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B8DF96B-B8D5-4EA2-8036-D03F02D2355B">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Not change from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-change-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not change the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02D03D00-AEEC-46B6-AF1B-5AA944239EE8">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F334D04-6941-417C-B265-6F322B84AC4F"/>
    <pav:createdOn>2014-04-05 13:56:32 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7366AAD5-7FCB-4D72-ACF8-B89D3B6AE6C1"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0CAA75D7-86F5-492D-9E3A-3E78584F7E23"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:01C60978-F3B0-4FCC-BFAB-4F864F65BA1C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8748274-7D24-4473-B677-A9A28F6D0729"/>
    <pav:lastSavedOn>2014-04-05 13:58:15 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0F4243FF-5048-4CF6-AFD9-11E2927F8F35"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:46E035B8-694E-40F2-A898-AB35D9E3D133</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBD22003-AD39-40DD-BE43-01FE6829A766"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:567C8304-7D83-4028-A1EC-AD9CBC5837C6">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-31 10:17:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C72D52E4-CD52-4DA5-9075-5F3A2EB7EC43"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:824B39AF-8D7F-4835-8566-F79A3F9C9DE0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE818BD4-E67C-4DBE-AEFE-82E4DD9E8B72"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:40B0A610-0D8B-487F-86C2-E891204D2184"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C10D838B-FD6A-4CB1-883A-8996C7D76046"/>
    <pav:lastSavedOn>2014-03-31 10:32:19 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:7C4B08E7-37E7-4BCB-A01D-FD7A79D934F5</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8C4ACC7-F6BD-4859-8787-7CA75B06C6B2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB6588D5-7195-482D-9D3D-5256CD1966F9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23EEEBBF-C789-4C60-A3B7-7E63732C1737">
    <pav:lineageUri>urn:domeoserver:annotation:7707750B-0FB9-4270-B073-56E803B5E65A</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:58308C5D-40B5-427A-AB8A-BA9B5B593ADB"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E631115D-5EAA-48D8-9AA3-A5F848BFD320"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:FAD2B35D-163E-419F-B2EA-3B98760DD126"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:96435AEC-7FC7-476B-8A38-A7462924508D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 00:35:11 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-31 00:34:50 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4AD4A6EB-985E-43C3-B39D-C2559410F086">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6408597-CB34-4462-B95D-5D3D7A2E00A3">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A73443EF-AA27-4534-A1A3-5EBEBDDDBFD7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:00B21812-A2F4-4DA0-B631-58EB798B6736"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C6ABE00-FAF3-4419-9BE0-CAFA7814B5C5"/>
    <pav:createdOn>2014-04-05 14:09:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C054AAE3-244B-4BE9-A823-466261F60423"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:3E7A89DE-4A49-4E5F-B1A5-C75D53FC14B3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3B92B9C-A1A9-48FE-AA37-A3DD6C06A609"/>
    <pav:lastSavedOn>2014-04-05 14:10:52 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DD15EA9-B9D8-497C-8F97-E7FFF0811BAF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC78FED1-9541-40D7-9769-79F974601806"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf791d9cb7d6348edbe26566d20d50c3c">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0">
    <ao:item rdf:resource="urn:domeoclient:uuid:9B6F3BBC-569B-4633-9956-6F42CEF42220"/>
    <pav:createdOn>2014-03-31 10:39:21 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:F3436ED7-F7CF-45B7-9755-008516311321"/>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AF4E0B6-E499-4258-8F27-FFBEF094F5D3"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:854DE4A1-DDC3-4A8E-B9BB-C7899206059F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29724E2D-1960-46FF-A0D8-F4983E7F4E75"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:3A8591CA-D976-4B39-BFF2-09E3872A65D9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4975EC23-CABC-4051-A0E9-C5B3FE1A0319"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95BF3221-3F94-441E-A477-FCEC2922FC24"/>
    <permissions:permissions rdf:nodeID="N0b288018d9624e598a5b7ab1ec79a182"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:38442337-288D-430D-AD0F-7D300206DE9E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:31DF67F9-071F-4029-B491-F2841EE2F707</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:3E30D4DE-0690-47CB-B227-CB6A0E9E7884"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA351472-1E09-47EF-873E-9BCDB949E496"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A8CB347A-DFD7-4A70-9132-54F898E94499"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:CC9F76F2-13E3-404A-8FB0-43E6EB01859D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C6C19597-2007-4097-B1F3-B2867D90E1ED"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E95F4032-CCE7-4649-A5BB-0E058C007B7C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4FA1E3B7-1CD1-435B-A9A9-FC269FF687AD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6316E18D-ABAA-4576-91B3-A14B067A8270"/>
    <pav:lastSavedOn>2014-03-31 11:41:19 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0EB58C72-3B7A-4423-88E9-715A8CECBC5D">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>G6PD</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1705AEDD-338D-427A-B93B-E5D62C6DB783">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <rdfs:label>Capecitabine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F67E2A6-A5CE-463D-A4E6-93AC42F1736B">
    <ao:exact>Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem.</ao:exact>
    <domeo:uuid>1F67E2A6-A5CE-463D-A4E6-93AC42F1736B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1F67E2A6-A5CE-463D-A4E6-93AC42F1736B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
    <pav:createdOn>2014-08-07 12:53:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In most patients maintained at a steady dosage, stable phenytoin serum levels are achieved. There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. </ao:prefix>
    <ao:suffix> Serum level determinations in such patients may be particularly helpful. As phenytoin is highly protein bound, free phenytoin levels may be altered in patients whose protein binding characteristics differ from normal</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF7ABF92-A568-4686-A511-8B19B0CB3AA4">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>acute coronary syndrome, percutaneous coronary intervention, cardiovascular event</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:919EA28E-CFD3-492A-8EE1-15C3067234A9">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F622CAE4-2C4A-4D35-AAE4-52D0FE00BB7A">
    <ao:exact>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit. In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F622CAE4-2C4A-4D35-AAE4-52D0FE00BB7A"/>
    <pav:createdOn>2014-04-05 15:30:19 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>F622CAE4-2C4A-4D35-AAE4-52D0FE00BB7A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>o adjuvant cytotoxic chemotherapy. In the Hubay study, tamoxifen was added to "low-dose" CMF (cyclophosphamide, methotrexate and fluorouracil). In the NSABP B-09 study, tamoxifen was added to melphalan [L-phenylalanine mustard (P)] and fluorouracil (F). </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A17A0520-0313-4484-8803-C9CA03B20B66">
    <ao:body rdf:resource="urn:linkedspls:uuid:1BF29CC9-C608-41B8-85E6-E2C684B0291C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2F2E1BD-DA94-455B-BCE8-504DDB9CCA35"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:669DBA0A-4127-47BB-9C45-9ADE5D3D48B5</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C96F5648-835D-48CE-B56B-D4B6189369D6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:55A9B321-4223-4FD6-A69B-8327A371FA1B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:79B2D094-0174-4838-92F0-966F2EAA6D21"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7135E5E-E2CC-4140-A69B-D6B978F182AD"/>
    <pav:lastSavedOn>2014-04-05 14:20:22 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-04-05 14:20:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F118E273-8979-4E21-9C19-2D9CFB1C0544">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>PATIENT MEDICATION INFORMATION (68498-5)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E731B81-5145-481F-8919-6A4EB66A7944">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2509D9DB-E2C5-42DE-AB65-03DCA3B7F3A1">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Refers to phenotyping. </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3436ED7-F7CF-45B7-9755-008516311321">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-31 10:41:02 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F7E0329-6BF9-4DD0-BC88-17C784954201"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6B089D9-574C-4C1C-A1B5-BDA08930B93C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:417A9CCF-F2A9-4ADF-8677-F5EBEA736745"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C0BC57D-CDF7-4B42-8F21-2A137AB07CE8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5E6BD54-CF9B-4C23-8FE8-040EA433AD90"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-31 10:43:21 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A118BD1B-6912-410D-8C56-28BAFDA74348"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:3C573B81-5D57-4755-8DAA-D1B21F97D486"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:837BB449-7B9C-4EA8-B13B-7EC05038D2E8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:05D0DCC4-6CFC-4B68-8371-508F96CC8EDF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:903A0C27-C16B-4458-884A-B7E17AC3498A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F1E0882B-40CA-45B0-8F3E-82475F71D568"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:38868500-428B-458D-9CEF-72F83B82EBAE"/>
    <pav:lastSavedOn>2014-04-05 16:02:51 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:45E07643-7CD1-4A77-8272-0241073F3336"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CD0E29D3-9614-4BF4-9ABA-4FA3F22E65AE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:200827ED-2E77-4C34-9CA9-A49627058B17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7EFE6C13-B696-4DA7-864B-D7641D424489"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-05 16:02:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D650174-CEF0-4E26-9480-84F302FF2D61"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5DE78EC2-5AE5-409E-A320-89BD6ED38772">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB97D9B3-7A2F-4BFB-841A-A9C180014EB0">
    <ao:body rdf:resource="urn:linkedspls:uuid:F2A7C468-3183-43C3-96A6-6F03CDA190EF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A2389CB-84FE-4A5C-98A0-3CEBA6E43DD7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8916D51C-B943-4982-88DC-F1B51F15BF9F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:06218F34-0177-4307-871A-29DDF8734A8C"/>
    <pav:lastSavedOn>2014-03-22 18:13:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:77C7B611-630A-4543-B977-C4F2EC5FF802</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-22 17:57:38 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:277A1FAA-CC1D-4B3E-85F9-8CCD51FC4929"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AEB2D80E-0E42-4F9D-8785-5C4D5A7639B9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:31F8C49E-11C4-4EBB-BF7A-4DB3A797CA1C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:39C15605-1B1F-4541-A2EF-CCDCFEB8DAB2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E768CCE6-FC0D-40B7-8C2E-A1397C4AE4DF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E768CCE6-FC0D-40B7-8C2E-A1397C4AE4DF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem.</ao:exact>
    <pav:createdOn>2014-08-07 12:55:30 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>E768CCE6-FC0D-40B7-8C2E-A1397C4AE4DF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
    <ao:prefix>Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59C5BF0A-B7D4-496A-B1E8-5A69855D28A1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:59C5BF0A-B7D4-496A-B1E8-5A69855D28A1"/>
    <pav:createdOn>2014-03-13 04:45:15 -0400</pav:createdOn>
    <ao:suffix> The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74962CD8-D19C-4A78-B5AD-7A5CA121D1F9">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7A6311E-21FF-456C-8779-7B193EA474EB">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2193F701-8874-4CBA-A7BF-09B4705DA7F1">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0BA76ECD-D180-4876-B9F7-9B8ED54B5682">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Required</rdfs:label>
    <dct:description>A required test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6D7C8C2-85A5-48C6-B3B4-C93C05C0ED36">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:471BC08B-331A-4DED-B600-1BC41F78F8E4">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:854DE4A1-DDC3-4A8E-B9BB-C7899206059F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9797BC9F-5D2E-4AB0-BB8D-96165595E525"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99D3FF5C-D7DF-4E2A-AE41-D86E28EFC2CC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9078D6CE-D692-4144-8366-17E60EAD0973"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:033D1863-DEEF-4F8F-8743-867CCE695424"/>
    <pav:createdOn>2014-03-31 11:25:15 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D109A2D9-1ABF-4256-9C5D-787737939A04"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:44CE23FF-1ACB-4636-9199-BC74D538CC29"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E1DE9EEC-D7E9-43DD-9614-254A64DA4566"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:40F50FDF-8AC1-45FB-8B05-1797ACB0DD04</pav:previousVersion>
    <pav:lastSavedOn>2014-03-31 11:30:46 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AFBD0952-D063-43AB-9BF8-D2765EC1F590">
    <ao:body rdf:resource="urn:linkedspls:uuid:7B9C0CF5-77BE-4351-8F4A-A03C7B56C33F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C784F374-FD0D-4D58-A395-967BCF50D373"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 00:34:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD0D46AB-DE27-42C2-ACF0-73D745788024"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6FF595AE-67B8-49FC-9B25-8FB5728E46BE</pav:previousVersion>
    <pav:createdOn>2014-03-31 00:33:55 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:42A10237-EFE8-4EC6-A4A2-556FF94B3F74"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C854F0D-6C24-4594-B749-D5DBEC2C1EE6">
    <ao:body rdf:resource="urn:linkedspls:uuid:0BA76ECD-D180-4876-B9F7-9B8ED54B5682"/>
    <pav:lastSavedOn>2014-08-08 10:53:45 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D089E01-D758-4E13-A627-9C4F5DC55FE6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D9E1DEE9-99F7-4AF0-952F-E05CF5631AE7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DFED23E1-3FD2-484D-B555-5C9BBB724598</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6C5C6C1-0C96-4407-B7F9-14A2EEF7C651"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E07FEF43-5464-4340-AB17-7DCF9775948D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D5393BF6-CC07-48B0-A45C-CC5746C469C6"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7767F592-8B22-47F6-873F-71CA967AFCFD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:81C35574-1F32-44B8-9423-70E510084484"/>
    <pav:createdOn>2014-08-08 10:50:01 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0EB58C72-3B7A-4423-88E9-715A8CECBC5D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FAD2B35D-163E-419F-B2EA-3B98760DD126">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Use specific</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827">
    <pav:createdOn>2014-04-14 14:04:16 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:55819029-EACE-49D3-9A09-5DA751DA0CDE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B9C6119C-3C0F-46B0-8614-1EBBBA8066D4"/>
    <pav:lineageUri>urn:domeoserver:annotation:801BC1FA-BBDA-4DB4-8D6A-73A41CF0C375</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F211EFB-8429-4BE7-8E97-2DC2313E9DBE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBA969DE-1978-4391-A338-E793E7F5F06C"/>
    <pav:lastSavedOn>2014-04-14 14:04:17 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7CB636F-0374-4648-9C14-E151AB0B6507"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:34FE8B53-03E6-4D06-9371-F1EA1CC5BEDD"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC">
    <ao:body rdf:resource="urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:291E17EF-EB0A-419A-9930-D6B0402634E2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84C9C2FD-017F-43C7-AD66-35BE4F24C7CC"/>
    <pav:previousVersion>urn:domeoserver:annotationset:04BA939A-F825-4DE6-B7F6-06D7E2C0A463</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lastSavedOn>2014-03-22 22:16:17 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0FDB6D8-3B29-4169-B943-7B9136C0BE5F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-22 22:15:46 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E69519CE-CDB4-4ADE-9142-E9FF4BAFBE3D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A1A1D97-0135-4D02-BE6F-5AC67E8421A7">
    <poc:MedicalCondition>known genotype</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD0EFE44-41B0-4C06-A553-537E290EA14B">
    <ao:prefix>Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD0EFE44-41B0-4C06-A553-537E290EA14B"/>
    <pav:createdOn>2014-08-07 12:55:21 -0400</pav:createdOn>
    <domeo:uuid>BD0EFE44-41B0-4C06-A553-537E290EA14B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:152C73E3-8FA1-4DCE-8BE9-A110F7ED502C">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>SJS, TEN, Patients taking carbamazapine</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01AED084-BA2D-45B8-8FDF-A1437A67CAFA">
    <pav:lastSavedOn>2014-08-08 10:53:45 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:201D0C85-E7FA-4932-A922-C6E54F934CD9"/>
    <pav:createdOn>2014-08-08 10:52:11 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CA6DAA60-CEEE-483A-94BD-35641DCBE220"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E731B81-5145-481F-8919-6A4EB66A7944"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:E07FEF43-5464-4340-AB17-7DCF9775948D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DFED23E1-3FD2-484D-B555-5C9BBB724598</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC574C73-1E0C-4C19-8D3C-D28777B31678"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:96E4CB7E-0FA4-484B-9FF5-B62030E81FCC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:58C43417-BD70-43A8-946E-AF85EE8B542B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D36A6837-4292-476E-B4E5-57120CAFD169"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9BFF2041-88B4-49AB-BD54-EFCBF740049A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9340C2C9-029B-4D12-868B-3B2F725F4E9B">
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-03-31 00:34:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9340C2C9-029B-4D12-868B-3B2F725F4E9B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A07FA31E-16B6-4FB1-94C8-1F0A5FA4B29D">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006678</dailymed:pharmgxBiomarker>
    <rdfs:label>DPD</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FA1E3B7-1CD1-435B-A9A9-FC269FF687AD">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D0784E6D-3217-4A54-A55F-1633AA67A039"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7FD460F-C987-4812-B8AA-8A86EA9D2598"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 10:52:18 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 10:52:15 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:231714C1-0EDE-4AC4-BF14-1539518DE7EB"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:677D27C9-9A5C-4574-A742-76DC50B4702E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A158D68-CC0D-4049-A37D-80094F766DF8"/>
    <pav:lineageUri>urn:domeoserver:annotation:66ACD030-541B-4981-97F8-3B6EF6C7CCC5</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CC99684-CC25-4A65-B92D-19573F301798"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB95BD00-4C63-47AF-901D-29FD47D723F2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F2F6955-D5F0-4EA6-B928-9444BC14F6A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22AA4D6F-924A-4CB6-96F1-47701A553139">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE6A6223-568D-4AAE-A89C-49AA319D9788">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F4FF2B3-9F03-4393-AE34-8C205B711209">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C147A604-3086-425A-842B-4E2330B30878">
    <ao:context rdf:resource="urn:domeoclient:uuid:889E70DD-660A-49E9-8EFE-6A2091ECBE3D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8A6028B-5370-4AAE-8B8D-E37423DE3F87"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17AE80BD-8220-46EA-8641-2EE1939DAEDA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-22 18:13:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-22 18:10:00 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:083FA2D6-1C04-4B80-8630-FD99166A73EA"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:E2199787-1222-4B4F-948D-5F6682310FE9</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD29CCDF-3F5C-4A5F-B055-6A7C5C5B8DE2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC9275BB-8C69-41D3-B188-020A00419CAF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:39A0192C-7300-49A9-84EB-6C78A91C2510"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA1DD9EF-EED2-4BA6-B09A-2383D9D12165"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFFB90EE-37A6-4F47-B758-64DDD8D2EAE0">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-22 22:03:47 -0400</pav:createdOn>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8559BFF1-73E9-4236-8F95-5AEDBA105C10">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E45345DE-09A6-4A1F-AD69-78ECCC2CD0A2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:559C0644-E2DD-42B2-BF02-24D4DE62CE3A">
    <ao:body rdf:resource="urn:linkedspls:uuid:4A99C9B5-B169-4344-83C9-569C10A54723"/>
    <pav:lineageUri>urn:domeoserver:annotation:0DFDAAC7-9912-49E6-9270-5DA522B2B8DB</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0FE9DAA-0CDC-4433-B1B9-90523C7903AE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B395286B-8734-4537-8BAB-C4E0411685BF"/>
    <pav:createdOn>2014-04-05 16:21:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-04-05 16:22:57 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8402D442-202E-4308-83DA-528F027BA84F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:75B308C9-1DDE-449E-8E9E-9A1D909FC01B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB1468A2-977C-431D-B642-407143AA67A3">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E575B6A-60A7-4FCF-AC39-1B97DE85AB2B">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30B2CAF0-1054-495A-BBDE-FD936808EF25">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30B2CAF0-1054-495A-BBDE-FD936808EF25"/>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-04-05 13:52:51 -0400</pav:createdOn>
    <ao:exact>Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>30B2CAF0-1054-495A-BBDE-FD936808EF25</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABA15473-2E51-4DEB-80EE-FFC28822C587">
    <ao:body rdf:resource="urn:linkedspls:uuid:1C2E3803-33B9-4804-86ED-72E7EAA938FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:60EB6CDE-6DBA-4D2D-9A39-84EE445B5FAA"/>
    <pav:lastSavedOn>2014-04-04 18:35:53 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4FBFA5F0-C880-4B49-A0BE-F5057F535038"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:33C47CF9-B746-4807-8239-B7A0034B5CA2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:520F789A-0184-4286-8FF2-E1F9214F9A6D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-04-04 18:35:49 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:F119B96E-AB5D-4E64-9A32-CBADC4DCB0DD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:80614695-DC56-44C3-B7EA-AB7E56B69546"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:92E3917B-F049-41BF-B9E8-4177940118E0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6C4E4DC-F3D7-41CF-A7C2-1197BEF909D1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6CA4418-5D3F-4F30-8BC2-9DCEEEA93293">
    <pav:createdOn>2014-03-22 18:11:50 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D6CA4418-5D3F-4F30-8BC2-9DCEEEA93293"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <ao:exact>Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine</ao:exact>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80E8B364-3435-40AE-9C30-BAB9083AC4D1">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>I mentioned high morphine concentrations because they refer to its use as a surrogate for genotype. </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88">
    <ao:body rdf:resource="urn:linkedspls:uuid:D43D74B1-E88C-4FBE-8716-B5F76BDE8FF1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-31 08:59:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:99B84487-54C4-4044-B319-C00A3689F0FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0EF2A15B-07C7-4714-B698-FA75EA02612F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A66F219-499B-4560-AA94-F96598D0B126"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2">
    <ao:body rdf:resource="urn:linkedspls:uuid:4079A418-64B5-4D13-BEAA-79C2F16D8E58"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1564A1CD-1DE3-44A9-B41C-23910512D5FC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB1D64ED-6852-4F82-BF48-6711B335904D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9EE83BC1-292A-4DC6-92A2-6BDA81A04501"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-22 22:03:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8FB07F0-0211-45FC-B75C-FC0ED5802AAD"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-22 22:03:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34AF151B-D880-42D9-899B-DB3190804290">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F467798-2BDD-4FD6-BB5C-009BDD4270B0">
    <pav:lineageUri>urn:domeoserver:annotationset:2A6C64C6-CBDB-44F0-9149-466C7982C228</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Nf791d9cb7d6348edbe26566d20d50c3c"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/VORICONAZOLE-ce3ef5cf-3087-4d92-9d94-9eb8287228db.html</ao:annotatesResource>
    <pav:createdOn>2014-08-08 11:04:17 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:561D4A85-FE0E-4531-B614-91D77BC7700C"/>
    <pav:lastSavedOn>2014-08-08 11:07:06 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F920E758-A4B8-4469-8C81-78234C8F1BE1">
    <pav:lastSavedOn>2014-04-05 13:47:17 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:404E3A01-9ACB-447C-A78D-63217942AFDE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B01A89BD-BD22-407A-B260-89223E106531"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A757FDCF-056E-429A-A9CA-12477A04E1F0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84D9D2B1-F3B6-4D62-B457-CAF8EEB82D57"/>
    <pav:previousVersion>urn:domeoclient:uuid:41F64B35-CD71-4D76-9044-39F5FB6161BA</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:58F824C6-C204-44BA-86CC-1DB720408DC3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9CD0B23-DB2C-4563-9DA4-14734F24DB6D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <pav:createdOn>2014-04-05 13:47:11 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB7D6096-DC59-4EB6-9CCE-BE2A132775E0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23F2D602-99DE-4EAA-9FC5-101C81D94E7C">
    <poc:MedicalCondition>node negative breast cancer, estrogen receptor status positive/negative/unknown</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4079A418-64B5-4D13-BEAA-79C2F16D8E58">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Need an option for discontinue</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:163946C5-D2BE-4C9A-9484-8ECD726ECFD5">
    <domeo:uuid>163946C5-D2BE-4C9A-9484-8ECD726ECFD5</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance (Table 1). 2 </ao:prefix>
    <ao:exact>Table 1 Relationship between S-Warfarin Clearance and CYP2C9 Genotype in Caucasian Patients\nCYP2C9 GenotypeNS-Warfarin Clearance/Lean Body Weight(mL/min/kg)Mean (SD)**SD=standard deviation.p&lt;0.001. Pairwise comparisons indicated significant differences among all 3 genotypes.*1/*11180.065 (0.025)*1/*2 or*1/*3590.041 (0.021)*2/*2, *2/*3or *3/*3110.020 (0.011)Total188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:163946C5-D2BE-4C9A-9484-8ECD726ECFD5"/>
    <pav:createdOn>2014-04-05 15:57:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB">
    <ao:item rdf:resource="urn:domeoclient:uuid:8FB8C61D-DC83-4A4B-8418-2C8DBC11CC34"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:25FFE7A0-65C7-4E16-A329-4A3275DA47D1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EEC8BF12-81F9-451B-B43E-5F6ED3A65AFE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C147A604-3086-425A-842B-4E2330B30878"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:76F83103-95C8-450C-9BF1-EDAE9CD22754</pav:lineageUri>
    <pav:createdOn>2014-03-13 04:29:46 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:986D129D-5352-4736-A5CA-C493341B06B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF4690CA-A190-417C-9878-67A0B05B369E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:1ECBE1B0-4C2C-4428-8A59-743AF7395292"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB97D9B3-7A2F-4BFB-841A-A9C180014EB0"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4B73F1A1-95CE-40EA-8375-C9700EBD6F4C"/>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <permissions:permissions rdf:nodeID="N2b63a27472284332b4b2f3903fc5c0f0"/>
    <pav:lastSavedOn>2014-05-30 21:38:48 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:07F75145-9335-44B3-9CC7-858202B8177E"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AED63615-7471-4449-AD16-6EFEA9B80F36"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:165964F5-7C38-4E72-90C9-A6806C4A2BEF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:25AF9BA3-192F-4D8A-A295-8A7742CC5E06"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>urn:domeoserver:annotationset:2C3EFFCF-8455-431F-9FC2-C031C38FF289</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:0328750E-3EFA-4DAD-8B0B-38538F765780"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:561D4A85-FE0E-4531-B614-91D77BC7700C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F6FDCDD-5D5D-4FF8-A53E-EFF54E693DB1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7218BA66-5AC4-49A0-88C4-BED2D225D29D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:B0ED99FF-919F-42C1-B9C3-53F56446F96C</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6D6B7AE6-E124-4530-94C1-A2A854309BB5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:0F467798-2BDD-4FD6-BB5C-009BDD4270B0</domeo:belongsToSet>
    <pav:lastSavedOn>2014-08-08 11:07:06 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8EF07C79-BA22-4296-A471-A62FD37EDA7D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ADB4624B-180F-4FC8-93CB-70984538DBB3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B5CDA5D-9A96-4645-BAED-6DC38A7DBB59"/>
    <pav:createdOn>2014-08-08 11:06:50 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B45A1161-E1F3-43A9-87F3-72B6694108A3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D22F7B0A-E1F0-49FC-8E1A-95DE0F9B7B17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:63850B6C-3C0C-4460-B237-61B45B217657"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:66710520-1FF6-45B8-BB01-D2C96ACD928C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14933636-B0CC-4A29-8AA3-41C40B4481A2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:DE2C2604-3963-4B66-85FC-ECCB3E6CC129</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B5C15C4-69DB-4101-A97A-F5E71FE34E31"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B970845-802E-4040-B226-6A4F84B3B6B3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3DBB4339-D188-4B25-BC32-0265176C1A6B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5034D1E8-1E2C-4493-90F2-D662231FF9CF"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-31 00:29:05 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-31 00:29:06 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5D769C96-B158-4628-8675-E329993925D2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E">
    <ao:suffix> For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:suffix>
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-22 22:10:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:660A71B3-3C67-440B-A0F5-DD14CC208C48">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> If you get a symptom from 2 or more of the following groups while taking ZIAGEN, call your doctor right away to determine if you should stop taking this medicine</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 09:10:10 -0400</pav:createdOn>
    <ao:exact>Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. Your doctor can determine with a blood test if you have this gene variation. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95BF3221-3F94-441E-A477-FCEC2922FC24">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E8670F6-48AF-4D85-8694-B22789C4891E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:499D6206-2A71-496D-9054-4784BC32BA1C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55BBBF50-6FB3-404D-A12B-AB8A409E5B36"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9227B8AA-2E85-48E3-BCA0-F0C6EB543ED7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <pav:createdOn>2014-03-31 11:29:11 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 11:30:46 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:34D31E31-C438-4861-84E8-E08DC610E12D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1788F15A-B6DA-4423-A477-031F211E89F0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:40F50FDF-8AC1-45FB-8B05-1797ACB0DD04</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6A3AEB8-C22C-4B17-A73A-5F1E4D3C8DDB">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F6A3AEB8-C22C-4B17-A73A-5F1E4D3C8DDB"/>
    <pav:createdOn>2014-03-31 10:28:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27395C78-FAA0-4CD7-A087-78E59DA28EF9">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F142EED4-D637-4CD6-8448-C837688D69ED">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdfs:label>Alternative Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:905C7271-23BC-4B86-8562-99C5DA12A7EA">
    <ao:body rdf:resource="urn:linkedspls:uuid:2D00C2C7-DAC1-4158-9F3A-51F66E05E8E3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD62DBE9-A22C-4E69-889F-CBABF0174ADF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:05B32788-CE44-4C1C-974B-C8CF01591D5B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-08-08 10:53:35 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE103847-B1B7-4B58-8D29-9AE2B991BA78"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2E7FE14-D7B3-4F05-9088-8940CBA8D021"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E45345DE-09A6-4A1F-AD69-78ECCC2CD0A2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5960AF4E-EAA5-455B-9835-632815B2CF37"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E07FEF43-5464-4340-AB17-7DCF9775948D</pav:lineageUri>
    <pav:lastSavedOn>2014-08-08 10:53:45 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DFED23E1-3FD2-484D-B555-5C9BBB724598</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6CF3E31C-7F28-458C-8F46-45C395562121"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A8591CA-D976-4B39-BFF2-09E3872A65D9">
    <pav:previousVersion>urn:domeoserver:annotationset:79F9F2D1-F486-43B3-B724-41A25FCA0D2B</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:79886681-5236-48AE-96FC-450031C1FE2C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DDADBAC-F1DA-4567-BB8D-FAF0090BDE7C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5E4B716-03DB-4B96-97E1-0692CCC51BA1"/>
    <pav:createdOn>2014-03-31 10:46:16 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-31 10:48:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A862BB3-66AF-4883-995D-FD5291544FF9"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:39C933AE-C2DB-4506-B014-05E285F7325E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:55553E99-5E52-42FE-A0D7-D283C734E439"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D420D7C4-C603-40BC-80A8-59AA14567DE4">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2142636-629B-4607-AA41-A14FE113DB04">
    <ao:body rdf:resource="urn:linkedspls:uuid:08810A50-5444-4303-A2F0-3317E49F6BE3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAFBB108-AFBA-440A-AD1E-AB08B951505D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:496B060E-2686-4FC2-82F8-55923A55B052"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:673ABC1F-282B-4E25-B6A8-D9FA1CDC54D9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8AAF25A5-CE7E-48E4-9329-44F8B3F7EB4E"/>
    <pav:lastSavedOn>2014-03-31 10:36:34 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:860D2637-CA8B-4282-AEC5-F55DA8529A7A</pav:lineageUri>
    <pav:createdOn>2014-03-31 10:35:51 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:507CE4C6-4117-4ECB-9271-639925D6D3F7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A98FC90B-0172-4B94-8197-2D6E42E0C094"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E6FC1D1E-F8C3-4C88-BD3E-144FCCB95879"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0D15111-C445-4596-9C63-C7EFADEB3394">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB29F991-E821-40B7-BEDC-BCF13D7DBF99"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-22 22:09:39 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E4B01B1-801C-4C26-86B8-852138AD8BE2"/>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA4519DC-727B-4A71-AFAE-85DE63C6BE8D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6DB437A-60FD-4998-97F4-9BA04097046A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4683D5EB-6628-4644-AF10-7D65325E3A8C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5542691E-3FD7-4CD4-B22C-7D237B921E99"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6">
    <ao:suffix> Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 13:47:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E66D545-65E2-405F-B2F8-FB4F13238634">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E7354E9-7EC9-43A3-9085-68D7F5B5FF5C">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:42FD1B02-37D3-44AF-BF17-1F9F35955DED"/>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2014-08-04 20:10:25 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N7f77d8cab574424e99f86508c155508f"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-04 20:16:17 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lineageUri>urn:domeoserver:annotationset:73C60FD8-BDF4-4C08-A5C4-A0671C82D7E4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B395286B-8734-4537-8BAB-C4E0411685BF">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0784E6D-3217-4A54-A55F-1633AA67A039">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:213D6C5B-3FC2-43E0-B0CA-153FFD1981E0">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D93754D-37DC-487D-9E3B-4292BDFEAA71">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdfs:label>CLINICAL STUDIES (34092-7)</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7FA8E18-3AE4-4614-BC08-00D63A72A86B">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2F20682-8D03-4BAB-B71A-98BF97B5D721">
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16C47415-C82E-41CD-A17D-865319AF5A1B">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AAF5C9C2-CA69-4FE0-B44F-E699BEE6E560">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AAF5C9C2-CA69-4FE0-B44F-E699BEE6E560"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Codeine is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine.</ao:exact>
    <pav:createdOn>2014-03-22 20:36:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A20C9968-442B-4EAA-842F-F950C36AFE49">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86477CA6-0F6B-47C0-B5C5-6FE456435E29">
    <pav:createdOn>2014-08-04 19:33:16 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0305355-93EC-45E7-AAEB-F368C6AECBBF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAC7144D-83A3-4BC7-BA03-F1BEC846458A"/>
    <pav:lastSavedOn>2014-08-04 19:33:27 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:7F302B0F-C432-425E-914B-1993464BD242</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE6E5FC3-C3DC-4769-8F5E-F798B06D841D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FE9FFAA-4E85-491C-B8CB-12AD2894769F"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:640E6CBB-2ECD-4B68-80C2-7FA279028E61"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55DF5491-8CA5-47E3-9224-23E7BAF182E2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:05557F68-5447-47D6-909A-0405158D7AB0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:77763CA5-72B3-4FD1-8566-6302D1BB2E6F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:22AA4D6F-924A-4CB6-96F1-47701A553139"/>
    <pav:lineageUri>urn:domeoserver:annotation:8D217329-F64A-4CDB-81C2-6EAC9D3F7CEC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EF9D0319-BDCA-4028-ADA1-E57A1130A0DA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8CB347A-DFD7-4A70-9132-54F898E94499">
    <ao:body rdf:resource="urn:linkedspls:uuid:2193F701-8874-4CBA-A7BF-09B4705DA7F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:110B2D4C-8FBA-4A0B-ACE7-187CD67F9A15"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5C5EE19-6E9E-4D65-83BC-A9E5E80ADB6B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A01999AD-BCED-4C44-AA67-75D0C46380C6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:73D3D865-BF7C-4E56-ADFB-B431179B8C4B"/>
    <pav:lastSavedOn>2014-03-31 10:51:40 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A811AD28-ECA2-4AD1-890F-F3AF8C07E145"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1AB9ABE8-1CA2-4991-BCDB-3D5BBC09146D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-31 10:49:37 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:585011DE-2B78-43DB-BC16-4860B73FEFD1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5F4FD78D-70B3-4C1F-84D0-F82DDD09079B</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94AC021B-D613-4455-9DB8-31BD437C6D7E">
    <pav:previousVersion>urn:domeoclient:uuid:BF348064-DE48-4997-9B87-A0E149330618</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:92A5DF92-D34E-422B-A682-9D87888F028C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:0317AB6B-3211-41B4-A7A4-911502DE79E2"/>
    <pav:createdOn>2014-08-04 19:45:14 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C17467B-0656-4CB8-AA1C-AB5DE9D43ABD"/>
    <pav:lastSavedOn>2014-08-04 19:48:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1B584A14-D17C-45B1-A670-921C8C6D6AD0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:91677CBE-0960-45DD-82D5-D6F7E8960A03"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:81E1502F-383B-4344-B8EE-9E11279AF395"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E637879C-C01E-4A84-8203-315652BB986B</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:EDC51AAD-92B0-4CA4-8F84-563B8F3DA6C2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F3DAD62-5D1B-4C5E-9D20-21B200ECAAE0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:532468D7-4E58-4797-963D-2701344AA9F6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:350AEC78-9F7B-4C87-B47F-ADD6D958FE47"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63A1772E-E277-4C40-AEA1-DB1681C1F6E5">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:683522B3-37B2-4440-ABF6-29F44BC55955">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5009C4FD-C9E9-4D13-AC05-BC449D443FEE">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C1C14740-937E-444D-806A-8CF4FDDC53FB">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Aripiprazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02A35020-3B50-4AE8-8449-3204B1C98466">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:suffix>Across Asian populations, nota</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:02A35020-3B50-4AE8-8449-3204B1C98466"/>
    <ao:exact>SJS/TEN and HLA-B*1502 Allele\nRetrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity.</ao:exact>
    <pav:createdOn>2014-03-31 10:47:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A932097-EFDE-4BC3-B50A-2357235EA316">
    <ao:suffix> (see </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <pav:createdOn>2014-03-13 04:27:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers or those patients taking cimetidine or another CYP2C19 inhibitor.</ao:exact>
    <domeo:uuid>2A932097-EFDE-4BC3-B50A-2357235EA316</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2A932097-EFDE-4BC3-B50A-2357235EA316"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4A61B93-A79D-4424-B631-2CACC8F8864B">
    <rdfs:label>Aripiprazole</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27AB9E5B-B171-4C45-B8C1-05118EE67913">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9965CDA3-C847-495D-8B9A-B254F1BCDC74">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C3380386-B2E2-4DC4-87FB-6859267429E2">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AEBF040F-C6A6-48A1-B676-CAAE042125E9">
    <poc:MedicalCondition>hla-b*5701 absent, hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293">
    <ao:item rdf:resource="urn:domeoclient:uuid:BE18C93E-F08F-4CA6-8DC9-67512351301A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AA95853-6352-4A19-AE15-6A6509370B0A"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:B4560117-AA1B-4B62-B27C-602B0530F074"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoserver:annotationset:E91D4FEA-5EFD-4452-9DB5-B2708709BC61</pav:previousVersion>
    <permissions:permissions rdf:nodeID="Nf5d285f1395e4e91bc2de94ca49d5c0c"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4336CA42-12B1-428D-B253-04717B03FE04"/>
    <pav:createdOn>2014-04-05 15:55:40 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:B21A0382-6079-4B5C-A4D7-3DD4BAA8E16D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4215D5F2-900F-4096-B0D9-E1903FA05B37"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:57AA2105-BDC1-406D-AC8A-EA8454C64C1F"/>
    <pav:lastSavedOn>2014-04-05 16:22:57 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:525A1A88-3E56-41E0-B8B0-F36EF85A756E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:837BB449-7B9C-4EA8-B13B-7EC05038D2E8"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:AE902754-FE31-4F84-88A5-178F0039C2FF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:9B1D41D3-765D-4219-97FB-CD526A2262F8"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:284642F9-56EF-4D2F-A2B9-88FF22D7B49D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F6F0822-6A5A-4AC9-8FEA-E9146DEE6263">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2742B3CC-24F8-4BB3-B4D9-7B40D3BD3390">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0114C96E-1A6E-4054-8A7D-E9FDE5179D39">
    <pav:lineageUri>urn:domeoserver:annotation:B7ADC17A-2431-450E-9092-251DAC90C8BA</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:00706460-7B8F-4A66-93D0-7F09DF19B730"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE1D55A7-C444-42D4-9265-8067EEB50B63"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-13 04:28:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:20BDC0BB-49CD-4BF1-826C-42DC4D12B075"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D690D50B-5476-446F-BC94-2ABF31A96DC6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:B0D1D641-0B64-4278-A509-1690C1185473"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7148865A-9774-4C02-823E-3B894AFA4478"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-13 04:20:39 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEA0830-ACA8-40DD-8D9F-78F87866EE0C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A8CECC3-ADF7-4BF5-A7F9-53CA959E9EC5"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B92F7523-BB92-4519-80B9-6CFEC0D2FFD7">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE818BD4-E67C-4DBE-AEFE-82E4DD9E8B72">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5734B9EA-E08F-4E0F-87D0-09241425D1D3">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB29F991-E821-40B7-BEDC-BCF13D7DBF99">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE8DE92B-D492-408D-B800-851E779CD6F2">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CLINICAL STUDIES (34092-7)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:167D11A4-A18B-4BB4-BC48-F27FAED5CCB6">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3C4BB835-7C91-4C6E-BC8A-7365DDB9D1A4">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF928AF5-30A2-4989-9A85-18DE16C1A97B">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2014-08-05 12:28:36 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N0396bf07dea3411e9af9d86aebbeae56"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-08-05 12:34:17 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E7EEF57-A445-4C55-965B-8D4E7A8AA86C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:BEFF5A1B-4FC2-4F0F-B1D2-EAFD4D88268B</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PEGINTERFERON_ALFA-2B-0a8f3137-0e3a-4a60-a872-cb7d761b30e1.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA67625B-2AC1-4E15-BC4C-50D4C7BE0F03">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A54084C7-81C5-4C71-AEA4-AD05D852A4AB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:494343BB-6FFA-4939-B751-481C13CA9DC4">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D75632BD-1FE9-4A16-BAE8-E8195344E8BC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D75632BD-1FE9-4A16-BAE8-E8195344E8BC"/>
    <ao:exact>TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 10:25:33 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E08C847-80F4-4998-AA08-71AE4C51F44B">
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304488c4b70144896ed8340009">
    <foafx:lastname>Hatfield</foafx:lastname>
    <foafx:name>JHatfield</foafx:name>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:email>jocelyn.hatfield1@gmail.com</foafx:email>
    <rdfs:label>JHatfield</rdfs:label>
    <foafx:middlename></foafx:middlename>
    <foafx:homepage></foafx:homepage>
    <foafx:title></foafx:title>
    <foafx:firstname>Jocelyn</foafx:firstname>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38442337-288D-430D-AD0F-7D300206DE9E">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-31 10:43:17 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:02622A38-2628-40D2-8B31-F1808AC2DD0E"/>
    <pav:lastSavedOn>2014-03-31 10:43:21 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F664256-E6FF-4291-8AB4-BF8829DCE5B5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:213D6C5B-3FC2-43E0-B0CA-153FFD1981E0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:31AEE449-5872-49E6-87A3-8034A2A4C06E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6246790C-2A80-41B2-9416-D6EA8ECFB253"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D01FB849-1606-42D2-9C6F-02D76517DD5F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFFB90EE-37A6-4F47-B758-64DDD8D2EAE0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D0C1888-2BD1-4D02-90A1-D11165D73CE1">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:578A8756-945D-4A96-98F7-B18C1DEFBA54"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:580FFB5D-DB6D-416B-9E2A-0B5737DDFB1E</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:70EB5D28-37B1-4D35-87F6-6830D8F2028C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA068865-47CE-4ACE-AF05-CA2B37666BDB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-04-05 15:36:54 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2FE75A6-6A24-4574-9C2C-838F6D9C0521"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4764F84A-FA58-414B-84F0-D7FD6A167557"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-04-05 15:36:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4ADE6966-459E-4B08-AFED-5B81E95AB46B">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4ADE6966-459E-4B08-AFED-5B81E95AB46B"/>
    <pav:createdOn>2014-03-22 20:42:43 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people.</ao:prefix>
    <ao:exact> Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression. Codeine is contraindicated in children who undergo tonsillectomy and/or adenoidectomy. Advise caregivers of children receiving codeine for other reasons to monitor for signs of respiratory depression.</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38047FFE-3CCD-49C1-AD55-511E11EA7254">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB4F592B-C531-4655-A925-49465B929C5E"/>
    <pav:lineageUri>urn:domeoserver:annotation:26FF7A1C-01DF-45EF-8F36-A3C4A3162E91</pav:lineageUri>
    <pav:lastSavedOn>2014-08-04 19:55:36 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:42BFEABF-90BF-40F9-A2D6-ED9624EC3A04"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-08-04 19:55:21 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:794627FA-8A1B-47EC-930C-89EAA96DCE8A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE179C73-2868-4229-85C1-5FFEC1FA8A63"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:694463F2-3B25-4313-BF76-A95FF8707C03"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C1B08A1-538C-4FCC-9013-665F0B7A9D8F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3B13FCE-B624-427A-8169-8E8BA5CE6CAC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1B584A14-D17C-45B1-A670-921C8C6D6AD0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F30FB396-4B2F-44D0-8EFC-CA7BB0E5B838"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AC52C4F-30F0-4DE2-8ACB-2AE73DBFFC8F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE31FFA7-9144-46C5-B3C4-AAAE94A99993">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1ECBE1B0-4C2C-4428-8A59-743AF7395292">
    <ao:body rdf:resource="urn:linkedspls:uuid:4115BCF2-08FE-450A-AC56-6939C29B1491"/>
    <pav:lastSavedOn>2014-03-13 04:45:19 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-13 04:45:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:66C3C4C0-37E4-4EFD-89BB-9FB861E1F5A6</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:973058EB-842F-48AB-968D-9583FA4F2CE4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:F649813A-110D-474C-86E0-3807B8F838E5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC0112AC-CA62-4C51-B57D-62EB9354B6C8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:58D51FB7-6F1E-491E-8784-7B322766B0A4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:59C5BF0A-B7D4-496A-B1E8-5A69855D28A1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B73F1A1-95CE-40EA-8375-C9700EBD6F4C">
    <ao:body rdf:resource="urn:linkedspls:uuid:AB944467-7A08-46EB-8806-930A83CC44C9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF97EA95-22B6-4573-839B-45244ACA8467"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5D3437A-86AF-4DFD-8D50-68FC52B89D04"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B661122E-6D89-4F4F-ACAE-7F95B60C3B97"/>
    <pav:createdOn>2014-05-29 14:08:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:36284728-D39E-4D0D-818B-103AE5464C1B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-05-29 14:10:49 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:36157F48-0A8E-4400-9EE6-A8303392D45C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2471E7F-FECD-4817-BF9E-1D554E5FEDBD"/>
    <pav:lineageUri>urn:domeoserver:annotation:A2970487-E9FB-42FB-9D04-D88AC8BA0389</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:031D63F5-2F31-4483-8E84-9813522A2A07"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D25BD49F-3406-4D9E-AFF6-06E7D37A86F1"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F5206FF4-43D0-486E-AD37-1641571853D8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1596CAE0-C0D3-4FEC-BA0A-D5D14218A61D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:790C43E6-17D7-494E-AF4E-E015257A54A5">
    <ao:body rdf:resource="urn:linkedspls:uuid:53292FFE-31F2-4574-8E4D-5515E025353A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-04-04 18:35:53 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:585DB1D6-47AF-45EC-B199-A38AE81D7FF2"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D784226A-C58C-4D32-A307-DDB685733265"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8FA5770-5F24-4B37-B3C2-9F126A0C01E5"/>
    <pav:createdOn>2014-04-04 18:33:59 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:44AFA8EA-D5AA-493A-BEE4-FB63F29B3842"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:90040F04-C3BE-4AC6-9AC3-7C490F12460C</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1AB9ABE8-1CA2-4991-BCDB-3D5BBC09146D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1AB9ABE8-1CA2-4991-BCDB-3D5BBC09146D"/>
    <ao:suffix>South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2 to 4%, but higher in some groups. HLA-B*1502 is present in &lt;1% of the population in Japan and Korea.</ao:suffix>
    <ao:exact>Across Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-31 10:49:37 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91077014-6C54-4675-94DC-46F4E4340867">
    <rdfs:label>chromosomal-aberration-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#chromosomal-aberration-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54BCBAAD-B674-4B98-ACD6-710B7081482A">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>PHARMACOKINETICS (43682-4)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51579B91-1412-4E4A-AB7B-CC97141050D4">
    <rdfs:label>DOSAGE AND ADMINISTRATION (34068-7)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7BB459F1-73DC-47B9-8697-FE88C063462C">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41F44366-B06D-4FF6-8536-F0E531955BAE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-31 10:36:34 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E917341D-315D-47DD-823A-B38F630BB493"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-31 10:33:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8405D1E5-BABE-4808-B711-F3A83D365C16"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E885AB9-8661-4503-9D66-904EB005FB1B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C48398C-4677-4B8D-9AD5-2D2F27BACDD5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4250C6C8-E1BB-44A8-92EB-9ECF059DB59B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:30165D55-F0C3-495F-B740-02B137587144"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:FECECB2B-5179-442A-B0C5-32E51A5344A5</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D213C3E5-F994-412D-8812-5E0CECE9C2BE">
    <pav:createdOn>2014-04-05 14:18:23 -0400</pav:createdOn>
    <ao:exact>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.</ao:exact>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D213C3E5-F994-412D-8812-5E0CECE9C2BE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>D213C3E5-F994-412D-8812-5E0CECE9C2BE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07B6B442-94F5-4541-9416-C726A6D785E6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:06CAC201-96AF-4344-AF49-DF7E60A6D48E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:FF7B2C15-5977-4CEB-9F55-237750EBC451</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:createdOn>2014-03-31 00:24:10 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B1BA362-4052-4B63-A708-937F9D8B21B8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:328E2B84-107D-4F11-A6DB-189C90C32279"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:355DB9A0-974D-4BD1-B6AA-3C439661E7B3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:484512E9-44DD-4E7D-9CB4-DA99B2BDD0FC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B66E5587-3003-49F2-95AB-8ED4901E5D99"/>
    <pav:lastSavedOn>2014-03-31 00:25:15 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA77FD1B-7D8E-4836-AA5A-E6071CA28333">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:350AEC78-9F7B-4C87-B47F-ADD6D958FE47">
    <sio:SIO_000111>34085-1 CONTROLLED SUBSTANCE SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34085-1 CONTROLLED SUBSTANCE SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A11C27FE-76FA-4738-9CA4-B4F1BC265504">
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE902754-FE31-4F84-88A5-178F0039C2FF">
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <pav:createdOn>2014-04-05 16:10:45 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:0E921441-E10D-4841-BC87-04997D35DA17</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1DEB6B49-CDBC-428D-90A7-C95573351E17"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF44CB0B-8D3B-4979-A4BF-84A8306DD07E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EC1647E1-C0BA-4B41-AE11-28F2709C2D8D"/>
    <pav:lastSavedOn>2014-04-05 16:10:53 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:B029387A-6DF6-4791-81C8-640DDABE9E7C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0AC6948-BA3A-4BB5-8083-0F2D1F325E92">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-08-07 12:52:12 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:01E309AD-60C5-49DF-9CE3-9B6BB3701C29"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4000002E-9DDB-4180-A461-8C8E5266C176"/>
    <pav:previousVersion>urn:domeoserver:annotationset:326EB39D-9549-4599-90B2-6D3F04F6D176</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:53DD663C-1281-4EBF-9EA1-CC825BAC4830</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D22B146B-D400-4905-ADDB-4FFC216CB489"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF903747-E225-4598-B9EF-86BD59E72E0F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF1B0A87-0850-4C5E-9029-B7477BD432CD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:9C2115AF-F110-4EE2-85ED-380B15F3C990</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B39A55ED-DE3F-41B7-AB3B-9296A2272AA8"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3B9A02A9-6FF6-4529-809A-FE09CBC3C0FC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:13A1814F-D1F4-4B44-82C2-5DE12C7CF6D0"/>
    <pav:lastSavedOn>2014-08-07 12:53:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:02D700A1-EB95-46CE-AFAD-9D741A4CF918"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E450586-ED8A-4854-AFFE-35D724A5BDC6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F127DBE1-AECA-4EBD-BEDC-B186666741B2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F127DBE1-AECA-4EBD-BEDC-B186666741B2"/>
    <ao:exact>The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-31 00:25:13 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>4</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>In an observational study, the risk of achieving INR &gt;3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5E6BD54-CF9B-4C23-8FE8-040EA433AD90">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0D1D641-0B64-4278-A509-1690C1185473">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> The maximum dose should also be limited to 20 mg/day in patients with hepatic impairment and in patients who are greater than 60 years of age because of expected higher exposures. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B0D1D641-0B64-4278-A509-1690C1185473"/>
    <pav:createdOn>2014-03-13 04:20:52 -0400</pav:createdOn>
    <ao:exact> The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected.</ao:exact>
    <ao:prefix>The citalopram dose should be limited in certain populations.</ao:prefix>
    <domeo:uuid>B0D1D641-0B64-4278-A509-1690C1185473</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EAC3FD4-72CA-479D-8CE2-0D4BA6860CC2">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE">
    <ao:body rdf:resource="urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F7F0EB3-F9C8-4AAE-BCD4-4A03CA215C14"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B4BFDF8-85C4-40F2-A42F-23B4B1176095"/>
    <pav:createdOn>2014-03-22 22:18:30 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AFDF697-A5A4-42EF-BE12-893415E6A1D6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4B5F9D6-6190-4D39-A50E-B39CD7193832"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-22 22:18:31 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94569D13-A994-40FA-BDCF-C0391FE365FD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:79ABCEB5-E291-4F30-AC29-AC52FD7620B8</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:40AC27D0-6D44-444E-A3B8-CE5689AD915D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:66E46BCE-D1C0-4FEE-9782-5795C4D11F93">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Your doctor can determine with a blood test if you have this gene variation. If you get a symptom from 2 or more of the following groups while taking ZIAGEN, call your doctor right away to determine if you should stop taking this medicine</ao:suffix>
    <ao:prefix>).</ao:prefix>
    <ao:exact> Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-31 09:09:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4D761CC-A903-47F8-AD08-52A5E7E6A9AA">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:E07FEF43-5464-4340-AB17-7DCF9775948D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CF696F8-B98E-49CA-85FD-0A90C6250EBC"/>
    <pav:lastSavedOn>2014-08-08 10:53:45 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAEDFA78-4ABE-4070-9AB8-BFF8C609E0AB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:34178809-00EF-47D7-8591-4F5BE26FF59A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B1228DD-587C-440D-B53F-1CB7F91F977A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DFED23E1-3FD2-484D-B555-5C9BBB724598</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:FCF11334-1046-42B4-A5C4-9FE4655BC1B7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1260362-9D96-409B-AD63-2DCC1C0465C9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:31299198-E64B-40FF-A5AD-23D8B3B7A5BF"/>
    <pav:createdOn>2014-08-08 10:51:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B1472FE-09F5-46BF-84F7-07F5E801036E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE6B3C32-A94E-4E13-833A-9EBA958B383F">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2D2D450-639D-4D10-B6B5-D0735D582167">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F696731F-DD89-46F8-A2A7-7E01184A366D">
    <domeo:uuid>F696731F-DD89-46F8-A2A7-7E01184A366D</domeo:uuid>
    <ao:prefix>In all patients, subsequent dosage adjustments must be made based on the results of PT/INR determinations.17, 18 </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F696731F-DD89-46F8-A2A7-7E01184A366D"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Table 5Range of Expected Therapeutic Warfarin Doses Based on CYP2C9 and VKORC1 Genotypes*\nVKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg</ao:exact>
    <pav:createdOn>2014-04-05 16:18:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D00C2C7-DAC1-4158-9F3A-51F66E05E8E3">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <rdfs:label>Rasburicase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BFB965F-D1FB-464F-A5BF-ADAD50C57F44">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:6D498FF3-33DF-467B-8B8F-1BDB7ED744FD</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:37276584-B74E-4FB5-8F92-BE77209E25DC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE145006-D521-4AD3-85BD-19F418544482"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AFFDC03-AB18-40B8-A042-A4208215CC79"/>
    <pav:createdOn>2014-03-31 00:22:02 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D15E0D1-9C28-416A-BD1F-7E1AEB24CAE5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-31 00:22:05 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E7CDA24-C918-4533-9893-1287CCF8183F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:486733A1-6BA0-491D-87AC-EA70B14043DF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73C1A497-1E52-406F-A8A2-D5631C088F35">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E9CAEA4-6AB1-433B-89F7-FB98C740D991">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07F75145-9335-44B3-9CC7-858202B8177E">
    <ao:context rdf:resource="urn:domeoclient:uuid:F0B08DC7-31C0-488B-86C2-1475F4406E78"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:46A8E276-BD15-46EC-AB82-26BA60DCDA2A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4821B246-2A1E-468A-9599-A97AAA977C8A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:613AE564-A210-49F5-A1A0-EA070D855469"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A20C9968-442B-4EAA-842F-F950C36AFE49"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7BD20C41-372E-4363-BD26-3680C8FE9C9F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:989136C2-9608-40D9-AF93-CBD2CE5FED91</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:99ACE7BD-56E1-435A-B8FE-9EBC9FE5D0CF"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-22 20:39:32 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-22 20:44:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB">
    <permissions:permissions rdf:nodeID="N1588e9c10a094ad390c00bf62827ce6f"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D2142636-629B-4607-AA41-A14FE113DB04"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:826B4026-D31D-4CC2-9C11-824030161DF1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:41F44366-B06D-4FF6-8536-F0E531955BAE"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D2D061DE-701E-465A-856F-97464D9F99E7</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:04DDC507-6A96-445A-A1B4-775A8E02726D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:567C8304-7D83-4028-A1EC-AD9CBC5837C6"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9ED84C74-7BDC-4251-9AB7-486C16BDEF6B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9053400-125E-4E9B-8276-7F18C8B85E71"/>
    <pav:createdOn>2014-03-31 10:15:41 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:AFAF347B-A09F-4EC6-9B56-FB86D57A5D3E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-04-21 12:31:02 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:C5397383-9AB4-4CAD-9F12-7A015B2B06DC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B04896AC-083F-49F3-B5F5-0106B388DDC4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CC0F0FB3-E2E2-453E-B7D3-D8BC825EAEBF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8BAC335F-B80C-45A8-A4D7-41C65A7105FB"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BB8C29B4-DAF1-49C7-B4C0-F9A3C922D9B0"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:B103237F-F633-4CA4-934C-2488AC33F8BF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:13A1814F-D1F4-4B44-82C2-5DE12C7CF6D0">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:AC93DEDB-7C87-4168-8104-9E2959E8F017">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:2976AD40-9424-4037-8069-627C2E58B16C"/>
    <permissions:permissions rdf:nodeID="N29a7495514b34265bd6bf1e51f04c536"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-04-05 15:10:04 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoserver:annotationset:50AEA52D-C09D-4D06-BD84-04DE9D0BF7A3</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5409FBA7-9762-4BAF-A5F9-AB669F959BBF"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:annotatesResource>
    <pav:lastSavedOn>2014-04-05 15:19:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:7BFB99BF-9A88-40DD-8810-1E0A1E7A6D0A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:ED0170B2-B4E0-4B2B-B614-54F18F28590F</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55B89580-2E0A-4A7D-B09D-AFAF8BF0A3CC">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81E91DC4-4573-49FA-BD0C-874A40A0B5CF">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B6F3BBC-569B-4633-9956-6F42CEF42220">
    <ao:body rdf:resource="urn:linkedspls:uuid:BBDE4495-5E29-4C3E-A9A7-2BC258F417F6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:79F9F2D1-F486-43B3-B724-41A25FCA0D2B</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:02A35020-3B50-4AE8-8449-3204B1C98466"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 10:48:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4AD4A6EB-985E-43C3-B39D-C2559410F086"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A488585E-8C31-494A-82C0-A0192B649F4B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:86C9129B-429C-46BA-BE2F-C6BC0ECD5371"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:95AE669C-DEBF-4988-AB1B-2E1481AA1261"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4668FD1-0217-4075-9EA8-765FA07E8A9C"/>
    <pav:createdOn>2014-03-31 10:47:59 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42437394-462B-4271-AE87-64417F6EAE21">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77C084D3-12B1-43F2-9CC0-51B291BC3723">
    <pav:createdOn>2014-03-22 18:10:25 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:77C084D3-12B1-43F2-9CC0-51B291BC3723"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:exact>However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeines active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2302A2D-0E55-4B59-AD91-58549A4767D7">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25D3033D-AEC4-4685-B22F-9ABAB9A62688">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2C36B0D-AE49-4B08-9DB2-0C4C2EFBF661">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 00:28:41 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>5 Similar observations have been reported in Asian patients.6,7</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B2C36B0D-AE49-4B08-9DB2-0C4C2EFBF661"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:612F4BF8-4B3A-4752-B0B4-E69D8D8CCF36">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7020787-473C-4FBE-9176-DF19F6E445A3">
    <domeo:belongsToSet>urn:domeoserver:annotationset:9C2115AF-F110-4EE2-85ED-380B15F3C990</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FADB7159-1AAB-491E-BC0F-0E9D3E17C759"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:428A5C10-8C0C-42CC-BC78-1E3D27230F69"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD0EFE44-41B0-4C06-A553-537E290EA14B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-08-07 12:55:21 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3471C78D-BAF5-4694-B1D4-61D380A8C2A6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4A639E7-B5E1-41AD-BDEA-3D6F86DBFF7A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D986E293-5E73-4523-95D3-9E70CA59FB2B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-07 12:55:38 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:5622D257-9150-434C-95DC-09172E9C6528</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6769DEE-47BA-4783-AEE7-77428FCD6B4E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC8004B8-4960-4BB3-9A93-4E98AF7609EB">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A4397F4-7E56-40D0-A81F-EC897E7F7876"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F8A134D5-7E29-44BD-A95B-6E0675223571"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:222B5AC7-FAF6-4D08-8831-026C35001C30"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDC6D3CE-8360-41F1-AC01-ADCAB96DBE01"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:AF56BE3C-BE1F-488A-8DE5-2468B589CC72</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:75B5D7CF-A4B7-429C-977F-A0AE4401ED25"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:40551475-996A-4ABF-A6A4-136400388D2E"/>
    <pav:lastSavedOn>2014-04-05 14:03:57 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-04-05 14:02:52 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7DEA0830-ACA8-40DD-8D9F-78F87866EE0C">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:05F5345C-0274-4DD9-B7AE-57C94E589013"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0114C96E-1A6E-4054-8A7D-E9FDE5179D39"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:96964BFA-354E-4532-B474-3F349EB93C0A"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:173A1A86-1EDE-49B2-B627-4D6639EC3F98</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:74CE124E-02A4-4A40-ACA1-877BF6FF59EE"/>
    <permissions:permissions rdf:nodeID="Nbffab71c5a354622885420f6eded1b3e"/>
    <pav:lastSavedOn>2014-03-13 04:28:47 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6A419A6-B4F0-4F0A-B706-3B241717BA9E"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:annotatesResource>
    <pav:createdOn>2014-03-13 04:03:03 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A1C26D7-0B06-49F9-AF2E-CBD25FBA7F7D">
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE145006-D521-4AD3-85BD-19F418544482">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAFBB108-AFBA-440A-AD1E-AB08B951505D">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA52B62C-8357-418B-89FF-C4533051A4A8">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F26FCFF9-482D-4C5F-8329-6E85F2D98D57">
    <pav:lastSavedOn>2014-04-05 14:13:02 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:B7AD770C-9B0F-4D66-BE40-2AE6CD8340DF</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:110E324A-6920-4313-B80B-2414B6E63C92"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B75599F3-C241-4E70-8315-2EB60B3F2748"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B888192-2482-4BEE-A04E-072CF1FAB33D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:60DBA1F1-8C76-4F8C-9E4A-A4A09F0BFEE1"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E070E033-6FF0-4935-BFD9-7D3615D5B5A6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D771262-567C-49F7-8CE1-5DE0613139D1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <pav:createdOn>2014-04-05 14:12:58 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:167D11A4-A18B-4BB4-BC48-F27FAED5CCB6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A85EF876-AF0D-4316-82E4-390553A6DEBD">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1EF2D05-6C08-4679-B2FF-628A6C723E25">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is not necessary.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-necessary</poc:TestRecommendation>
    <rdfs:label>Not necessary</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55B0054E-EEB6-4DFF-B81D-806E6A676921">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15CB17DA-0B65-4CC0-BFBC-EB15907156EB">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:232541B6-1FA8-43DE-B45A-960569AFD4D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:69654F1F-F8B9-43CE-87A1-63A39B364922"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:05242102-A177-47F2-AF99-897858A48917"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:20AD692D-3407-4D6C-ACDE-626037F984D4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2014-04-05 15:28:10 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:DCADFC08-6D38-41F7-A21E-3B48E106AFC0</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C819DC9-698D-4ABD-AE1B-95BA9238755B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-04-05 15:28:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0697AC43-D2AD-49FB-AE5B-3618ED26027D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E8670F6-48AF-4D85-8694-B22789C4891E">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AFAF347B-A09F-4EC6-9B56-FB86D57A5D3E">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 10:36:34 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:946CCAEA-86B4-4DF7-BEBC-FDBE635A40E4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E38545AE-81EC-46FA-9B39-FB05D4F40582"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11E0D331-7AD3-4D77-9754-5827D1F13665"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:888E1F10-7B19-406B-985C-7B49F664BAC8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:08A6A966-51CF-4992-BC36-3C12B4E8EC7A"/>
    <pav:lineageUri>urn:domeoserver:annotation:516DB85B-85F0-48ED-9C88-E0C1CEA1992D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F142EED4-D637-4CD6-8448-C837688D69ED"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F398BCE-3F13-4B4C-AB09-ABCCFC5F0E87"/>
    <pav:createdOn>2014-03-31 10:34:44 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85F385E4-9413-42B6-8DB2-0C7BC7FF3E08">
    <ao:body rdf:resource="urn:linkedspls:uuid:9E66D545-65E2-405F-B2F8-FB4F13238634"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:52378A32-A66F-4759-B323-7D93B80FFBB1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CE5BCC1A-A623-4C88-A17D-090E8284CD20</pav:previousVersion>
    <pav:createdOn>2014-04-05 13:52:51 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF7ABF92-A568-4686-A511-8B19B0CB3AA4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:74AFE340-9F0B-44D6-B3FE-0DDE02300229"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC7035A1-EACF-4229-B006-22F5E1E3984C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-04-05 13:53:59 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E112DEF-DB5E-4B6C-917E-5838F9434D76"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:30B2CAF0-1054-495A-BBDE-FD936808EF25"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7767F592-8B22-47F6-873F-71CA967AFCFD">
    <pav:createdOn>2014-08-08 10:50:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7767F592-8B22-47F6-873F-71CA967AFCFD"/>
    <ao:exact>Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek therapy</ao:exact>
    <domeo:uuid>7767F592-8B22-47F6-873F-71CA967AFCFD</domeo:uuid>
    <ao:prefix> Immediately and permanently discontinue Elitek if hemolysis occurs. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <ao:suffix> (</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Risk Factor: HLA-B*5701 Allele: Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:prefix>If symptoms consistent with hypersensitivity are not identified, reintroduction can be undertaken with continued monitoring for symptoms of a hypersensitivity reaction. Make patients aware that a hypersensitivity reaction can occur with reintroduction of ZIAGEN or any other abacavir-containing product and that reintroduction of ZIAGEN or any other abacavir-containing product needs to be undertaken only if medical care can be readily accessed by the patient or others. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-22 22:22:30 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF4C86C0-5930-466F-9514-287D558A207E">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B">
    <ao:context rdf:resource="urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2D2D450-639D-4D10-B6B5-D0735D582167"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:65137868-B001-4C93-B966-A8E06E33B0E9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B52DDA70-3E7C-4358-8558-ADAC22E0B522"/>
    <pav:lastSavedOn>2014-03-22 22:03:57 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF75BAC3-9B1E-4E6C-9666-F407F87B964F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B4047A9-42A5-46E5-9848-74F5005C2F7D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-22 22:01:43 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91373757-CDC9-41DF-834E-F17713AEE49F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BABEA1E-A976-4ED1-94A6-747F34824572">
    <domeo:uuid>9BABEA1E-A976-4ED1-94A6-747F34824572</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n\nClinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n\nGenetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BABEA1E-A976-4ED1-94A6-747F34824572"/>
    <ao:prefix>An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding. Initial Dosage </ao:prefix>
    <pav:createdOn>2014-04-05 16:15:49 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF1F10F0-D061-4FDE-925A-1B1B7243A890">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58F824C6-C204-44BA-86CC-1DB720408DC3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D5BB4439-E5AB-4498-903F-279826D0E714">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB6588D5-7195-482D-9D3D-5256CD1966F9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F91D0EF-2A93-43B1-AE98-431E75007AFD">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>estrogen receptor positive breast cancer, progesterone receptor positive breast cancer, hormone receptor unknown breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E631115D-5EAA-48D8-9AA3-A5F848BFD320">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E631115D-5EAA-48D8-9AA3-A5F848BFD320"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 00:34:50 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.</ao:suffix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3B92B9C-A1A9-48FE-AA37-A3DD6C06A609">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3471C78D-BAF5-4694-B1D4-61D380A8C2A6">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D31B622F-C174-4F7D-BAF4-793A9A8636EC">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdfs:label>CLINICAL STUDIES (34092-7)</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36157F48-0A8E-4400-9EE6-A8303392D45C">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6B089D9-574C-4C1C-A1B5-BDA08930B93C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F664256-E6FF-4291-8AB4-BF8829DCE5B5">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3">
    <ao:exact>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-22 22:14:51 -0400</pav:createdOn>
    <ao:suffix> Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D6B7AE6-E124-4530-94C1-A2A854309BB5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6D6B7AE6-E124-4530-94C1-A2A854309BB5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In vivo studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 1520% of Asian populations may be expected to be poor metabolizers. For Caucasians and Blacks, the prevalence of poor metabolizers is 35%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolizers have, on average, 4-fold higher voriconazole exposure (AUC) than their homozygous extensive metabolizer counterparts. Subjects who are heterozygous extensive metabolizers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metabolizer counterparts.</ao:exact>
    <ao:prefix>studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 [ see Drug Interactions (7) ]. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/VORICONAZOLE-ce3ef5cf-3087-4d92-9d94-9eb8287228db.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>6D6B7AE6-E124-4530-94C1-A2A854309BB5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-08 11:07:06 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C6333EE-9F99-4318-846F-FE03FA8AC3DE">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4FE06C9D-AEEF-4C99-9805-AA0671345438">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04DDC507-6A96-445A-A1B4-775A8E02726D">
    <pav:previousVersion>urn:domeoserver:annotationset:6F877E8C-2C55-432D-8DB8-80CE14A50DE1</pav:previousVersion>
    <pav:lastSavedOn>2014-03-31 10:31:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-03-31 10:26:49 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:186091FB-EEC9-4591-98FB-AD76970B0DC2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:04E5CF0F-8728-4B7C-98FD-2CD37F1C7F2B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CAEB6DD-B050-435A-96A3-80DA7E44D15C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8FA1C920-FFA6-4D34-AD90-D74FA680DF16"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:227925F9-980E-4C3A-A58F-0BC3D56216FC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:03775CD7-A3F2-454F-9C46-3BC24CEAAA5B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product.</ao:prefix>
    <ao:exact> Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-22 22:20:08 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DA602EE-E5A7-49A6-A52F-F12866E00AF2">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>CLINICAL STUDIES (34092-7)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA126820-256D-4C0A-BAEB-B5A5EC5C0F33">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF354C62-D918-4027-A939-E0A37FC7CC79">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E885AB9-8661-4503-9D66-904EB005FB1B">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80FCC504-904B-4054-BA91-33F2876696EF">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A">
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:553C66AA-28FD-4DCE-AC6B-2F38BE38D2E2"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F81D2DEA-DB8F-47CA-A14E-9C5191A0857B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9DC2E5C7-FF6C-48B5-92A6-2038376377E3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7AB24D19-F216-48AD-B258-D1B39106017C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8915E9AD-A17B-4C7A-BBF8-8A0ACC445C99</pav:previousVersion>
    <pav:createdOn>2014-04-05 15:23:14 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:0D0C1888-2BD1-4D02-90A1-D11165D73CE1"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <permissions:permissions rdf:nodeID="N9392de071d0e4fea8d352ef4196810f2"/>
    <pav:lastSavedOn>2014-04-05 15:39:53 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5460E36B-8649-4E6B-ADDB-97AAB6BE01FB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:15CB17DA-0B65-4CC0-BFBC-EB15907156EB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9C8BA4E0-09FA-4D55-8F6B-E48072DE18D9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:62EDFBD2-816F-43B9-BBFC-D10369B759AD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE1D55A7-C444-42D4-9265-8067EEB50B63">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <rdfs:label>Citalopram</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CCA2D84-A393-40F3-8233-DAC50B8E925E">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5397383-9AB4-4CAD-9F12-7A015B2B06DC">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:37501176-3685-49F3-BC85-966B644473FF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7A6311E-21FF-456C-8779-7B193EA474EB"/>
    <pav:createdOn>2014-03-31 10:22:04 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 10:22:07 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:CCCC01C4-A92F-4944-A245-4FE4E2DC339D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:AAA8CEFF-4B6B-4855-AB92-1E71CA821963"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8E88DF83-1F99-4A0D-ACAA-0630C6A3B444"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B92F7523-BB92-4519-80B9-6CFEC0D2FFD7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F565F96-125A-42EA-8266-29B4F096939C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5DDFC8B-5353-4209-BFF6-2CE49D8A541B">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60FBB145-D76F-422C-A632-269FA8998274">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:24E6F1B0-21A6-49CB-814E-700D437D14D5">
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:9C2115AF-F110-4EE2-85ED-380B15F3C990">
    <ao:item rdf:resource="urn:domeoclient:uuid:D7020787-473C-4FBE-9176-DF19F6E445A3"/>
    <pav:lastSavedOn>2014-08-07 12:55:38 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:A0AC6948-BA3A-4BB5-8083-0F2D1F325E92"/>
    <pav:lineageUri>urn:domeoserver:annotationset:53DD663C-1281-4EBF-9EA1-CC825BAC4830</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:552BD933-C74D-47EF-9805-895F654A5575</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:8EE31FDE-D252-4C26-AE66-BA41A977CFC7"/>
    <pav:createdOn>2014-08-07 12:28:28 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:03D084C1-E526-46CF-8BB8-43BB154BA0EF"/>
    <permissions:permissions rdf:nodeID="N47e92b592bb94acb8e8825e3cbe3faef"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A686C96D-11C6-4B43-B7C5-7CEFE89F1862"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:803BFCAB-DAC3-458B-9ACC-D5D3CE725015">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2777A6B3-0358-4D0B-876C-939F5956C915">
    <ao:suffix> Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the babys doctor i</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <pav:createdOn>2014-03-22 20:44:14 -0400</pav:createdOn>
    <ao:exact>Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2777A6B3-0358-4D0B-876C-939F5956C915"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06D9069F-B714-4BE9-931F-B7D717B435C2">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>WARNINGS AND PRECAUTIONS (43685-7)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:496B060E-2686-4FC2-82F8-55923A55B052">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <ao:exact>Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:496B060E-2686-4FC2-82F8-55923A55B052"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 10:35:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC9F76F2-13E3-404A-8FB0-43E6EB01859D">
    <pav:lastSavedOn>2014-03-31 11:41:19 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E7F2371-A92D-42D3-8889-4993B0939BE0"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:391186E1-69F8-4086-9B16-3FFAB6492435"/>
    <pav:createdOn>2014-03-31 11:40:55 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:CE7649EF-40E7-4363-8928-2EEF0AAE78C1</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7FA8E18-3AE4-4614-BC08-00D63A72A86B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD1C3D7E-1401-4C75-88BC-4B423E5DDD2C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:59C676DC-D957-4F73-AFDF-D3DE61C60E20"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF5181A8-730E-48BB-9435-15F38AE3D7C5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA77FD1B-7D8E-4836-AA5A-E6071CA28333"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABC14B97-37E5-420B-8F6E-8B9826EA0EF0">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E38545AE-81EC-46FA-9B39-FB05D4F40582">
    <pav:createdOn>2014-03-31 10:34:44 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:exact> Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles).</ao:exact>
    <ao:suffix> Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E38545AE-81EC-46FA-9B39-FB05D4F40582"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07AF0E1C-FB1E-413A-8673-A37109B1A62F">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:442430E7-389A-467E-BBB9-C440249A2205">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3A, *3C</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74CE124E-02A4-4A40-ACA1-877BF6FF59EE">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:2A932097-EFDE-4BC3-B50A-2357235EA316"/>
    <pav:lastSavedOn>2014-03-13 04:28:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-13 04:27:39 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:0BCC8D59-3133-47D7-A7B1-33AEA32D683F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:68B8CDE5-CF36-42FF-AF3C-924428246A99"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2149C6EF-CB6E-4CBD-A1BE-17C5A03881D2"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEA0830-ACA8-40DD-8D9F-78F87866EE0C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E3DCE7DB-25F9-42AF-8BF4-905E9E4027A8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:80FCC504-904B-4054-BA91-33F2876696EF"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:275D20C4-ABA0-49C9-8CA0-CE21B5A4C774"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:585011DE-2B78-43DB-BC16-4860B73FEFD1">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4764F84A-FA58-414B-84F0-D7FD6A167557">
    <domeo:uuid>4764F84A-FA58-414B-84F0-D7FD6A167557</domeo:uuid>
    <ao:prefix>Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. </ao:prefix>
    <ao:exact>The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4764F84A-FA58-414B-84F0-D7FD6A167557"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-05 15:36:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CCEBADBE-4BC6-41E7-B69A-50F0DD51057D">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2E7FE14-D7B3-4F05-9088-8940CBA8D021">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:826B4026-D31D-4CC2-9C11-824030161DF1">
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:66E46BCE-D1C0-4FEE-9782-5795C4D11F93"/>
    <pav:lastSavedOn>2014-03-31 10:31:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F6A3AEB8-C22C-4B17-A73A-5F1E4D3C8DDB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:2DDD3BEC-4F61-45C8-B334-A382E94D6B8E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF67E3D0-C3D3-4CD4-B895-70A031A8052E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6F877E8C-2C55-432D-8DB8-80CE14A50DE1</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E450586-ED8A-4854-AFFE-35D724A5BDC6"/>
    <pav:createdOn>2014-03-31 10:28:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52C73F4E-45A5-4B1C-B5C6-AAE7CABE871F">
    <pav:createdOn>2014-04-05 13:57:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE6A6223-568D-4AAE-A89C-49AA319D9788"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:240A151F-8525-41A6-94B0-89BF2D5B4B09"/>
    <pav:previousVersion>urn:domeoserver:annotationset:46E035B8-694E-40F2-A898-AB35D9E3D133</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:06D9069F-B714-4BE9-931F-B7D717B435C2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A72F2706-DCC8-46D5-93ED-1CB1BEAC89B5"/>
    <pav:lastSavedOn>2014-04-05 13:58:15 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B04A39F7-A9EE-4865-B7C3-458FB6246DED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5194EC8F-81D4-49A0-ADE9-92D222AFDA94"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5514923D-64AA-41A0-89DF-D04328FC8AE8"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:15D8BCC3-9814-462C-A460-8C95DE79D543"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED1EF381-5C5D-483A-BB09-B2B2686C95F3">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D109A2D9-1ABF-4256-9C5D-787737939A04">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:991AF447-FA2E-4568-A865-00C16B645701">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix> In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the var</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:991AF447-FA2E-4568-A865-00C16B645701"/>
    <pav:createdOn>2014-03-31 00:27:12 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35854347-5E25-4E06-8FE0-3FAE40D98AFE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C3600C1-C32F-4A85-A242-C6AEA8B1BDDA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C3600C1-C32F-4A85-A242-C6AEA8B1BDDA"/>
    <domeo:uuid>9C3600C1-C32F-4A85-A242-C6AEA8B1BDDA</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-04-05 14:17:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <ao:exact>A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome trials.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3B13FCE-B624-427A-8169-8E8BA5CE6CAC">
    <domeo:uuid>E3B13FCE-B624-427A-8169-8E8BA5CE6CAC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>). It is very important that your doctor knows if you are taking a blood thinner such as warfarin because XELODA may increase the effect of this medicine and could lead to serious side effects. If you are taking blood thinners and XELODA, your doctor needs to check more often how fast your blood clots and change the dose of the blood thinner, if needed. Who should not take XELODA? </ao:prefix>
    <ao:exact>1.\nDO NOT TAKE XELODA IF YOU\n\nare nursing a baby. Tell your doctor if you are nursing. XELODA may pass to the baby in your milk and harm the baby.\n\nare allergic to 5-fluorouracil\n\nare allergic to capecitabine or to any of the ingredients in XELODA\n\nhave been told that you lack the enzyme DPD (dihydropyrimidine dehydrogenase)</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3B13FCE-B624-427A-8169-8E8BA5CE6CAC"/>
    <pav:createdOn>2014-08-04 19:55:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:062BE966-4BEB-4364-9138-0368C4A46DA7">
    <ao:context rdf:resource="urn:domeoclient:uuid:0A6FA3DF-4A4F-404D-B7C4-580545510F5E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1F430D8A-1C56-4C85-B1E4-7D879764BF3B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:684DEB11-4F24-438A-9FEB-1A6BAA9E2767"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F240620-91BE-4843-B33E-03E7959F89F9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E57FFBDF-5B83-4A8E-B0FF-EAF9A92CF5D8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B40A4D75-7B63-41C7-9E3F-D717D899B7DE</pav:lineageUri>
    <pav:createdOn>2014-03-31 09:24:14 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D7956072-12AD-4BD6-BAD8-A112393E8467"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C1C14740-937E-444D-806A-8CF4FDDC53FB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8559BFF1-73E9-4236-8F95-5AEDBA105C10"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-31 09:24:08 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:32885D72-6EC1-450C-97CD-5635EE42A329"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F81D2DEA-DB8F-47CA-A14E-9C5191A0857B">
    <pav:lastSavedOn>2014-04-05 15:28:13 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF440220-03B7-4A3A-B485-7718DB5337E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D53DDA2-4DC2-4C6F-9A6F-676B4E30032E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <pav:createdOn>2014-04-05 15:27:22 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B3C45053-B687-47A2-BC3B-6F24989DCD68"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8511084F-F493-4148-8C31-16FDEA7C26C9"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:85BCED0C-4294-49D2-BD75-119C23BD8293"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DCADFC08-6D38-41F7-A21E-3B48E106AFC0</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:986D129D-5352-4736-A5CA-C493341B06B0">
    <ao:body rdf:resource="urn:linkedspls:uuid:1251D584-05EA-4CF8-80FC-10E3FEDB7270"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0E52ED2A-ACCC-40D5-B641-BCCC55EFB1A4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-22 18:07:39 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9B9E7CF-06A9-4A88-BB1C-FA61FD224758"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-22 18:13:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:77C084D3-12B1-43F2-9CC0-51B291BC3723"/>
    <pav:lineageUri>urn:domeoserver:annotation:0C67BEB5-FDF2-45AA-AA83-95CFBA3412D7</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:308C686D-59C9-4C6B-BEB2-B9157C1C47F8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6109457-C6B6-48D5-9ED4-CF1EE9C4CC17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C57DECE4-94D2-4E66-B95D-0B92ED09F101"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11D6F896-9E64-4FC1-877F-B1EBC732316A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7BD20C41-372E-4363-BD26-3680C8FE9C9F">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5460E36B-8649-4E6B-ADDB-97AAB6BE01FB">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:771DAD36-FDFF-4326-8752-7D37A9631792"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F622CAE4-2C4A-4D35-AAE4-52D0FE00BB7A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:39FF81A6-2ABD-4B50-BF46-B2316E7869AC</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-04-05 15:30:19 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:27AB9E5B-B171-4C45-B8C1-05118EE67913"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D31B622F-C174-4F7D-BAF4-793A9A8636EC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC28F8C1-5BBE-454C-B415-4F511895791A"/>
    <pav:lastSavedOn>2014-04-05 15:30:22 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:294E3750-362F-4FE6-90F5-16F26618EB8C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E173CFF-7AAD-48C8-9F3E-CFABD85C4AD5">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF5BD2DF-A230-4457-84BA-3BD31B498F42">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>-1639G&gt;A</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:694463F2-3B25-4313-BF76-A95FF8707C03">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37CA09E5-F358-49C4-BA0D-E7CD4C8107AC">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83C6A2FD-3A87-4268-8958-BC9996F17280">
    <pav:lineageUri>urn:domeoserver:annotation:F6A13C8C-C750-4748-9380-E62BF140926B</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF7BFA68-8803-4ED6-B362-ADFADE3DD243"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:16190606-ABD8-4160-99D0-3FC9526D8679"/>
    <pav:createdOn>2014-08-08 10:57:13 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C93DC7C-0402-4A68-BAC2-C24F1EE6282A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E690B7CC-1153-4150-A9A7-D2E45B970390"/>
    <pav:lastSavedOn>2014-08-08 10:57:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D411AF1C-0789-4014-AE57-160CCD4866C7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:747EE432-4037-4D95-9292-FEEB7F9998F5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC313370-013E-4D31-9C91-0639B09C70C0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DFED23E1-3FD2-484D-B555-5C9BBB724598</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:75EE9F1E-A916-4153-8DF1-89E9DF696CA4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A">
    <ao:exact>Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 09:01:41 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A"/>
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen i</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:20357999-5EED-49EE-A2FD-ABC698D4E7DE">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42A10237-EFE8-4EC6-A4A2-556FF94B3F74">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-change-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not change the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Not change from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C6C6DFC-27DB-403B-93F4-AA8F21F6BE11">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8957BAD4-9280-4C41-93FC-626858C292B6">
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n\nClinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n\nGenetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <pav:createdOn>2014-04-05 16:15:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8957BAD4-9280-4C41-93FC-626858C292B6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>             </ao:suffix>
    <domeo:uuid>8957BAD4-9280-4C41-93FC-626858C292B6</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>216A1896-63FD-45FE-ACBB-80F82EB9ACE5</domeo:uuid>
    <pav:createdOn>2014-04-14 14:04:16 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6665398F-6567-4B45-B480-3780C704AF11">
    <ao:body rdf:resource="urn:linkedspls:uuid:3697CCA7-3EDD-4F5E-A8C1-95621A186214"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:00BD4F7B-1E4D-4A8F-8252-8A0ECFB48473"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7BB459F1-73DC-47B9-8697-FE88C063462C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2336D1A4-8B85-4B22-9E42-5C0D4CCF2690"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6AB46253-D7F4-4C5F-BE59-387B8EA69282"/>
    <pav:lastSavedOn>2014-04-05 13:53:59 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:CE5BCC1A-A623-4C88-A17D-090E8284CD20</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A516DDD-4828-4B59-B4AF-626A4955BF4D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D58ABFB7-7267-4EFC-9CE1-CD3A95126950"/>
    <pav:createdOn>2014-04-05 13:51:52 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA0F134C-C2D3-4E23-AC59-D8499F4D1688"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28FC1226-CCD5-41C3-9CDC-FBA0E5A59645">
    <pav:lineageUri>urn:domeoserver:annotation:14809635-2A09-43E9-9121-3DB5BF623E03</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D5BB4439-E5AB-4498-903F-279826D0E714"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA824956-AE81-47F1-9357-A368B65EAA14"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C9E8E94-0F78-4F71-ABB4-FDEA73577724"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1F430D8A-1C56-4C85-B1E4-7D879764BF3B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:471BC08B-331A-4DED-B600-1BC41F78F8E4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-31 09:32:37 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6122C146-F947-43E6-A37B-054986F13726"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84254A2E-F8CA-4431-BCC6-03588023BB79"/>
    <pav:lastSavedOn>2014-03-31 09:33:27 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FA6D6EF-BA00-42D2-8690-515DF2623380"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9">
    <ao:item rdf:resource="urn:domeoclient:uuid:2BFB965F-D1FB-464F-A5BF-ADAD50C57F44"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E62D8698-C5C9-4D90-A8ED-34B080403274"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14933636-B0CC-4A29-8AA3-41C40B4481A2"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:31A84B76-BC19-4DF9-B0D8-7A1F05A7A87E"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2B342CE-A4D1-41BE-9933-46296B0395B4"/>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:07B6B442-94F5-4541-9416-C726A6D785E6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:559C0644-E2DD-42B2-BF02-24D4DE62CE3A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B7B29D0C-ED74-476B-8E7E-E1D984A5E594"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:02887C31-D6D3-434D-BD70-6EA1045D8380"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AFBD0952-D063-43AB-9BF8-D2765EC1F590"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B6B7344-5691-4A81-8539-22F0C0A83EE0"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F8BA75B7-A26A-4146-B457-FB4621BD472A</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-04-05 16:22:57 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N57a61d86f3954c1bb64df4fbe2bc00f3"/>
    <pav:createdOn>2014-03-31 00:19:41 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:42854403-5CD5-4B14-9405-3A37D9EE0956"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E1FD229B-39CC-4BAB-8D93-ECB99A7C3810"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23EEEBBF-C789-4C60-A3B7-7E63732C1737"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:462C8AA1-56F4-4DAB-8833-C9765CCE4D3D">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35B7AC3A-BD6E-4708-9E4D-398053CE44F1">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5A57AAE-E3B1-469C-A440-7CFA52375EC2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1B584A14-D17C-45B1-A670-921C8C6D6AD0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N77e4a82d60a742d2bc48f601890e4006"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2014-08-04 19:55:35 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:20520409-EEC7-4EFF-8DD6-BC12649DB326"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:94AC021B-D613-4455-9DB8-31BD437C6D7E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:38047FFE-3CCD-49C1-AD55-511E11EA7254"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E637879C-C01E-4A84-8203-315652BB986B</pav:lineageUri>
    <pav:createdOn>2014-08-04 19:42:24 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:57EB0907-E87B-476C-954C-68657AC1F3A3</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29B730A8-552F-4E0F-9F23-76CAF542C66D">
    <ao:body rdf:resource="urn:linkedspls:uuid:89EF8354-538E-4D1E-8113-DA4B2C6DCDE5"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A335FC5-DF33-46BF-BFAF-E005DC6CC4E2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C504F222-A2CF-4F52-B31C-954FE303DF26"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AE5C8BE-EDDF-4D74-AF9A-7F3C72DCB62D"/>
    <pav:lineageUri>urn:domeoserver:annotation:A55E1574-873D-40AF-BCC8-C18B1404B37F</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:35BB37D2-E4A1-4CD9-B58B-43AAF9ADE24E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A68FF7A-67FC-4F64-821D-48C557589E3E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E631D057-E51B-45DB-BFB7-AC3BD397D24E"/>
    <pav:lastSavedOn>2014-08-08 10:57:19 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DFED23E1-3FD2-484D-B555-5C9BBB724598</domeo:belongsToSet>
    <pav:createdOn>2014-08-08 10:56:25 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:284642F9-56EF-4D2F-A2B9-88FF22D7B49D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:494343BB-6FFA-4939-B751-481C13CA9DC4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A97D100-3273-419A-8927-856738C54D03">
    <rdfs:label>Citalopram</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB7D6096-DC59-4EB6-9CCE-BE2A132775E0">
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D2F4F60-D852-49E3-BB2B-44066FA6486A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3D2F4F60-D852-49E3-BB2B-44066FA6486A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Application of HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive Asian patients treated with carbamazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as AED dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied.</ao:suffix>
    <pav:createdOn>2014-03-31 11:36:00 -0400</pav:createdOn>
    <domeo:uuid>3D2F4F60-D852-49E3-BB2B-44066FA6486A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:771DAD36-FDFF-4326-8752-7D37A9631792">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1E0882B-40CA-45B0-8F3E-82475F71D568">
    <ao:exact>In an observational study, the risk of achieving INR &gt;3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.</ao:exact>
    <domeo:uuid>F1E0882B-40CA-45B0-8F3E-82475F71D568</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-05 16:02:47 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F1E0882B-40CA-45B0-8F3E-82475F71D568"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>4</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C8BA4E0-09FA-4D55-8F6B-E48072DE18D9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D9689F2-4FA1-42BC-AF7A-85B246D98E51"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D93754D-37DC-487D-9E3B-4292BDFEAA71"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA938CDA-3F80-4691-AA39-EEA9047C64AD"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACAD1467-1EAA-4047-A039-2BD0A336E02C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-05 15:26:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3CCED7A6-21A9-4D3F-8F4D-7F78B4D22EFC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:9CE91031-3A16-48EB-8A5C-F29863F487A7</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:5031419A-DE0B-4707-825D-60B5CA04FD01"/>
    <pav:lastSavedOn>2014-04-05 15:26:37 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86445432-60AC-48E9-B4D3-3174134B2621">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D2F3687-643A-4C09-8059-F59606AE90E9">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:227925F9-980E-4C3A-A58F-0BC3D56216FC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E534935E-978B-49F9-BD34-30E0B499285A">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A4CB19A-F445-468B-872A-2BADFCF31271">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85BCED0C-4294-49D2-BD75-119C23BD8293">
    <pav:createdOn>2014-04-05 15:27:22 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:85BCED0C-4294-49D2-BD75-119C23BD8293"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>85BCED0C-4294-49D2-BD75-119C23BD8293</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone. Among these patients, 54% had node-positive disease and 46% had node-negative disease. </ao:prefix>
    <ao:exact>Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).\nThe effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7E9F34C-FBC5-4A10-BA14-E092F7B3F910">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:187A1491-8B85-4716-9532-45AB1D9E5913">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D411AF1C-0789-4014-AE57-160CCD4866C7">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>G6PD</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F45B669D-6119-44E3-AF92-7C631E9FCF91">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F45B669D-6119-44E3-AF92-7C631E9FCF91"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>NSABP B-14, a prospective, double-blind, randomized study, compared tamoxifen to placebo in women with axillary node-negative, estrogen receptor positive ( 10 fmol/mg cytosol protein) breast cancer (as adjuvant therapy, following total mastectomy and axillary dissection, or segmental resection, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F45B669D-6119-44E3-AF92-7C631E9FCF91</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-05 15:31:36 -0400</pav:createdOn>
    <ao:suffix>One additional randomized stud</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31299198-E64B-40FF-A5AD-23D8B3B7A5BF">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A6FA3DF-4A4F-404D-B7C4-580545510F5E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A6FA3DF-4A4F-404D-B7C4-580545510F5E"/>
    <ao:prefix> </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed </ao:suffix>
    <pav:createdOn>2014-03-31 09:24:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <ao:exact>PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AEA168CE-C26E-449B-81B7-61CB074395E3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3DBB4339-D188-4B25-BC32-0265176C1A6B">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C">
    <domeo:uuid></domeo:uuid>
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and shoul</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C"/>
    <pav:createdOn>2014-03-22 22:09:39 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31A84B76-BC19-4DF9-B0D8-7A1F05A7A87E">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF777739-AFDC-43F3-A8B4-F58883D3836C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:CB024805-C764-4CAB-A3C5-9E86E954C589</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <pav:lastSavedOn>2014-03-31 00:32:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 00:32:29 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:144D94CA-9F40-4777-95A3-126DC102C392"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2FDE0DE-8423-4B35-8195-4D7DEEF0F0D9"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:42437394-462B-4271-AE87-64417F6EAE21"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2A7C468-3183-43C3-96A6-6F03CDA190EF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:418940C6-C826-44B4-86A4-C4CD12F7A471">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF9D0319-BDCA-4028-ADA1-E57A1130A0DA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</ao:exact>
    <pav:createdOn>2014-08-04 19:33:16 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EF9D0319-BDCA-4028-ADA1-E57A1130A0DA"/>
    <domeo:uuid>EF9D0319-BDCA-4028-ADA1-E57A1130A0DA</domeo:uuid>
    <ao:suffix>In addition, certain drugs inh</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AMITRIPTYLINE-e454fe56-0896-4d40-862c-95ef0fc0bc82.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1F430D8A-1C56-4C85-B1E4-7D879764BF3B">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:062BE966-4BEB-4364-9138-0368C4A46DA7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9300E29A-D993-4A70-9BF5-ACA2C9539CA0"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-04-14 15:24:56 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-03-31 09:20:26 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C11B6B8F-9C21-437D-876F-40B9FDD65488</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:28C9239B-4580-4643-A1B4-349E39BA5FC0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:28FC1226-CCD5-41C3-9CDC-FBA0E5A59645"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N4dc444063a974317acaa19185b635034"/>
    <pav:previousVersion>urn:domeoserver:annotationset:A93943B4-59DE-45BE-94FC-5133B0E564DA</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:673ABC1F-282B-4E25-B6A8-D9FA1CDC54D9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5096B64A-7898-4023-B577-E6F070F5D83A">
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:291E17EF-EB0A-419A-9930-D6B0402634E2">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AED16BD-776D-456D-A6A7-E6A794974FC4">
    <rdfs:label>Aripiprazole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B1BA362-4052-4B63-A708-937F9D8B21B8">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CAA75D7-86F5-492D-9E3A-3E78584F7E23">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-05 13:58:07 -0400</pav:createdOn>
    <ao:exact>CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0CAA75D7-86F5-492D-9E3A-3E78584F7E23"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <domeo:uuid>0CAA75D7-86F5-492D-9E3A-3E78584F7E23</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25FFE7A0-65C7-4E16-A329-4A3275DA47D1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:660A71B3-3C67-440B-A0F5-DD14CC208C48"/>
    <pav:createdOn>2014-03-13 04:31:24 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-22 18:13:29 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FEFE02F-7BE5-4491-AC45-494E15972825"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD256387-6739-48CA-A137-E3FBCFE0276D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:3B0B0B79-2260-4C75-9F6E-1DE7BE67410B</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:524FA29B-279F-4873-ABB9-881E8E3FADC2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:418940C6-C826-44B4-86A4-C4CD12F7A471"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD149D7A-E9F0-440C-894B-8D7ABD8F1CEA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:01E309AD-60C5-49DF-9CE3-9B6BB3701C29">
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9300E29A-D993-4A70-9BF5-ACA2C9539CA0">
    <domeo:belongsToSet>urn:domeoserver:annotationset:1F430D8A-1C56-4C85-B1E4-7D879764BF3B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A22312C9-4AFD-4D76-853D-23AD2C8DBD03"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4A61B93-A79D-4424-B631-2CACC8F8864B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E575B6A-60A7-4FCF-AC39-1B97DE85AB2B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:73202F59-2CAB-45EC-A6D1-ED8AEF4F8ABA</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FD888C51-22E2-46BE-9A6D-62F06CE2FB1E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:63CD03D5-538E-4158-8C99-312CA91D33CA"/>
    <pav:lastSavedOn>2014-03-31 09:33:27 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 09:33:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4560117-AA1B-4B62-B27C-602B0530F074">
    <ao:context rdf:resource="urn:domeoclient:uuid:F753BE50-C871-456B-8398-1CB493CA2C50"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DDEF9222-4731-4C1C-A5C4-C46BA8A44143</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:51579B91-1412-4E4A-AB7B-CC97141050D4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F8D1B18-EB03-4CA0-94D9-8576A215322A"/>
    <pav:lastSavedOn>2014-04-05 16:18:00 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A1A1D97-0135-4D02-BE6F-5AC67E8421A7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-05 16:17:57 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D45FCAE-03CD-4E86-92EE-FF587EDE2CD7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:165964F5-7C38-4E72-90C9-A6806C4A2BEF">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB4D099C-DAE0-44E6-9DED-57D52563F4BC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:82EDBD4A-D28C-4573-A121-F077D37550FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6C686CA-6C8C-40E4-851D-6DCA8476D1B3"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0DE3E89-95FD-44B5-BD90-ADA5087080D0"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B8B819A7-A923-499B-85EA-017C36BBFF19</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:6BFE0B84-A189-4CBE-9F0E-9F4FFFEB4DB2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F15D4128-1B73-4F0C-B05A-CE3BCB6BD992"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:81568992-1F6F-4A94-BFA4-E950385F06E1"/>
    <pav:createdOn>2014-03-22 18:05:17 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-22 18:13:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:BAF13428-5D58-473E-878D-C4A2CE55D839"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:835F173A-438C-45DE-A6D7-D97785DF01E9">
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89FE2A25-18DD-476D-B0A1-AD253E4442DB">
    <ao:body rdf:resource="urn:linkedspls:uuid:B98BD87A-C676-4189-9E5E-C6C44FA2C4DC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F54C758-D4E0-4429-966D-86A62BCB99DE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D487312C-26D1-49CD-A7C0-B5ED285FF3FB"/>
    <pav:lineageUri>urn:domeoserver:annotation:FEEB330C-ABBC-4458-8E53-6A1093EED63B</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:5DE78EC2-5AE5-409E-A320-89BD6ED38772"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:5940DFA3-0716-4600-B609-84C37191F161"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F118E273-8979-4E21-9C19-2D9CFB1C0544"/>
    <pav:createdOn>2014-04-05 14:23:38 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9DAD48B4-7C26-41F3-AD42-9012780017DA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5009C4FD-C9E9-4D13-AC05-BC449D443FEE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-04-05 14:23:42 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B888192-2482-4BEE-A04E-072CF1FAB33D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2,*3,*4,*5,*6,*7,*8</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA">
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1161E82-9339-49AD-AAC4-F58471BF51EA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F007A3E0-FB60-4CDA-9A07-BC6E3A3F95D1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:73C1A497-1E52-406F-A8A2-D5631C088F35"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0C9BAA5-CE9B-433F-BC0C-0552964F164A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C11F474C-5FE5-41F1-BF97-71793CD0C79E"/>
    <pav:createdOn>2014-03-22 22:05:18 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A58610AC-F282-4291-8FE6-C83CF8DB27A2">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbffab71c5a354622885420f6eded1b3e">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B4047A9-42A5-46E5-9848-74F5005C2F7D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2AFF2F69-98C3-4807-971A-2B2183C43330">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:486733A1-6BA0-491D-87AC-EA70B14043DF">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52378A32-A66F-4759-B323-7D93B80FFBB1">
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DC4A72C-CE40-447F-9659-46FA2BF64DA7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DC4A72C-CE40-447F-9659-46FA2BF64DA7"/>
    <ao:suffix> [see Dosage and Administration (2.3)].</ao:suffix>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-04-05 13:53:47 -0400</pav:createdOn>
    <domeo:uuid>0DC4A72C-CE40-447F-9659-46FA2BF64DA7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96964BFA-354E-4532-B474-3F349EB93C0A">
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEA0830-ACA8-40DD-8D9F-78F87866EE0C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF354C62-D918-4027-A939-E0A37FC7CC79"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C0B6C84E-33E9-426C-B4B7-EDF94F342325"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:500D2BFA-D162-492A-84D8-7565B933C44A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1692D076-721B-4852-B172-DACBB93A44DE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C302DD1A-5312-4CBB-84A3-A9157160B0CD"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:51743ED0-BC14-4FB0-A750-4DB17BE99915"/>
    <pav:lineageUri>urn:domeoserver:annotation:942180E1-6407-47F9-9BF1-FB341A62D01A</pav:lineageUri>
    <pav:lastSavedOn>2014-03-13 04:28:47 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:30590FDF-8852-4985-8AAF-0D446C7B20CB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:429FAE35-1F2E-49B3-8C8F-435F1C92F106"/>
    <pav:createdOn>2014-03-13 04:10:49 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:31DDB828-1349-49DC-BBFE-E00734E9921A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A68FF7A-67FC-4F64-821D-48C557589E3E">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>G6PD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007749</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E4A83A6-A990-4861-BCF6-169897B6B8D9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype. </ao:exact>
    <pav:createdOn>2014-03-31 00:20:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E4A83A6-A990-4861-BCF6-169897B6B8D9"/>
    <ao:suffix>Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29724E2D-1960-46FF-A0D8-F4983E7F4E75">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F3529E8-EC47-4F12-93B6-0C90DB27001C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6197856-D7DC-4524-90AF-D1E78B927C1F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F2B3AA26-9162-428D-9542-DFA6CC39645F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-31 11:41:19 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:05FBFE1D-7AF2-45D4-99A1-A5A5C734EF21</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:31707A99-58BE-45A2-8CF1-E07C41D243DC"/>
    <pav:createdOn>2014-03-31 11:39:14 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:84CDF7A6-6379-47FD-AE15-BDF59079AC5B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:80AFE396-60AD-4068-9D06-83718E17862F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:87600A57-7205-475E-B752-EEEB82A227DF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03D084C1-E526-46CF-8BB8-43BB154BA0EF">
    <ao:body rdf:resource="urn:linkedspls:uuid:BD507E05-6BCF-49EE-A25A-B71210D9C9C6"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:26381EB6-C0A8-49A8-BEBF-A8377DBA26C8"/>
    <pav:createdOn>2014-08-07 12:54:45 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CCB44E3B-1232-4E13-B6EF-4FAE9CE313C9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA0CC3C4-BB85-43B2-9E26-22491D1149A9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:E768CCE6-FC0D-40B7-8C2E-A1397C4AE4DF"/>
    <pav:lineageUri>urn:domeoserver:annotation:A18EA8A0-994F-47A7-A5FF-6C592E7BA215</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3705BEB-6268-4FDB-A31F-0C593030101E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:9C2115AF-F110-4EE2-85ED-380B15F3C990</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E3C7CAE-0309-46E4-BDC9-AD2A529B0C68"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C9DDA46-72CB-41F2-8F6B-9B06E851D824"/>
    <pav:lastSavedOn>2014-08-07 12:55:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1CB11C3A-49AC-4CCB-B8BF-B376CCA3FC2F">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A99C9B5-B169-4344-83C9-569C10A54723">
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9053400-125E-4E9B-8276-7F18C8B85E71">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:25D3033D-AEC4-4685-B22F-9ABAB9A62688"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-31 10:29:51 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:6F877E8C-2C55-432D-8DB8-80CE14A50DE1</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F355DB1-F2E0-4D1C-8E14-13AAB95AF32B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CCEBADBE-4BC6-41E7-B69A-50F0DD51057D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:EC18DD8F-9AD6-4420-83ED-4DA3D360372A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0BFFAC07-01A5-4D15-9B29-27CC35619E56"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:202E0251-F3E5-4A87-BC3C-3B5568C95DB7"/>
    <pav:lastSavedOn>2014-03-31 10:31:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:43892A47-95DE-41E2-942D-9045332A7579"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:DFED23E1-3FD2-484D-B555-5C9BBB724598">
    <pav:createdOn>2014-08-08 10:44:31 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-08 10:57:19 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:83C6A2FD-3A87-4268-8958-BC9996F17280"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N7e93a99a0c5c4eed8d64bcb0e23a99ec"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:previousVersion>urn:domeoclient:uuid:837E2E45-4C18-4AA2-AB06-263EC99B7E17</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:905C7271-23BC-4B86-8562-99C5DA12A7EA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5C854F0D-6C24-4594-B749-D5DBEC2C1EE6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F4D761CC-A903-47F8-AD08-52A5E7E6A9AA"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29B730A8-552F-4E0F-9F23-76CAF542C66D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:834DB3E7-6992-440B-A032-B1037CC4E06F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:01AED084-BA2D-45B8-8FDF-A1437A67CAFA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:E07FEF43-5464-4340-AB17-7DCF9775948D</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:778855ED-2195-47AA-B944-D2FC7015EEAC">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB8C29B4-DAF1-49C7-B4C0-F9A3C922D9B0">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:FF2F4189-EA5C-45A7-823E-0B497E77192F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:33B2C016-C14E-453B-A5CE-4FB7B680ACD2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:601FD11F-6A89-4296-AB93-6E510E747B4A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CEDFE1C-AE4B-4114-B8EA-5BC9F86A43A8"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D75632BD-1FE9-4A16-BAE8-E8195344E8BC"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8407F7CB-A711-4DBB-BF88-93BD1283B015"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E4D5687-D441-4894-9473-A7154570A841"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:76AA619E-BB2C-4392-85C3-DD3451E9B993"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F38969D3-27ED-472F-85C7-83C05232C92D"/>
    <pav:createdOn>2014-03-31 10:25:33 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-31 10:26:00 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8"/>
    <pav:createdOn>2014-03-22 22:01:43 -0400</pav:createdOn>
    <ao:suffix> HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:suffix>
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2FE75A6-6A24-4574-9C2C-838F6D9C0521">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20520409-EEC7-4EFF-8DD6-BC12649DB326">
    <ao:body rdf:resource="urn:linkedspls:uuid:A58610AC-F282-4291-8FE6-C83CF8DB27A2"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:260C6870-3C13-4DA2-B87B-5DA88E1CAF61"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A07FA31E-16B6-4FB1-94C8-1F0A5FA4B29D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFF0AA0B-E0D4-4D0D-A73B-8D1EFC8DF7BF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BEF25133-BCDC-4938-883C-8434B942E3DD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:74962CD8-D19C-4A78-B5AD-7A5CA121D1F9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E637879C-C01E-4A84-8203-315652BB986B</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6D7C8C2-85A5-48C6-B3B4-C93C05C0ED36"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1705AEDD-338D-427A-B93B-E5D62C6DB783"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:07AF0E1C-FB1E-413A-8673-A37109B1A62F"/>
    <pav:previousVersion>urn:domeoclient:uuid:BF348064-DE48-4997-9B87-A0E149330618</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:49DBB352-A20E-4BB5-BF17-E97E2B9E4D2C"/>
    <pav:lastSavedOn>2014-08-04 19:48:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-08-04 19:48:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1B584A14-D17C-45B1-A670-921C8C6D6AD0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA351472-1E09-47EF-873E-9BCDB949E496">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:814409FF-CD69-4B0F-B3C5-CF0010960853"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7215D99B-4C7C-4B46-90F3-E5013DDC6ADA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2742B3CC-24F8-4BB3-B4D9-7B40D3BD3390"/>
    <pav:createdOn>2014-03-31 10:42:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 10:43:21 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E964018E-0C78-41BB-A861-1878480EC47A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8CA311B-6880-4B71-9C68-9253C95469D0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD404436-B0A0-4A86-A4BF-0CBB25951730"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8AB88976-04C8-482C-B348-379DD3FEA061"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:35854347-5E25-4E06-8FE0-3FAE40D98AFE"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:973058EB-842F-48AB-968D-9583FA4F2CE4">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:01C60978-F3B0-4FCC-BFAB-4F864F65BA1C">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFF0AA0B-E0D4-4D0D-A73B-8D1EFC8DF7BF">
    <rdfs:label>DPYD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3012</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D5CBE3D-C4E0-4455-8867-F3CF56A56E80">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:520F789A-0184-4286-8FF2-E1F9214F9A6D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Higher event rates corresponds to decreased efficacy</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692"/>
    <ao:prefix> </ao:prefix>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-22 22:14:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6316E18D-ABAA-4576-91B3-A14B067A8270">
    <ao:context rdf:resource="urn:domeoclient:uuid:ACEB6342-E9BD-49A1-A32D-5853FA3C4FDC"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:46ACEFD6-B68B-4706-9724-666A000466DD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:187C74D5-58D7-4466-B5FD-47486A2199CC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 11:30:46 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5DDFC8B-5353-4209-BFF6-2CE49D8A541B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:40F50FDF-8AC1-45FB-8B05-1797ACB0DD04</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-31 11:30:43 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:47ABA217-9567-40AE-B181-951C9C73F456"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:37CA09E5-F358-49C4-BA0D-E7CD4C8107AC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD3749D6-BF72-4361-BFF3-B479BACAB810"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF7BFA68-8803-4ED6-B362-ADFADE3DD243">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8">
    <ao:body rdf:resource="urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF5332EA-A40B-4668-AF2A-6572169A6CFD"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:158713E6-223A-4BE2-8C4A-663906E57A2A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB39F2CB-5442-4479-A939-6FDB899B3B62"/>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 09:04:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A54084C7-81C5-4C71-AEA4-AD05D852A4AB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F140206-4891-4319-B539-857B384767DF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7361D556-97F9-41F3-98DD-3F6C66FA6CCB"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE179C73-2868-4229-85C1-5FFEC1FA8A63">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006678</dailymed:pharmgxBiomarker>
    <rdfs:label>DPD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E88DF83-1F99-4A0D-ACAA-0630C6A3B444">
    <pav:createdOn>2014-03-31 10:22:04 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8E88DF83-1F99-4A0D-ACAA-0630C6A3B444"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:exact>Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>TPMT * 2, TPMT * 3A and TPMT * 3C. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31">
    <ao:body rdf:resource="urn:linkedspls:uuid:990A861C-8128-4BEB-B3B9-1F189E42FDD0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA844F00-D043-44E7-BDA4-C852FD04CEA0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA126820-256D-4C0A-BAEB-B5A5EC5C0F33"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A8CCA59-FFB8-48B8-8E0F-797519671DF1"/>
    <pav:createdOn>2014-03-22 22:11:34 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A"/>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D50CE73F-31C8-4AAD-BF2E-EEDBE1F40F42"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N29a7495514b34265bd6bf1e51f04c536">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8EE31FDE-D252-4C26-AE66-BA41A977CFC7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:88CEE075-27A4-45CF-9AD6-7D8200984247"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E035B94B-194E-4AF0-9111-8C1C23B403CE"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3B3FBA15-03F1-4FEE-9A6F-995B333D2B36"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3FC1B95-BF74-48EA-BDD9-D5D59413425D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:20357999-5EED-49EE-A2FD-ABC698D4E7DE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:9C2115AF-F110-4EE2-85ED-380B15F3C990</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A3FE565-F624-4631-B7B9-ED12E84E6F92"/>
    <pav:lastSavedOn>2014-08-07 12:46:13 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C2C497F-8D6A-4163-BD73-962E88B2A0AA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D83A0668-C43F-4010-87C9-8F47C20C71E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4ADCD079-2F7C-4A13-AF93-09BEC50EB85F"/>
    <pav:previousVersion>urn:domeoclient:uuid:1974F1B4-BE4E-45BB-B6BA-6175EBB4AFFE</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:152C73E3-8FA1-4DCE-8BE9-A110F7ED502C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-08-07 12:45:23 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:53DD663C-1281-4EBF-9EA1-CC825BAC4830</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:76CA930A-8FB7-4D0E-B8A0-16806DF17946"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A262DEB7-6684-4B04-8389-10AF1D25D441"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0B08DC7-31C0-488B-86C2-1475F4406E78">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0B08DC7-31C0-488B-86C2-1475F4406E78"/>
    <ao:exact>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-22 20:39:32 -0400</pav:createdOn>
    <ao:suffix> Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression. Codeine is</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73D3D865-BF7C-4E56-ADFB-B431179B8C4B">
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8195F57-B3E9-4619-9637-6684DBB32A9D">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B">
    <ao:body rdf:resource="urn:linkedspls:uuid:16C3120F-E19F-453E-9222-0C4CAA7503EB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8624524-9CEA-4109-AD60-7041876D4E8C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:19F33D58-FE1E-46C1-B076-70725190FF1F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:961BA50E-515C-49B1-9E13-9A89032FBDD0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:15CFACDA-93A0-4CF4-81F6-D807D5C1DDD5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:549211CB-8AFF-415A-B1BD-09BC38B52755"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547"/>
    <pav:createdOn>2014-03-31 09:01:41 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:092FCB2C-F420-49DE-99EC-10B74EE7E198">
    <ao:exact>Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:092FCB2C-F420-49DE-99EC-10B74EE7E198"/>
    <pav:createdOn>2014-03-31 10:21:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8EF07C79-BA22-4296-A471-A62FD37EDA7D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD0D46AB-DE27-42C2-ACF0-73D745788024">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD0D46AB-DE27-42C2-ACF0-73D745788024"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>dose based on the expected maintenance dose, taking into account the above factors. Routine use of loading doses is not recommended as this may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>Modify this dose based on consideration of patient-specific clinical factors. Consider lower initiation doses for elderly and/or debilitated patients (see</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 00:33:55 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99D3FF5C-D7DF-4E2A-AE41-D86E28EFC2CC">
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1596CAE0-C0D3-4FEC-BA0A-D5D14218A61D">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B661122E-6D89-4F4F-ACAE-7F95B60C3B97">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34066-1) BOXED WARNING</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34066-1) BOXED WARNING</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:238F68F4-362D-4185-A6FE-D064350DDEA0">
    <rdfs:label>intermediate-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0328750E-3EFA-4DAD-8B0B-38538F765780">
    <ao:body rdf:resource="urn:linkedspls:uuid:ED1EF381-5C5D-483A-BB09-B2B2686C95F3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF9D1335-3298-4C64-8A6F-68008EB52A2C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7304D83C-0ACB-4723-AA46-CEEC360AD87B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B320883-7E40-4EE6-934D-64133E41A51F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-22 20:42:43 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:6943D8EC-25DB-4498-B7EB-229A9093F33B"/>
    <pav:lastSavedOn>2014-03-22 20:44:27 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:D8F119EC-E02E-4B11-A39F-D8CFC47B7109</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:14BCF077-5B5D-4F5B-8368-DC46C36ED32D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1CB11C3A-49AC-4CCB-B8BF-B376CCA3FC2F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4ADE6966-459E-4B08-AFED-5B81E95AB46B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:667C10F3-838C-4BD0-B241-8DA04851D35E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D34F5E9-96AA-4877-9714-2B8FC0A4FB80"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF3B359B-24F3-4160-9884-CBC1CB42FEBF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B98BD87A-C676-4189-9E5E-C6C44FA2C4DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BAC335F-B80C-45A8-A4D7-41C65A7105FB">
    <ao:body rdf:resource="urn:linkedspls:uuid:612F4BF8-4B3A-4752-B0B4-E69D8D8CCF36"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C6C6DFC-27DB-403B-93F4-AA8F21F6BE11"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:16C47415-C82E-41CD-A17D-865319AF5A1B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:36466390-592B-408A-A206-8E537F60D10B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5A57AAE-E3B1-469C-A440-7CFA52375EC2"/>
    <pav:createdOn>2014-03-31 10:36:26 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lastSavedOn>2014-03-31 10:36:34 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:79DDFD55-7F6C-4B87-8668-D61DCBD3B340"/>
    <pav:lineageUri>urn:domeoserver:annotation:362DCE1B-41AC-4539-BEBE-E46FCB9F96F8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13E8EB9A-0971-4A3C-9333-ED18408DB6FB">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix> Modify this dose based on consideration of patient-specific clinical factors. Consider lower initiation doses for elderly and/or debilitated patients (see</ao:suffix>
    <ao:prefix> dose based on the expected maintenance dose, taking into account the above factors. Routine use of loading doses is not recommended as this may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation.</ao:prefix>
    <domeo:uuid>13E8EB9A-0971-4A3C-9333-ED18408DB6FB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:13E8EB9A-0971-4A3C-9333-ED18408DB6FB"/>
    <pav:createdOn>2014-04-05 16:16:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B9C6119C-3C0F-46B0-8614-1EBBBA8066D4">
    <rdfs:label>HLA-B</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6769DEE-47BA-4783-AEE7-77428FCD6B4E">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58C43417-BD70-43A8-946E-AF85EE8B542B">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777">
    <ao:body rdf:resource="urn:linkedspls:uuid:1523E385-B7C2-4B6B-B365-918336BC31D4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E33403E1-9E18-4800-B583-B5ECE131DDBB"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7"/>
    <pav:createdOn>2014-03-22 22:01:09 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A572B29E-DA06-4D69-9DBD-1D5AA92BBB2C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B0497B5-2A21-46A2-983F-7992EF169EE9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:6535077F-E961-482C-8B57-F786CEC0E8B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D742086D-FBE4-4E5E-8129-F5C607743253"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lastSavedOn>2014-03-22 22:03:57 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4975EC23-CABC-4051-A0E9-C5B3FE1A0319">
    <ao:body rdf:resource="urn:linkedspls:uuid:0974CEC2-E37C-43A6-B1C8-AB0F4FEE33A9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-31 11:26:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:04168134-D13A-48ED-B29A-33D10973411D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C23F3CF2-7C50-4437-9BD9-FC11F54CDF3E"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:569FC6B8-F847-4E16-8DC6-2565BB94DAC8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:40F50FDF-8AC1-45FB-8B05-1797ACB0DD04</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:79E7780C-E197-4433-BC48-27D6D8269513"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <pav:lastSavedOn>2014-03-31 11:30:46 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2F47C0B-E158-4C14-8DDC-CDF53715554D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F">
    <pav:lastSavedOn>2014-03-22 22:22:32 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AEBF040F-C6A6-48A1-B676-CAAE042125E9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B8FAA54-48A6-4B88-A9A5-5D1373EB3B83"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA2F9D10-3477-4544-BF32-2176E0DB7BE0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:073BA57C-2916-4E35-9AF3-AA99E504958C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8063FB58-0C19-4F4D-87DC-7AFA705FCE00"/>
    <pav:lineageUri>urn:domeoserver:annotation:421C505C-D5B7-4F6A-BA3F-FDEB87152F0A</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94"/>
    <pav:createdOn>2014-03-22 22:20:08 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F354582-DE01-47DD-929D-B501E8EB5B46">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6669B83-B750-4BCE-A012-641844F7058E">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51">
    <ao:item rdf:resource="urn:domeoclient:uuid:ABA15473-2E51-4DEB-80EE-FFC28822C587"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F26FCFF9-482D-4C5F-8329-6E85F2D98D57"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A0A6E639-4576-459E-8B02-5BEA74529A1B"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:E32B1380-2520-4C2E-8368-55260433604F"/>
    <pav:lastSavedOn>2014-04-05 14:23:41 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6665398F-6567-4B45-B480-3780C704AF11"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A17A0520-0313-4484-8803-C9CA03B20B66"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:52C73F4E-45A5-4B1C-B5C6-AAE7CABE871F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:85F385E4-9413-42B6-8DB2-0C7BC7FF3E08"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:89FE2A25-18DD-476D-B0A1-AD253E4442DB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F920E758-A4B8-4469-8C81-78234C8F1BE1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:FC8004B8-4960-4BB3-9A93-4E98AF7609EB"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <permissions:permissions rdf:nodeID="Na9191ddb5a6b46b38da84b79d6faaf9f"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8927CE51-5237-447F-8CA7-F9F9EA7F48DC</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:790C43E6-17D7-494E-AF4E-E015257A54A5"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:224881D2-F277-4416-8846-C1FFCA3A476D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <pav:createdOn>2014-04-04 18:33:09 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:02D03D00-AEEC-46B6-AF1B-5AA944239EE8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:463DA05A-C9F4-4374-B46A-88AD1B544247"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C6408597-CB34-4462-B95D-5D3D7A2E00A3"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:42490B2B-BD32-4D24-864D-EAB7E9D9DB05"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6588EE1-9AA6-48E8-8A53-8CE76A8CF524">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>(5.1)</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 08:55:42 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33C9F7CE-B041-40EE-8E53-5C94B51B626C">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CAEB6DD-B050-435A-96A3-80DA7E44D15C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A524395-D3F0-418A-8DBD-D4B470A69417">
    <rdfs:label>Citalopram</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e143044e90f26014518a19cf70063">
    <foafx:lastname>Consensus</foafx:lastname>
    <foafx:homepage></foafx:homepage>
    <foafx:name>PgxConsensus</foafx:name>
    <foafx:email>codehop.dev@gmail.com</foafx:email>
    <foafx:middlename></foafx:middlename>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:title></foafx:title>
    <rdfs:label>PgxConsensus</rdfs:label>
    <foafx:firstname>Pharmgx</foafx:firstname>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D45FCAE-03CD-4E86-92EE-FF587EDE2CD7">
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42FD1B02-37D3-44AF-BF17-1F9F35955DED">
    <ao:body rdf:resource="urn:linkedspls:uuid:91077014-6C54-4675-94DC-46F4E4340867"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-08-04 20:15:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACCBA572-A5EC-4D2D-B2EA-B8F9D87DBFA5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2FC0361E-34A6-4ABA-9BF0-68DEC792FC43"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:4E7354E9-7EC9-43A3-9085-68D7F5B5FF5C</domeo:belongsToSet>
    <pav:lastSavedOn>2014-08-04 20:16:17 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA52B62C-8357-418B-89FF-C4533051A4A8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C19D1E6-4AC6-4752-869C-72A7C1CD4A47"/>
    <pav:lineageUri>urn:domeoserver:annotation:153C364B-6DDA-4896-A7AE-A2C4038F6985</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5C0696FE-A773-429A-9F0F-FECCA3ADA78F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2022E8DF-EF29-4D97-99BA-C818C7DF1CAD"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E95F4032-CCE7-4649-A5BB-0E058C007B7C">
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:648B76D4-14FF-42F7-A62D-19B52C07FAD0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:40F50FDF-8AC1-45FB-8B05-1797ACB0DD04</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CF1DB3F-D571-4659-87C3-A8418E8E1024"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:57E28BDC-5839-4CA3-A456-7AD2FC18721C"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7241BFA4-7117-43E4-AFE8-A1EB7220D99C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2AFF2F69-98C3-4807-971A-2B2183C43330"/>
    <pav:lastSavedOn>2014-03-31 11:30:46 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:86445432-60AC-48E9-B4D3-3174134B2621"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:81E91DC4-4573-49FA-BD0C-874A40A0B5CF"/>
    <pav:createdOn>2014-03-31 11:23:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B63EEDAC-49F4-4BAE-B608-CFF4F96C4A7B">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>G6PD</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007749</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BAF13428-5D58-473E-878D-C4A2CE55D839">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5194EC8F-81D4-49A0-ADE9-92D222AFDA94">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB838C8F-5589-40AB-870E-B48F04B59FE0">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2F47C0B-E158-4C14-8DDC-CDF53715554D">
    <domeo:uuid>D2F47C0B-E158-4C14-8DDC-CDF53715554D</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2F47C0B-E158-4C14-8DDC-CDF53715554D"/>
    <pav:createdOn>2014-03-31 11:26:03 -0400</pav:createdOn>
    <ao:prefix>Carbamazepine Extended-Release Capsules should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. </ao:prefix>
    <ao:exact>Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:601FD11F-6A89-4296-AB93-6E510E747B4A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4336CA42-12B1-428D-B253-04717B03FE04">
    <pav:createdOn>2014-04-05 16:15:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FF427BD-C1B1-4D0C-BDFF-8CADC74AD460"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <pav:lastSavedOn>2014-04-05 16:18:00 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7B2733E-8102-4490-A2DE-08845682375B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DDEF9222-4731-4C1C-A5C4-C46BA8A44143</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2F20682-8D03-4BAB-B71A-98BF97B5D721"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BABEA1E-A976-4ED1-94A6-747F34824572"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.</ao:exact>
    <pav:createdOn>2014-03-31 09:04:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FBD508F-A001-4AFA-98B6-03BE9C49A86D">
    <domeo:uuid></domeo:uuid>
    <ao:exact>Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. </ao:exact>
    <ao:prefix> </ao:prefix>
    <ao:suffix>TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable. </ao:suffix>
    <pav:createdOn>2014-03-31 10:30:50 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9FBD508F-A001-4AFA-98B6-03BE9C49A86D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D089E01-D758-4E13-A627-9C4F5DC55FE6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <rdfs:label>Rasburicase</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1692D076-721B-4852-B172-DACBB93A44DE">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84254A2E-F8CA-4431-BCC6-03588023BB79">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DF0573F-1E06-4F3F-8818-9CA8BAAB5223">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9DF0573F-1E06-4F3F-8818-9CA8BAAB5223"/>
    <domeo:uuid>9DF0573F-1E06-4F3F-8818-9CA8BAAB5223</domeo:uuid>
    <ao:exact>The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>In postmenopausal women, estro</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-05 15:18:06 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA4D8CB8-B8F8-4FBB-B8A9-1F499DD7A9C8">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5C5EE19-6E9E-4D65-83BC-A9E5E80ADB6B">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Asian</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9FDBF52F-E105-46EB-B7C2-505A62F6C955">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F15D4128-1B73-4F0C-B05A-CE3BCB6BD992">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D58ABFB7-7267-4EFC-9CE1-CD3A95126950">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decreased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C0696FE-A773-429A-9F0F-FECCA3ADA78F">
    <ao:exact>1INDICATIONS AND USAGE\n1.1Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML)\nNewly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase.\n1.2Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy\nPatients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.\n1.3Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL)\nAdult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia.\n1.4Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL)\nPediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.</ao:exact>
    <ao:suffix>							</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-04 20:15:49 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5C0696FE-A773-429A-9F0F-FECCA3ADA78F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>5C0696FE-A773-429A-9F0F-FECCA3ADA78F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FDB20A03-F525-4339-8EEA-2CFD60F6E2CD">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F649813A-110D-474C-86E0-3807B8F838E5">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4250C6C8-E1BB-44A8-92EB-9ECF059DB59B">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F20CE66-F8C3-45F5-997D-6DA3618A2E36">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A686C96D-11C6-4B43-B7C5-7CEFE89F1862">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:15E88ACA-8339-49D6-8E7D-2735AEA84E01"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A11C27FE-76FA-4738-9CA4-B4F1BC265504"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3668EBC9-213F-40B4-B79E-E760C14351FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B5E4576-3B52-46ED-A373-960974ED6CC7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:53DD663C-1281-4EBF-9EA1-CC825BAC4830</pav:lineageUri>
    <pav:createdOn>2014-08-07 12:50:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1F67E2A6-A5CE-463D-A4E6-93AC42F1736B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:326EB39D-9549-4599-90B2-6D3F04F6D176</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91F0C018-333F-4F61-B4EF-B16606136A9D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0C80D29-6020-4593-B721-8D44A21693D0"/>
    <pav:lastSavedOn>2014-08-07 12:53:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:38A49BE9-743E-4568-A7D3-2B9CBECD8F52"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BFEE0445-4DB1-4335-9E42-9FC2CC6135A7"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:9C2115AF-F110-4EE2-85ED-380B15F3C990</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9ED84C74-7BDC-4251-9AB7-486C16BDEF6B">
    <ao:body rdf:resource="urn:linkedspls:uuid:5CCA2D84-A393-40F3-8233-DAC50B8E925E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F147215B-DCB9-4E3B-B2BC-93F0B2976E64"/>
    <pav:lastSavedOn>2014-03-31 10:31:27 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:6F877E8C-2C55-432D-8DB8-80CE14A50DE1</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C3380386-B2E2-4DC4-87FB-6859267429E2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:35B7AC3A-BD6E-4708-9E4D-398053CE44F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:23479765-E2D0-4F87-B129-EB38C21F3251"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-31 10:18:58 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAB45A3E-C885-423C-8180-616EBB2B70D7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8B38C2C-60A1-4BB9-A29B-91AB3B1103AC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A8CCA59-FFB8-48B8-8E0F-797519671DF1">
    <rdfs:label>Recommended</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEC8BF12-81F9-451B-B43E-5F6ED3A65AFE">
    <ao:body rdf:resource="urn:linkedspls:uuid:E7511CC4-4C2A-4BF1-ABEB-7A7E224C66E0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5FED7CB-8323-4BDC-BD71-E1C16F06B46F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C1EE3F2-8B30-438E-BCF0-903E5A1B07A4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2777A6B3-0358-4D0B-876C-939F5956C915"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:16683E2C-EFB3-4C34-876E-B857B8791568</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E9CAEA4-6AB1-433B-89F7-FB98C740D991"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A5FA49C-7A7C-4C31-A2CB-18FD6E93C717"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-22 20:44:27 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-22 20:44:14 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:683522B3-37B2-4440-ABF6-29F44BC55955"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:5883AF2A-A3C9-4878-B47E-A7F548D38525"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:10FCC8D9-8DEB-49C0-8FFE-CC0378BC383D">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E636CF6F-E042-41D1-AAD8-549FB93E1DF2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:355DB9A0-974D-4BD1-B6AA-3C439661E7B3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>ing 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:355DB9A0-974D-4BD1-B6AA-3C439661E7B3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:exact>
    <pav:createdOn>2014-03-31 00:24:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF3E7D6E-9DB0-4936-A18A-707ABCA6A729">
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:463DA05A-C9F4-4374-B46A-88AD1B544247">
    <ao:body rdf:resource="urn:linkedspls:uuid:238F68F4-362D-4185-A6FE-D064350DDEA0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4897DBA4-A296-4D96-A20A-621B927D8158"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-04-05 14:18:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:20DE2157-9373-4B68-A4AF-834E82048CDF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D213C3E5-F994-412D-8812-5E0CECE9C2BE"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CD60D915-F0BB-41CB-9DAE-18833C8D2C41</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE10C1A9-AA47-4CBA-B514-90670EDD6BCF"/>
    <pav:lastSavedOn>2014-04-05 14:18:30 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:187A1491-8B85-4716-9532-45AB1D9E5913"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:778855ED-2195-47AA-B944-D2FC7015EEAC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FADB7159-1AAB-491E-BC0F-0E9D3E17C759">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Phenytoin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FDB8AA0-86D0-4A1C-9FC4-6789AB6D932F">
    <pav:createdOn>2014-04-05 15:19:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9FDB8AA0-86D0-4A1C-9FC4-6789AB6D932F"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <domeo:uuid>9FDB8AA0-86D0-4A1C-9FC4-6789AB6D932F</domeo:uuid>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8916D51C-B943-4982-88DC-F1B51F15BF9F">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2B3AA26-9162-428D-9542-DFA6CC39645F">
    <ao:suffix> Complete pretreatment blood c</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <domeo:uuid>F2B3AA26-9162-428D-9542-DFA6CC39645F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>For genetically at-risk patients [See WARNINGS], high-resolution 'HLA-B*1502 typing' is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 11:39:14 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F2B3AA26-9162-428D-9542-DFA6CC39645F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:476620C9-1693-43B1-9388-D0A05A007BB0">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDA1AD1E-4296-4464-99A3-8CEA4E171E9F">
    <ao:prefix> </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>HLA-B*1502 is present in &lt;1% of the population in Japan and Korea.</ao:exact>
    <pav:createdOn>2014-03-31 10:51:36 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BDA1AD1E-4296-4464-99A3-8CEA4E171E9F"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE">
    <ao:item rdf:resource="urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31"/>
    <pav:lastSavedOn>2014-04-14 14:04:17 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401"/>
    <pav:createdOn>2014-03-22 21:59:50 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:4BD531B7-C313-4175-81A7-D9BCA0951071</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C"/>
    <permissions:permissions rdf:nodeID="N76b4bb14f5394f7bbd3ca867b70ac4af"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F7E0329-6BF9-4DD0-BC88-17C784954201">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81C35574-1F32-44B8-9423-70E510084484">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:328E2B84-107D-4F11-A6DB-189C90C32279">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:989B7D49-98D9-409A-9E6F-43F710EDFEBB">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57AA2105-BDC1-406D-AC8A-EA8454C64C1F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6B1E14A-EBCE-4D74-B7A4-BF434698ED1E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:929876C3-7A0F-4C27-860D-6ECFBB206325"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:D956BAE8-49DF-4A38-83D0-7D96397F914D</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5EDB7F4-DCB6-4225-9C67-19232653963B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A1249AF-CF60-425D-A82E-E86B80DFAFAC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E81029A-B4F2-4E40-BEC8-C0DA8FF61D0B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8AE4545-2A2F-4FA9-AEA1-0F3A085FD0C8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-04-05 15:57:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:911FE15A-A1D1-45B8-80F8-B2A7A19AF0EC"/>
    <pav:createdOn>2014-04-05 15:56:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F565F96-125A-42EA-8266-29B4F096939C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E32B1380-2520-4C2E-8368-55260433604F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lastSavedOn>2014-04-05 14:13:41 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:012DA029-7E44-4D0D-B210-D01737D086E5</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE31FFA7-9144-46C5-B3C4-AAAE94A99993"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6786A69E-5900-4CCB-A648-E48F53E356EF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C8770BF-5D70-48BF-B2E6-F7ACE2B8D532"/>
    <pav:createdOn>2014-04-05 14:13:38 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C6333EE-9F99-4318-846F-FE03FA8AC3DE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:724637DE-1892-4854-AF72-E081712C9608"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:84CB3302-4893-423F-8351-EC515FEE5767"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:586F4664-AA85-4036-86AE-C71007BEED1D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6786A69E-5900-4CCB-A648-E48F53E356EF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix></ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6786A69E-5900-4CCB-A648-E48F53E356EF"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6786A69E-5900-4CCB-A648-E48F53E356EF</domeo:uuid>
    <ao:exact> Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patients CYP2C19 genotype. </ao:exact>
    <pav:createdOn>2014-04-05 14:13:38 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAEE8F63-75A3-4EBB-9785-D52BCC522BE0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2022E8DF-EF29-4D97-99BA-C818C7DF1CAD">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Delimited medical conditions with semi-colons deu to commas being used within conditions. </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F302B0F-C432-425E-914B-1993464BD242">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-08-04 19:33:27 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AMITRIPTYLINE-e454fe56-0896-4d40-862c-95ef0fc0bc82.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Nde21f8155cec49cd93dc31d53a73c955"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lineageUri>urn:domeoserver:annotationset:ECAD0A99-BC25-4C4E-A7AD-C88A6E67DD4F</pav:lineageUri>
    <pav:createdOn>2014-08-04 19:30:48 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:86477CA6-0F6B-47C0-B5C5-6FE456435E29"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50A04DD0-6066-4535-9705-BDCF80948C12">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D047DF87-6A8B-4F66-BACD-ED6380B97179">
    <poc:MedicalCondition>Respiratory Depression, Tonsillectomy, Adenoidectomy</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BEF25133-BCDC-4938-883C-8434B942E3DD">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54402707-B133-4DCD-824E-663EC10200AA">
    <dailymed:HGNCGeneSymbol>http://www.fakeuri.com</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>IFNL3</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD1C3D7E-1401-4C75-88BC-4B423E5DDD2C">
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0305355-93EC-45E7-AAEB-F368C6AECBBF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2B342CE-A4D1-41BE-9933-46296B0395B4">
    <ao:body rdf:resource="urn:linkedspls:uuid:BB838C8F-5589-40AB-870E-B48F04B59FE0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2302A2D-0E55-4B59-AD91-58549A4767D7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6926D7F6-0DBB-42DA-9D4B-AC61BC569818"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:CB024805-C764-4CAB-A3C5-9E86E954C589</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <pav:createdOn>2014-03-31 00:32:48 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-31 00:32:52 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F7C5F16-ED8A-43AA-B057-CD1C38FA8BCA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC0F0FB3-E2E2-453E-B7D3-D8BC825EAEBF">
    <ao:body rdf:resource="urn:linkedspls:uuid:DF1C5027-4FFF-42CB-8F40-9C54620B46E6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:392C0811-F5EB-432A-90A8-6ADE9CF407BB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E534935E-978B-49F9-BD34-30E0B499285A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-31 10:22:07 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9965CDA3-C847-495D-8B9A-B254F1BCDC74"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:092FCB2C-F420-49DE-99EC-10B74EE7E198"/>
    <pav:createdOn>2014-03-31 10:21:25 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E3DC621D-E18B-48E9-A061-5CC00B8B2927"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E4D5687-D441-4894-9473-A7154570A841">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-31 09:05:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact> Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <ao:prefix>In any patient treated with abacavir, the clinical diagnosis of hypersensitivity reaction must remain the basis of clinical decision-making.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55DF5491-8CA5-47E3-9224-23E7BAF182E2">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D5556386-79D8-44C1-917E-42046FE5A12A">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65137868-B001-4C93-B966-A8E06E33B0E9">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EBFA671F-4897-41BF-B422-6D53F3A5C5F7">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Biomarker list needs to be updated with F5</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3159C02E-C7B4-4007-B54F-02DA2E3AC3D5">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9EE83BC1-292A-4DC6-92A2-6BDA81A04501">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBD22003-AD39-40DD-BE43-01FE6829A766">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:110B2D4C-8FBA-4A0B-ACE7-187CD67F9A15">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9078E0F8-EAEC-4C32-B62A-B358F0B62C79">
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C93DC7C-0402-4A68-BAC2-C24F1EE6282A">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28C9239B-4580-4643-A1B4-349E39BA5FC0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1F430D8A-1C56-4C85-B1E4-7D879764BF3B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6588EE1-9AA6-48E8-8A53-8CE76A8CF524"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1D1D0D0A-CA17-46DB-A6BB-2A1394675015"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:867F97C5-1697-4CDE-BDAD-6B1188AE8969"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AED16BD-776D-456D-A6A7-E6A794974FC4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C1D5751F-A704-409B-9346-DB60DB0695BF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:83A57F69-3CAF-45A2-AAE6-9B5C666AA6A3"/>
    <pav:lastSavedOn>2014-03-31 09:24:08 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-31 09:21:32 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0216D027-571F-4B41-A606-57E6505EEF51"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AEB202EC-C200-402F-B2DD-E41CC9351D9D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:3194300C-AA45-4535-8BD5-82436DB85AF8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5302694-7A8E-4EB5-9CB4-29EB5FBD84BB">
    <poc:MedicalCondition>obstructive sleep apnea, post-operative, tonsillectomy, adenoidectomy</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76AA619E-BB2C-4392-85C3-DD3451E9B993">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF3B359B-24F3-4160-9884-CBC1CB42FEBF">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC">
    <ao:body rdf:resource="urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E6A2736-0750-43A7-A6E9-E7C80E5447ED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9953D1B9-8B96-4EC4-AEF7-D059402BDC26"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-22 22:22:30 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CA30A28-B75A-4D14-87B5-8F1D73A58AF0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:3E74BD7A-0A67-4373-A844-A3EFAC3B28D2</pav:lineageUri>
    <pav:lastSavedOn>2014-03-22 22:22:32 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE6A11BA-9F40-4FCC-AD6B-A61A5202A894"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4897DBA4-A296-4D96-A20A-621B927D8158">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:834DB3E7-6992-440B-A032-B1037CC4E06F">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-08-08 10:48:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA3CD1CE-D935-4293-8B9D-9E9637B4728B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABC14B97-37E5-420B-8F6E-8B9826EA0EF0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E51D6570-58A4-4650-B5E1-E1D4463384B7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91588194-37E0-42F4-B20F-F937A8704976"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:96459EB0-915A-4FFF-ACCE-4EBA8EEA516A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A1DEFF0-2B38-467C-8BDB-57D01AAB839D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DFED23E1-3FD2-484D-B555-5C9BBB724598</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D339484-75A7-4F61-986B-34254401FBDC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-08-08 10:53:45 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:E07FEF43-5464-4340-AB17-7DCF9775948D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B63EEDAC-49F4-4BAE-B608-CFF4F96C4A7B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D34F5E9-96AA-4877-9714-2B8FC0A4FB80">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55553E99-5E52-42FE-A0D7-D283C734E439">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:613AE564-A210-49F5-A1A0-EA070D855469">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF97EA95-22B6-4573-839B-45244ACA8467">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Tonsillectomy, Adenoidectomy, Respiratory Depression</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17885E5A-0B08-4791-8E05-BD3606CC3AC3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F147215B-DCB9-4E3B-B2BC-93F0B2976E64">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F147215B-DCB9-4E3B-B2BC-93F0B2976E64"/>
    <pav:createdOn>2014-03-31 10:31:23 -0400</pav:createdOn>
    <ao:suffix> The most common non-functional alleles associated with reduced levels of TPMT activity are</ao:suffix>
    <ao:exact>It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62EDFBD2-816F-43B9-BBFC-D10369B759AD">
    <pav:lastSavedOn>2014-04-05 15:35:22 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF81C9AA-3F33-4BDF-AAC9-DC884A248792"/>
    <pav:createdOn>2014-04-05 15:35:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA9A6EB1-B1BC-4FE6-99BB-502901A16ADA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:3C4BB835-7C91-4C6E-BC8A-7365DDB9D1A4"/>
    <pav:previousVersion>urn:domeoserver:annotationset:BC941944-3B09-42DA-A6F4-E655B8203428</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8472DF2-885B-471C-B394-64841BCBEFCB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3159C02E-C7B4-4007-B54F-02DA2E3AC3D5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E3E3B7C1-31DA-4515-A45D-0487C9D87BF8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:224881D2-F277-4416-8846-C1FFCA3A476D">
    <pav:createdOn>2014-04-05 13:53:47 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:CE5BCC1A-A623-4C88-A17D-090E8284CD20</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:13CCADC7-F7B8-4142-9875-12217ED75EE5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DB8FA0B-465E-4FB6-885F-E8906A821B76"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4734F15E-5E9A-406B-8261-68A584AE0192"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9FD9B2E4-A468-4445-A352-D37CBAD1BC3A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F4FF2B3-9F03-4393-AE34-8C205B711209"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0DC4A72C-CE40-447F-9659-46FA2BF64DA7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7E9F34C-FBC5-4A10-BA14-E092F7B3F910"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-04-05 13:53:59 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B21A0382-6079-4B5C-A4D7-3DD4BAA8E16D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EDADF29B-ED0B-4CFB-A561-C1C48DAF8568"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B29A0DD-F4CA-40E4-A73D-50262CE8D533"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:DDEF9222-4731-4C1C-A5C4-C46BA8A44143</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <pav:createdOn>2014-04-05 16:15:18 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8957BAD4-9280-4C41-93FC-626858C292B6"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:803BFCAB-DAC3-458B-9ACC-D5D3CE725015"/>
    <pav:lastSavedOn>2014-04-05 16:18:00 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9797BC9F-5D2E-4AB0-BB8D-96165595E525">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E62D8698-C5C9-4D90-A8ED-34B080403274">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-31 00:35:11 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 00:35:10 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6EAC3FD4-72CA-479D-8CE2-0D4BA6860CC2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7F5105A-3886-4258-9032-560D597BDDD1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2011113-168F-413E-A516-232113392669"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A99DF291-EDBE-490B-A5F9-A395B25AB97A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:63D7E2FE-3955-457C-B316-DC74C8D3F26E</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF4690CA-A190-417C-9878-67A0B05B369E">
    <pav:createdOn>2014-03-13 04:40:29 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:97D03A6D-0E7E-4379-84F2-E1C39FE5D581"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9FDBF52F-E105-46EB-B7C2-505A62F6C955"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:743D6172-1048-4A9D-AC8E-97AE01170639"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A315369F-5508-4EC6-B61B-43EFF3097378</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE3EF123-F169-4856-A367-0910456D1C13"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1084982E-C983-483C-A085-E7347F911842"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-22 18:13:29 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E56A6FA-66C5-4927-B877-5DEC2CA98CB3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A67F2809-2631-458A-895E-EF6D2A274649"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D6CA4418-5D3F-4F30-8BC2-9DCEEEA93293"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DC2E5C7-FF6C-48B5-92A6-2038376377E3">
    <ao:body rdf:resource="urn:linkedspls:uuid:1DA602EE-E5A7-49A6-A52F-F12866E00AF2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-05 15:31:36 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F45B669D-6119-44E3-AF92-7C631E9FCF91"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lastSavedOn>2014-04-05 15:33:01 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:09211774-5719-4BD2-AED6-A9E429469FCC</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E636CF6F-E042-41D1-AAD8-549FB93E1DF2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A4CB19A-F445-468B-872A-2BADFCF31271"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4925ECB-8672-4676-BB41-B92BE271909E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E49CBEE-CB52-4586-94DB-B7BE7FEE31B3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F69F59C5-45E1-414D-8043-4CC914956AA4">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C17467B-0656-4CB8-AA1C-AB5DE9D43ABD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Capecitabine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1D1D0D0A-CA17-46DB-A6BB-2A1394675015">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7135E5E-E2CC-4140-A69B-D6B978F182AD">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>cardiovascular event, death, myocardial infarction, stroke, stent thrombosis</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11D6F896-9E64-4FC1-877F-B1EBC732316A">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42490B2B-BD32-4D24-864D-EAB7E9D9DB05">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:93A68F9D-E824-4EDA-A0D3-30BA1EE9E2CE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <pav:lastSavedOn>2014-04-05 14:17:42 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C3600C1-C32F-4A85-A242-C6AEA8B1BDDA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:2A432FB2-3F68-4D45-8B42-5236A63C78CD</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE6B3C32-A94E-4E13-833A-9EBA958B383F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:919EA28E-CFD3-492A-8EE1-15C3067234A9"/>
    <pav:createdOn>2014-04-05 14:17:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:AAB10463-4594-41C7-8967-D01D6D1D6676"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA56D95F-F5FD-4A92-B8AB-0D7141F9DD42"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:49EE63F5-AA50-43BB-9A16-C8EF5565FBA5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:27027F5C-200C-4EC5-A1DF-38AF71320ECA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F30FB396-4B2F-44D0-8EFC-CA7BB0E5B838">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8AAF25A5-CE7E-48E4-9329-44F8B3F7EB4E">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA184D35-B996-4FF0-922B-6B732D552E7C">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC574C73-1E0C-4C19-8D3C-D28777B31678">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>G6PD</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007749</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE18C93E-F08F-4CA6-8DC9-67512351301A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFDA1212-D9CD-482F-9553-0B68581B090C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:555BF551-79D8-499F-87C6-DE997DC5352E"/>
    <pav:lastSavedOn>2014-04-05 16:18:00 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA180FC3-7F01-4E53-B1A1-8A0A0C1A181A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B7CAC00-6C83-48B7-902E-9E55A8CE3770"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:DDEF9222-4731-4C1C-A5C4-C46BA8A44143</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:13E8EB9A-0971-4A3C-9333-ED18408DB6FB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A41FEF50-F825-483B-A5B2-792BE459747E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <pav:createdOn>2014-04-05 16:16:50 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E56A6FA-66C5-4927-B877-5DEC2CA98CB3">
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AF4E0B6-E499-4258-8F27-FFBEF094F5D3">
    <ao:body rdf:resource="urn:linkedspls:uuid:EF568213-74DA-4759-BEFD-27B2A9615A8D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3EAC0C18-79AF-481C-83A0-97B57A16EF37"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1517B2B9-4BD1-4482-B77E-7F97953816EB"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:5F4FD78D-70B3-4C1F-84D0-F82DDD09079B</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:BDA1AD1E-4296-4464-99A3-8CEA4E171E9F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4308B677-10F5-497C-956D-F89B21E462C7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D932D2D-B0E1-42D0-A2E1-8D78B86A2FCF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-31 10:51:36 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8746A5D-3C7C-4436-89ED-9F65C5B50AE0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55B0054E-EEB6-4DFF-B81D-806E6A676921"/>
    <pav:lastSavedOn>2014-03-31 10:51:40 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70">
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:231FB605-C0BA-4076-A03F-F60FA03C8005"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6EB23E7A-2869-485D-965A-820F1D704C25"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 09:02:38 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA4D8CB8-B8F8-4FBB-B8A9-1F499DD7A9C8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F9CF447-9D4F-4E5C-9689-2FDCB70C37A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1D9B7794-EB80-4C0A-A5B6-F9B8661691D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA67625B-2AC1-4E15-BC4C-50D4C7BE0F03"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC1647E1-C0BA-4B41-AE11-28F2709C2D8D">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0974CEC2-E37C-43A6-B1C8-AB0F4FEE33A9">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1517B2B9-4BD1-4482-B77E-7F97953816EB">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FD888C51-22E2-46BE-9A6D-62F06CE2FB1E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FD888C51-22E2-46BE-9A6D-62F06CE2FB1E"/>
    <ao:prefix>. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Aripiprazole does not inhibit or induce the CYP2D6 pathway.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <pav:createdOn>2014-03-31 09:33:25 -0400</pav:createdOn>
    <ao:exact>The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB95BD00-4C63-47AF-901D-29FD47D723F2">
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C7B0E6E-61C4-46E9-B914-A9C8A6052BE4">
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1523E385-B7C2-4B6B-B365-918336BC31D4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E6A2736-0750-43A7-A6E9-E7C80E5447ED">
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:677D27C9-9A5C-4574-A742-76DC50B4702E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 10:52:15 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:677D27C9-9A5C-4574-A742-76DC50B4702E"/>
    <ao:exact>HLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans).</ao:exact>
    <ao:prefix>HLA-B*1502 is present in &lt;1% of the population in Japan and Korea. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:201D0C85-E7FA-4932-A922-C6E54F934CD9">
    <rdfs:label>Required</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <dct:description>A required test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68EEEAD6-D1ED-476F-AE7B-4902D32FD03E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68EEEAD6-D1ED-476F-AE7B-4902D32FD03E"/>
    <ao:prefix>Total188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians. Excretion: Pharmacogenomics </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-05 16:01:37 -0400</pav:createdOn>
    <domeo:uuid>68EEEAD6-D1ED-476F-AE7B-4902D32FD03E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8402D442-202E-4308-83DA-528F027BA84F">
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C0BC57D-CDF7-4B42-8F21-2A137AB07CE8">
    <ao:suffix> HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXT</ao:suffix>
    <pav:createdOn>2014-03-31 10:41:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE\nSERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C0BC57D-CDF7-4B42-8F21-2A137AB07CE8"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2FDE0DE-8423-4B35-8195-4D7DEEF0F0D9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-03-31 00:32:29 -0400</pav:createdOn>
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n\nClinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n\nGenetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2FDE0DE-8423-4B35-8195-4D7DEEF0F0D9"/>
    <ao:suffix>             </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C2C497F-8D6A-4163-BD73-962E88B2A0AA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdfs:label>Recommended</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7304D83C-0ACB-4723-AA46-CEEC360AD87B">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B9A02A9-6FF6-4529-809A-FE09CBC3C0FC">
    <pav:createdOn>2014-08-07 12:52:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3B9A02A9-6FF6-4529-809A-FE09CBC3C0FC</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3B9A02A9-6FF6-4529-809A-FE09CBC3C0FC"/>
    <ao:exact>Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In most patients maintained at a steady dosage, stable phenytoin serum levels are achieved. There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:391186E1-69F8-4086-9B16-3FFAB6492435">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF1C5027-4FFF-42CB-8F40-9C54620B46E6">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0DE3E89-95FD-44B5-BD90-ADA5087080D0">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Not Important</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5031419A-DE0B-4707-825D-60B5CA04FD01">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5031419A-DE0B-4707-825D-60B5CA04FD01"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-05 15:26:34 -0400</pav:createdOn>
    <ao:exact> Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone. Among these patients, 54% had node-positive disease and 46% had node-negative disease.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years.</ao:prefix>
    <domeo:uuid>5031419A-DE0B-4707-825D-60B5CA04FD01</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41A82909-5376-4F76-BBBE-7727172FAA1C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91F0C018-333F-4F61-B4EF-B16606136A9D">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99ACE7BD-56E1-435A-B8FE-9EBC9FE5D0CF">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83A57F69-3CAF-45A2-AAE6-9B5C666AA6A3">
    <ao:suffix> PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EM</ao:suffix>
    <ao:exact>Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83A57F69-3CAF-45A2-AAE6-9B5C666AA6A3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <pav:createdOn>2014-03-31 09:21:32 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1564A1CD-1DE3-44A9-B41C-23910512D5FC">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:667C10F3-838C-4BD0-B241-8DA04851D35E">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:553C66AA-28FD-4DCE-AC6B-2F38BE38D2E2">
    <ao:body rdf:resource="urn:linkedspls:uuid:BE825745-A408-46CC-A2DF-3EC188BFF1B7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EBFA671F-4897-41BF-B422-6D53F3A5C5F7"/>
    <pav:createdOn>2014-04-05 15:39:42 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:2CB3E759-D86B-4DF5-BCBA-D74920F266AD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3BC4EB7-7B55-4A32-B1F3-F18E60EA2784"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4D9C262-7169-4552-95F8-1DC215AEE0EF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-04-05 15:39:53 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1EF2D05-6C08-4679-B2FF-628A6C723E25"/>
    <pav:lineageUri>urn:domeoserver:annotation:89A56C20-7EC2-40F1-B4DB-A920C2B09C5A</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF81C9AA-3F33-4BDF-AAC9-DC884A248792">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-05 15:35:19 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF81C9AA-3F33-4BDF-AAC9-DC884A248792"/>
    <domeo:uuid>BF81C9AA-3F33-4BDF-AAC9-DC884A248792</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5409FBA7-9762-4BAF-A5F9-AB669F959BBF">
    <domeo:belongsToSet>urn:domeoserver:annotationset:AC93DEDB-7C87-4168-8104-9E2959E8F017</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6818E0F-917B-415A-8423-5F2F4246E58F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:85AB55BF-99C3-42CB-B17F-7BC782CA7B6D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9FDB8AA0-86D0-4A1C-9FC4-6789AB6D932F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6595EA04-1E7C-449E-BBE5-6569547FC2B8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:ED0170B2-B4E0-4B2B-B614-54F18F28590F</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-05 15:12:17 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-04-05 15:19:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE22753A-792C-4BF3-B52C-6071587AD3D9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA95EF6A-69CD-4E8E-B0AF-39CEB701AEC9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B">
    <ao:context rdf:resource="urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:0AE4805A-9064-4B43-9C66-7F8E47ECAB77"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:043B155D-EEAD-4248-B52C-FA7437F0A139"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-22 22:15:15 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:79A46039-020F-4CFF-8F4F-224895ADAB3C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-22 22:13:30 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4157B9C9-C9C5-4812-8433-5DE9EDAC7F15</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFBCF9E3-E6EB-44EB-9FA9-FA8288501BCA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E30D4DE-0690-47CB-B227-CB6A0E9E7884">
    <pav:createdOn>2014-03-31 11:36:00 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:2010B203-56DB-4F65-9F71-89F69C107739"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:52DF1CE4-D460-4636-BA89-D115DAAE5E10</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E09CDF6-D796-47AF-9202-E054F28A749F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A22AC452-44D3-45A4-A9E2-418CAAA413B3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D79C5BB-E112-4A3A-BDAB-DA2CED022D2C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:18C26EFF-090B-4295-9AC1-BB1A5010E96D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <pav:lastSavedOn>2014-03-31 11:36:27 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3D2F4F60-D852-49E3-BB2B-44066FA6486A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:555BF551-79D8-499F-87C6-DE997DC5352E">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Use specific</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4157B9C9-C9C5-4812-8433-5DE9EDAC7F15</pav:previousVersion>
    <pav:createdOn>2014-03-22 22:15:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC17395A-7D36-45CC-BFB3-4271FD68383B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:476620C9-1693-43B1-9388-D0A05A007BB0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25F3A5BA-0A71-49F5-A250-1863F45FE3A9"/>
    <pav:lastSavedOn>2014-03-31 14:04:24 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE0E9429-8355-4751-A26E-F3D2FD5518A5">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>What is most appropriate for biomarker here?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:824B39AF-8D7F-4835-8566-F79A3F9C9DE0">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Are they recommending that testing be done?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B73E5996-7642-4482-8767-64D56ECCF0D0">
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B73E5996-7642-4482-8767-64D56ECCF0D0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix> Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine </ao:suffix>
    <pav:createdOn>2014-03-22 18:12:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E4B01B1-801C-4C26-86B8-852138AD8BE2">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E">
    <ao:body rdf:resource="urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC"/>
    <pav:lastSavedOn>2014-03-22 22:03:57 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6669B83-B750-4BCE-A012-641844F7058E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:BCD381EE-901B-423A-AB9C-3DE76C7BF9E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAEE8F63-75A3-4EBB-9785-D52BCC522BE0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-22 22:02:44 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F1294AA-1E74-402F-9AED-0611A4B739AB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81568992-1F6F-4A94-BFA4-E950385F06E1">
    <pav:createdOn>2014-03-22 18:11:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Codeine is secreted into human milk.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:81568992-1F6F-4A94-BFA4-E950385F06E1"/>
    <ao:exact> In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent.</ao:exact>
    <ao:suffix> However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeines active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously hi</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3EAC0C18-79AF-481C-83A0-97B57A16EF37">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79DDFD55-7F6C-4B87-8668-D61DCBD3B340">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00B21812-A2F4-4DA0-B631-58EB798B6736">
    <poc:Comment>Should the *1 and *2/*3 alleles be separated in this statement? </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05F5345C-0274-4DD9-B7AE-57C94E589013">
    <pav:createdOn>2014-03-13 04:13:18 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:382CB003-5208-4FB6-A6E7-5EE37F94B2D5</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:FFCFDE69-5158-40CA-8CA3-4BDAF8815742"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5734B9EA-E08F-4E0F-87D0-09241425D1D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A97D100-3273-419A-8927-856738C54D03"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC67D62E-76A8-484C-B632-32B086C0C237"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C61F89D-783E-4303-8058-D5AB9C43C44E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4CAB570-4A2C-4C38-B29A-418C75D230C7"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEA0830-ACA8-40DD-8D9F-78F87866EE0C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:74B44044-2B72-4A73-A53D-DE7DBB4FBE1C"/>
    <pav:lastSavedOn>2014-03-13 04:28:47 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BFEE0445-4DB1-4335-9E42-9FC2CC6135A7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:158713E6-223A-4BE2-8C4A-663906E57A2A">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>HLA-B*5701 positive on abacavir</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACCBA572-A5EC-4D2D-B2EA-B8F9D87DBFA5">
    <poc:MedicalCondition>Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia; Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase; Ph+ CML in Blast Crisis, Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy; Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase; Adult patients with Ph+ Acute Lymphoblastic Leukemia; Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia;  Pediatric patients with Ph+ Acute Lymphoblastic Leukemia; Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia   </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC18DD8F-9AD6-4420-83ED-4DA3D360372A">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4FBFA5F0-C880-4B49-A0BE-F5057F535038">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06CAC201-96AF-4344-AF49-DF7E60A6D48E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8DFD9785-24ED-4DD7-90ED-AE68E1963F4F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8DFD9785-24ED-4DD7-90ED-AE68E1963F4F"/>
    <pav:createdOn>2014-03-31 10:50:45 -0400</pav:createdOn>
    <ao:suffix> HLA-B*1502 is present in &lt;1% of the population in Japan and Korea.</ao:suffix>
    <ao:prefix>s Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China.</ao:prefix>
    <ao:exact> South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2 to 4%, but higher in some groups.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:814409FF-CD69-4B0F-B3C5-CF0010960853">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4215D5F2-900F-4096-B0D9-E1903FA05B37">
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:68EEEAD6-D1ED-476F-AE7B-4902D32FD03E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A9A0113-CA08-49FE-A7FE-E0A08C5601C9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:54BCBAAD-B674-4B98-ACD6-710B7081482A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4651603-DDAF-415C-B87C-F2E172EC6820"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E36349D-A55A-478F-B303-057062C970F8"/>
    <pav:lastSavedOn>2014-04-05 16:01:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-04-05 16:01:37 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6727EEEC-0FA1-4F5D-A001-BF4BF5B6EBA0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0862483-2AC9-4C81-9DC2-BDBBAC721E69"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7A4011DF-08A3-4FEE-88A6-B3B8B6B9E3E2</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00BD4F7B-1E4D-4A8F-8252-8A0ECFB48473">
    <pav:createdOn>2014-04-05 13:51:52 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:suffix> Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are av</ao:suffix>
    <domeo:uuid>00BD4F7B-1E4D-4A8F-8252-8A0ECFB48473</domeo:uuid>
    <ao:exact>The effectiveness of clopidogrel bisulfate is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1)]. Clopidogrel bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:00BD4F7B-1E4D-4A8F-8252-8A0ECFB48473"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A262DEB7-6684-4B04-8389-10AF1D25D441">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E964018E-0C78-41BB-A861-1878480EC47A">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1BF29CC9-C608-41B8-85E6-E2C684B0291C">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D2BFB3C-0E2A-4B9E-B9CC-2D21C8035D95">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF903747-E225-4598-B9EF-86BD59E72E0F">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:043B155D-EEAD-4248-B52C-FA7437F0A139">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8405D1E5-BABE-4808-B711-F3A83D365C16">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FFCFDE69-5158-40CA-8CA3-4BDAF8815742">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA844F00-D043-44E7-BDA4-C852FD04CEA0">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5883AF2A-A3C9-4878-B47E-A7F548D38525">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A1249AF-CF60-425D-A82E-E86B80DFAFAC">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C6ABE00-FAF3-4419-9BE0-CAFA7814B5C5">
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B04896AC-083F-49F3-B5F5-0106B388DDC4">
    <pav:createdOn>2014-03-31 10:24:12 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:331B19A5-A857-4FEB-BD96-9730D10BC729"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:65395299-1975-47CB-9026-09307D5750DB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2509D9DB-E2C5-42DE-AB65-03DCA3B7F3A1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9F014F6B-A606-4F8D-884B-FF6351D0438D</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-31 10:31:27 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9FBD508F-A001-4AFA-98B6-03BE9C49A86D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A65CDE07-A7B4-46CF-A0B5-2C3A69D3D796"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:255EC879-A704-4760-8479-1B715952C652"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A1C26D7-0B06-49F9-AF2E-CBD25FBA7F7D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6F877E8C-2C55-432D-8DB8-80CE14A50DE1</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F29EB7E4-5368-46FC-8E0A-46A8DEF367A5">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E161E15B-D38D-44C8-ACA1-A5798BD2EA2E">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51743ED0-BC14-4FB0-A750-4DB17BE99915">
    <rdfs:label>Citalopram</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31DDB828-1349-49DC-BBFE-E00734E9921A">
    <pav:createdOn>2014-03-13 04:23:23 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <domeo:uuid>31DDB828-1349-49DC-BBFE-E00734E9921A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (see </ao:suffix>
    <ao:exact>Citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:31DDB828-1349-49DC-BBFE-E00734E9921A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716"/>
    <ao:exact> Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-22 22:16:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E3DC621D-E18B-48E9-A061-5CC00B8B2927">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA068865-47CE-4ACE-AF05-CA2B37666BDB">
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D7FD036-EB64-4C5A-B838-B9A9C1CF132B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:508FAE65-0963-4DF7-9CCD-11FAFAEDDD84"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9949892E-EB19-49D8-A737-FAF19F57740B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BE588D93-C0EC-4E98-AC83-D151CAD07967"/>
    <pav:createdOn>2014-03-31 08:58:47 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D2BFB3C-0E2A-4B9E-B9CC-2D21C8035D95"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8624524-9CEA-4109-AD60-7041876D4E8C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:02622A38-2628-40D2-8B31-F1808AC2DD0E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BBDE4495-5E29-4C3E-A9A7-2BC258F417F6">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0FE9DAA-0CDC-4433-B1B9-90523C7903AE">
    <domeo:uuid>F0FE9DAA-0CDC-4433-B1B9-90523C7903AE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-05 16:21:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype. </ao:exact>
    <ao:prefix>ties. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis ofacid residues in the proteins which are essential for biological activity. Mechanism of Action </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0FE9DAA-0CDC-4433-B1B9-90523C7903AE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AE5C8BE-EDDF-4D74-AF9A-7F3C72DCB62D">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <rdfs:label>Rasburicase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E690B7CC-1153-4150-A9A7-D2E45B970390">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Required</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <dct:description>A required test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:40B0A610-0D8B-487F-86C2-E891204D2184">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5514923D-64AA-41A0-89DF-D04328FC8AE8">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D742086D-FBE4-4E5E-8129-F5C607743253">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0EF2A15B-07C7-4714-B698-FA75EA02612F">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7241BFA4-7117-43E4-AFE8-A1EB7220D99C">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF67E3D0-C3D3-4CD4-B895-70A031A8052E">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7">
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this oc</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-22 22:01:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5542691E-3FD7-4CD4-B22C-7D237B921E99">
    <poc:MedicalCondition>abacavir naiive</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42854403-5CD5-4B14-9405-3A37D9EE0956">
    <ao:body rdf:resource="urn:linkedspls:uuid:E161E15B-D38D-44C8-ACA1-A5798BD2EA2E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B2C36B0D-AE49-4B08-9DB2-0C4C2EFBF661"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E638CC1-F722-47BF-B15F-70520BF73577"/>
    <pav:lastSavedOn>2014-03-31 00:29:06 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 00:28:41 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:DE2C2604-3963-4B66-85FC-ECCB3E6CC129</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B969AF7-491B-4B0D-9C3C-CADF2A313CEB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F6F0822-6A5A-4AC9-8FEA-E9146DEE6263"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E3DCE7DB-25F9-42AF-8BF4-905E9E4027A8">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C957728-B534-467B-A2B7-559DDE5060EB">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CF696F8-B98E-49CA-85FD-0A90C6250EBC">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>G6PD</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93EC19C9-FE86-456F-9737-C8F58AC581D3">
    <poc:Comment>This should be annotated, but the tables needs to be fixed</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B7CAC00-6C83-48B7-902E-9E55A8CE3770">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D769C96-B158-4628-8675-E329993925D2">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.</ao:exact>
    <pav:createdOn>2014-03-31 00:29:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5D769C96-B158-4628-8675-E329993925D2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03775CD7-A3F2-454F-9C46-3BC24CEAAA5B">
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6C686CA-6C8C-40E4-851D-6DCA8476D1B3">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Serious and sometimes fatal hypersensitivity reactions have been associated with ZIAGEN and other abacavir-containing products. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <pav:createdOn>2014-03-22 22:07:26 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix> Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57E28BDC-5839-4CA3-A456-7AD2FC18721C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <domeo:uuid>57E28BDC-5839-4CA3-A456-7AD2FC18721C</domeo:uuid>
    <ao:suffix> Carbamazepine Extended-Release Capsules should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:57E28BDC-5839-4CA3-A456-7AD2FC18721C"/>
    <pav:createdOn>2014-03-31 11:23:58 -0400</pav:createdOn>
    <ao:exact>Prior to initiating Carbamazepine Extended-Release Capsule therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A862BB3-66AF-4883-995D-FD5291544FF9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE103847-B1B7-4B58-8D29-9AE2B991BA78">
    <rdfs:label>G6PD</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:747EE432-4037-4D95-9292-FEEB7F9998F5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8FB8C61D-DC83-4A4B-8418-2C8DBC11CC34">
    <ao:context rdf:resource="urn:domeoclient:uuid:50E89487-AEBD-4C92-8435-DA6E6DF542E7"/>
    <pav:lastSavedOn>2014-05-29 14:12:38 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5096B64A-7898-4023-B577-E6F070F5D83A"/>
    <pav:createdOn>2014-05-29 14:12:32 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:550C1A49-FA8D-41AB-9B3E-D59B873B44BF</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:63A1772E-E277-4C40-AEA1-DB1681C1F6E5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A880675-91C7-47AA-ADC7-D8E10E68AE4A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:61075185-39E7-4D6C-983B-843944A0649C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D047DF87-6A8B-4F66-BACD-ED6380B97179"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:41A82909-5376-4F76-BBBE-7727172FAA1C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1665415C-50E8-4DEC-8A24-3A0E50710FC5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1BD1263F-1D46-44FC-A11C-29A8F2B0B2FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB21A51C-F18D-4AA6-9FA2-596E554A26A0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:989B7D49-98D9-409A-9E6F-43F710EDFEBB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31F8C49E-11C4-4EBB-BF7A-4DB3A797CA1C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:31F8C49E-11C4-4EBB-BF7A-4DB3A797CA1C"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-22 18:11:28 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <ao:exact>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing)</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A22312C9-4AFD-4D76-853D-23AD2C8DBD03">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4CAB570-4A2C-4C38-B29A-418C75D230C7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>This is the same biomarker. From an end user perspective, I could see this being useful if annotated separately for each variant as well as one joined annotation for poor and extensive metabolizers since they are being compared. Thoughts?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7366AAD5-7FCB-4D72-ACF8-B89D3B6AE6C1">
    <rdfs:label>DOSAGE AND ADMINISTRATION (34068-7)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08810A50-5444-4303-A2F0-3317E49F6BE3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:202E0251-F3E5-4A87-BC3C-3B5568C95DB7">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D07A471E-9AE7-4A93-BF39-B8A753C23859">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99B84487-54C4-4044-B319-C00A3689F0FA">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF9D1335-3298-4C64-8A6F-68008EB52A2C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05C79F1F-1666-4FA3-951B-22B271498D59">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:05C79F1F-1666-4FA3-951B-22B271498D59"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-05 15:19:16 -0400</pav:createdOn>
    <domeo:uuid>05C79F1F-1666-4FA3-951B-22B271498D59</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C751B6F1-6EDE-4C87-A5FE-1A6E0D3D4C92">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2976AD40-9424-4037-8069-627C2E58B16C">
    <ao:body rdf:resource="urn:linkedspls:uuid:7DF7B261-AB15-4E08-A5CB-F162C9C105CF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:764C28A6-ECBD-4FA5-A5A4-E81D3E2E88F3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB1468A2-977C-431D-B642-407143AA67A3"/>
    <pav:createdOn>2014-04-05 15:11:10 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-04-05 15:19:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C957728-B534-467B-A2B7-559DDE5060EB"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:05C79F1F-1666-4FA3-951B-22B271498D59"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AC93DEDB-7C87-4168-8104-9E2959E8F017</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2541641-9CF3-49C1-8121-194DE9983852"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:ED0170B2-B4E0-4B2B-B614-54F18F28590F</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6CF3E31C-7F28-458C-8F46-45C395562121">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Do not start</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35BB37D2-E4A1-4CD9-B58B-43AAF9ADE24E">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49DBB352-A20E-4BB5-BF17-E97E2B9E4D2C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D771262-567C-49F7-8CE1-5DE0613139D1">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02887C31-D6D3-434D-BD70-6EA1045D8380">
    <ao:context rdf:resource="urn:domeoclient:uuid:F127DBE1-AECA-4EBD-BEDC-B186666741B2"/>
    <pav:createdOn>2014-03-31 00:25:13 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4302688-2092-43B3-AA5A-F2E208E250B8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:462C8AA1-56F4-4DAB-8833-C9765CCE4D3D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:92D4A343-08E7-4448-A01D-A251DBEB233A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A4274FC-E56A-4CF3-B0FF-E69ACB8124B2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-31 00:25:15 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:58E59978-E28B-4ADC-AB4A-815E87565940"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FF7B2C15-5977-4CEB-9F55-237750EBC451</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA824956-AE81-47F1-9357-A368B65EAA14">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8748274-7D24-4473-B677-A9A28F6D0729">
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A4397F4-7E56-40D0-A81F-EC897E7F7876">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7AB24D19-F216-48AD-B258-D1B39106017C">
    <ao:context rdf:resource="urn:domeoclient:uuid:ACAEA188-F33B-4EF8-B4D8-744200091CA7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9B031F8-0FE1-467C-A320-1BEC8CFFB046"/>
    <pav:createdOn>2014-04-05 15:32:58 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE8DE92B-D492-408D-B800-851E779CD6F2"/>
    <pav:lastSavedOn>2014-04-05 15:33:01 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A6B23527-C142-4C26-B6ED-D03FB29B707A</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:BF3EB2B9-D0B9-4976-828B-BBCC879824CB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:23F2D602-99DE-4EAA-9FC5-101C81D94E7C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AEA168CE-C26E-449B-81B7-61CB074395E3"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:09211774-5719-4BD2-AED6-A9E429469FCC</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A757FDCF-056E-429A-A9CA-12477A04E1F0">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A757FDCF-056E-429A-A9CA-12477A04E1F0</domeo:uuid>
    <ao:exact>Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5)\nConsider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A757FDCF-056E-429A-A9CA-12477A04E1F0"/>
    <ao:suffix>. (2.3, 5.1</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-05 13:47:11 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4000002E-9DDB-4180-A461-8C8E5266C176">
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C8770BF-5D70-48BF-B2E6-F7ACE2B8D532">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6B1E14A-EBCE-4D74-B7A4-BF434698ED1E">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C054AAE3-244B-4BE9-A823-466261F60423">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*1</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAEDFA78-4ABE-4070-9AB8-BFF8C609E0AB">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DB04C01-D293-476A-98CF-50A111D3CA0A">
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38868500-428B-458D-9CEF-72F83B82EBAE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>PHARMACOKINETICS (43682-4)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D83A0668-C43F-4010-87C9-8F47C20C71E1">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C0B6C84E-33E9-426C-B4B7-EDF94F342325">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:499D6206-2A71-496D-9054-4784BC32BA1C">
    <domeo:uuid>499D6206-2A71-496D-9054-4784BC32BA1C</domeo:uuid>
    <ao:exact>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE]).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 11:29:11 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:499D6206-2A71-496D-9054-4784BC32BA1C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration in determining the need for screening of genetically at-risk patients currently on Carbamazepine Extended-Release Capsules. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA2F9D10-3477-4544-BF32-2176E0DB7BE0">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:13CCADC7-F7B8-4142-9875-12217ED75EE5">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96">
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8542DCD4-98AF-4508-A038-FFFE27F30205"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D513D738-4472-4743-A187-3200479661B2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55B89580-2E0A-4A7D-B09D-AFAF8BF0A3CC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947"/>
    <pav:lastSavedOn>2014-03-22 22:15:15 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4157B9C9-C9C5-4812-8433-5DE9EDAC7F15</pav:previousVersion>
    <pav:createdOn>2014-03-22 22:14:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:207BA609-3844-44A9-98B4-E6695EA86595"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F54C376-30A1-41D7-8621-445FDA308DB9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0A6E639-4576-459E-8B02-5BEA74529A1B">
    <ao:context rdf:resource="urn:domeoclient:uuid:6E273AC2-D475-4307-B956-36A5EF1FD482"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:835F173A-438C-45DE-A6D7-D97785DF01E9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B8B5B40-43F1-4AFF-BBE5-2D809EE85569"/>
    <pav:previousVersion>urn:domeoserver:annotationset:AF56BE3C-BE1F-488A-8DE5-2468B589CC72</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:CEC913EF-B4E2-4564-9058-3722E71E013F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE0E9429-8355-4751-A26E-F3D2FD5518A5"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-04-05 14:03:34 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B4C34B7-D8BB-40B0-87FD-B1C741C54B51</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC48DCC3-79AE-45A9-B2F5-5F4D71A28BA7"/>
    <pav:lastSavedOn>2014-04-05 14:03:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E1FD229B-39CC-4BAB-8D93-ECB99A7C3810">
    <pav:lastSavedOn>2014-03-31 00:34:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B8DF96B-B8D5-4EA2-8036-D03F02D2355B"/>
    <pav:createdOn>2014-03-31 00:34:18 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:D29BBA81-587C-4066-A8FA-C57C38744BA3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA0A95C1-EEC6-42D7-90A0-41E65CD09812"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6FF595AE-67B8-49FC-9B25-8FB5728E46BE</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:9340C2C9-029B-4D12-868B-3B2F725F4E9B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68B8CDE5-CF36-42FF-AF3C-924428246A99">
    <rdfs:label>Citalopram</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AED63615-7471-4449-AD16-6EFEA9B80F36">
    <ao:body rdf:resource="urn:linkedspls:uuid:D5556386-79D8-44C1-917E-42046FE5A12A"/>
    <pav:lineageUri>urn:domeoserver:annotation:9AD5E683-ADBB-4565-AB6C-DF45517ECA1E</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A411F30C-B738-4C16-9002-C2FDBBFF7D03"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB2B85AF-54D1-44F4-A254-FF1B0025A8D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5302694-7A8E-4EB5-9CB4-29EB5FBD84BB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:AAF5C9C2-CA69-4FE0-B44F-E699BEE6E560"/>
    <pav:createdOn>2014-03-22 20:36:19 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:39DA1C67-F3A8-4D3F-86D3-D78C2733C9CB</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:9078E0F8-EAEC-4C32-B62A-B358F0B62C79"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DEDFB9A-D108-4F65-BF83-1DB8E7491065"/>
    <pav:lastSavedOn>2014-03-22 20:44:27 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:34AF151B-D880-42D9-899B-DB3190804290"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304488c4b70144896f4a03000b">
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:lastname>Adams</foafx:lastname>
    <foafx:title></foafx:title>
    <foafx:email>soa18@pitt.edu</foafx:email>
    <foafx:firstname>Solomon</foafx:firstname>
    <foafx:middlename></foafx:middlename>
    <foafx:homepage></foafx:homepage>
    <foafx:name>Solomon</foafx:name>
    <rdfs:label>Solomon</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:186091FB-EEC9-4591-98FB-AD76970B0DC2">
    <pav:createdOn>2014-03-31 10:30:22 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:186091FB-EEC9-4591-98FB-AD76970B0DC2"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> </ao:suffix>
    <ao:exact>TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7f77d8cab574424e99f86508c155508f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8A6028B-5370-4AAE-8B8D-E37423DE3F87">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43892A47-95DE-41E2-942D-9045332A7579">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6AB46253-D7F4-4C5F-BE59-387B8EA69282">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:260C6870-3C13-4DA2-B87B-5DA88E1CAF61">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <pav:createdOn>2014-08-04 19:48:18 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:260C6870-3C13-4DA2-B87B-5DA88E1CAF61"/>
    <ao:exact>Rarely, unexpected, severe toxicity (eg, stomatitis, diarrhea, neutropenia and neurotoxicity) associated with 5-fluorouracil has been attributed to a deficiency of dihydropyrimidine dehydrogenase (DPD) activity. A link between decreased levels of DPD and increased, potentially fatal toxic effects of 5-fluorouracil therefore cannot be excluded.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>260C6870-3C13-4DA2-B87B-5DA88E1CAF61</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4683D5EB-6628-4644-AF10-7D65325E3A8C">
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:532468D7-4E58-4797-963D-2701344AA9F6">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>DPD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006678</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC0112AC-CA62-4C51-B57D-62EB9354B6C8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*1,*1xN, *2xN</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7361D556-97F9-41F3-98DD-3F6C66FA6CCB">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A335FC5-DF33-46BF-BFAF-E005DC6CC4E2">
    <pav:createdOn>2014-08-08 10:56:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4A335FC5-DF33-46BF-BFAF-E005DC6CC4E2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> In clinical studies, hemolysis occurs in &lt;1% patients receiving Elitek; severe hemolytic reactions occurred within 24 days of the start of Elitek. Immediately and permanently discontinue Elitek administration in any patient developing hemolysis. Instit</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <ao:exact>Elitek is contraindicated in patients with G6PD deficiency because hydrogen peroxide is one of the major by-products of the conversion of uric acid to allantoin.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A335FC5-DF33-46BF-BFAF-E005DC6CC4E2"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E7EEF57-A445-4C55-965B-8D4E7A8AA86C">
    <ao:body rdf:resource="urn:linkedspls:uuid:0AA45B3A-5961-4083-BEE0-F2EC6C600E93"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C0D2D71-30BE-4C6F-9E76-83570D870A36"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D420D7C4-C603-40BC-80A8-59AA14567DE4"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-08-05 12:33:39 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A66B4A39-E0C6-4822-83EB-94A40AAABE20"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:4B5EC119-F89E-47A1-9A02-58B15B7F06F3</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A08A96C-6C74-4E35-8BC1-AF29037EF9B7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:54402707-B133-4DCD-824E-663EC10200AA"/>
    <pav:lastSavedOn>2014-08-05 12:34:17 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A84C1F4-ACB2-4D98-B2F7-F5606AF22F3F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E35458E-5CDA-46AC-9775-514F2615A569"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:97B839E1-AC98-4EFF-B82A-4758C6D6FA67"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:FF928AF5-30A2-4989-9A85-18DE16C1A97B</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4308B677-10F5-497C-956D-F89B21E462C7">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A66F219-499B-4560-AA94-F96598D0B126">
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:20AD692D-3407-4D6C-ACDE-626037F984D4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA3CD1CE-D935-4293-8B9D-9E9637B4728B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16C3120F-E19F-453E-9222-0C4CAA7503EB">
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26381EB6-C0A8-49A8-BEBF-A8377DBA26C8">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34FE8B53-03E6-4D06-9371-F1EA1CC5BEDD">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:743D6172-1048-4A9D-AC8E-97AE01170639">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC28F8C1-5BBE-454C-B415-4F511895791A">
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B0497B5-2A21-46A2-983F-7992EF169EE9">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DAD48B4-7C26-41F3-AD42-9012780017DA">
    <domeo:uuid>9DAD48B4-7C26-41F3-AD42-9012780017DA</domeo:uuid>
    <ao:exact> Clopidogrel tablets may not work as well in people who:\nhave certain genetic factors that affect how the body breaks down clopidogrel tablets. Your doctor may do genetic tests to make sure clopidogrel tablets are right for you.</ao:exact>
    <ao:prefix>1.</ao:prefix>
    <pav:createdOn>2014-04-05 14:23:38 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9DAD48B4-7C26-41F3-AD42-9012780017DA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E7F2371-A92D-42D3-8889-4993B0939BE0">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Asian descent </poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E09CDF6-D796-47AF-9202-E054F28A749F">
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6BFE0B84-A189-4CBE-9F0E-9F4FFFEB4DB2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>I wasn't sure how to best annotate this. I think that we had discussed it before, as it is somewhat challenging to classify. Just to make sure, extensive usually refers to normal metabolism if I remember correctly. </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75EE9F1E-A916-4153-8DF1-89E9DF696CA4">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>G6PD</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007749</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB2B85AF-54D1-44F4-A254-FF1B0025A8D3">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1EF0B4A4-3F75-4AB9-8AA1-84A028AD5EE7">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37276584-B74E-4FB5-8F92-BE77209E25DC">
    <pav:createdOn>2014-03-31 00:22:02 -0400</pav:createdOn>
    <ao:suffix> (Table 1).2</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:37276584-B74E-4FB5-8F92-BE77209E25DC"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C1D5751F-A704-409B-9346-DB60DB0695BF">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F3DAD62-5D1B-4C5E-9D20-21B200ECAAE0">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55A9B321-4223-4FD6-A69B-8327A371FA1B">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7956072-12AD-4BD6-BAD8-A112393E8467">
    <rdfs:label>Active ingredient</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD3749D6-BF72-4361-BFF3-B479BACAB810">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F398BCE-3F13-4B4C-AB09-ABCCFC5F0E87">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D784226A-C58C-4D32-A307-DDB685733265">
    <ao:exact>Effectiveness of clopidogrel bisulfate depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-04 18:33:59 -0400</pav:createdOn>
    <ao:suffix> (5.1) </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D784226A-C58C-4D32-A307-DDB685733265"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7B29D0C-ED74-476B-8E7E-E1D984A5E594">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DB04C01-D293-476A-98CF-50A111D3CA0A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F29EB7E4-5368-46FC-8E0A-46A8DEF367A5"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:991AF447-FA2E-4568-A865-00C16B645701"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C7B0E6E-61C4-46E9-B914-A9C8A6052BE4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:createdOn>2014-03-31 00:27:12 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 00:29:06 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFDBBDAE-1D40-4207-988F-1E8CEC5ADA04"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DE2C2604-3963-4B66-85FC-ECCB3E6CC129</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC78FED1-9541-40D7-9769-79F974601806">
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D43D74B1-E88C-4FBE-8716-B5F76BDE8FF1">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59C676DC-D957-4F73-AFDF-D3DE61C60E20">
    <ao:exact>	Carbamazepine Extended-Release Capsules may cause rare but serious rashes that may lead to death. These serious skin reactions are more likely to happen within the first four months of Carbamazepine Extended-Release Capsules treatment but may occur at later times. These reactions can happen in anyone, but are more likely in people of Asian descent. If you are of Asian descent you may need a genetic blood test before you take Carbamazepine Extended-Release Capsules to see if you are at a higher risk for serious skin reactions with this medicine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>59C676DC-D957-4F73-AFDF-D3DE61C60E20</domeo:uuid>
    <ao:suffix> Symptoms may include:</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:59C676DC-D957-4F73-AFDF-D3DE61C60E20"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <pav:createdOn>2014-03-31 11:40:55 -0400</pav:createdOn>
    <ao:prefix>1.</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87600A57-7205-475E-B752-EEEB82A227DF">
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2">
    <ao:body rdf:resource="urn:linkedspls:uuid:50A04DD0-6066-4535-9705-BDCF80948C12"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16"/>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-22 22:07:26 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:52CB1ACE-5349-4E7A-A0E1-84BC726E8B27"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D22D3EE5-70D2-4E6B-98C6-A6D895D3172C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:AC497212-D269-4238-AA69-CFE2271A33C3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7215D99B-4C7C-4B46-90F3-E5013DDC6ADA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1260362-9D96-409B-AD63-2DCC1C0465C9">
    <rdfs:label>G6PD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007749</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4115BCF2-08FE-450A-AC56-6939C29B1491">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:255EC879-A704-4760-8479-1B715952C652">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E7CDA24-C918-4533-9893-1287CCF8183F">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DF7B261-AB15-4E08-A5CB-F162C9C105CF">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Maraviroc</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA1DD9EF-EED2-4BA6-B09A-2383D9D12165">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:20DE2157-9373-4B68-A4AF-834E82048CDF">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AAA8CEFF-4B6B-4855-AB92-1E71CA821963">
    <poc:MedicalCondition>heterozygous</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:578A8756-945D-4A96-98F7-B18C1DEFBA54">
    <rdfs:label>INDICATIONS AND USAGE (34067-9)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F6FDCDD-5D5D-4FF8-A53E-EFF54E693DB1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1D9B7794-EB80-4C0A-A5B6-F9B8661691D2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Reinitiating abacavir</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9CD0B23-DB2C-4563-9DA4-14734F24DB6D">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9953D1B9-8B96-4EC4-AEF7-D059402BDC26">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80AFE396-60AD-4068-9D06-83718E17862F">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52CB1ACE-5349-4E7A-A0E1-84BC726E8B27">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79A46039-020F-4CFF-8F4F-224895ADAB3C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC5E8713-E77E-4C1D-8205-DC59E3CD350E">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E33403E1-9E18-4800-B583-B5ECE131DDBB">
    <poc:MedicalCondition>abacavir naiive</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7148865A-9774-4C02-823E-3B894AFA4478">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC7035A1-EACF-4229-B006-22F5E1E3984C">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39C933AE-C2DB-4506-B014-05E285F7325E">
    <ao:suffix> The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:39C933AE-C2DB-4506-B014-05E285F7325E"/>
    <pav:createdOn>2014-03-31 10:46:41 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>SJS/TEN and HLA-B*1502 Allele\nRetrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0216D027-571F-4B41-A606-57E6505EEF51">
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6C19597-2007-4097-B1F3-B2867D90E1ED">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CA8516E-11AD-4AA1-B2AC-E66A7CF5F4C0</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:5F4FD78D-70B3-4C1F-84D0-F82DDD09079B</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:B40A4559-7EE7-483F-8B7C-94D2B9C637A3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB66D283-6593-4F13-B316-171AA63A1E6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D5CBE3D-C4E0-4455-8867-F3CF56A56E80"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F02AF8F9-61D2-4DAD-8522-4971DB7C4DD1"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lastSavedOn>2014-03-31 10:51:40 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8DFD9785-24ED-4DD7-90ED-AE68E1963F4F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D2F3687-643A-4C09-8059-F59606AE90E9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:27395C78-FAA0-4CD7-A087-78E59DA28EF9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:37863929-E644-4CAF-A730-6DA1B4C8C31C"/>
    <pav:createdOn>2014-03-31 10:50:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34"/>
    <pav:createdOn>2014-03-31 09:02:38 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outwei</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B">
    <ao:context rdf:resource="urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdOn>2014-03-22 22:10:26 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2118E19-85E9-439B-A2BE-5001150AB7C2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F20CE66-F8C3-45F5-997D-6DA3618A2E36"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6477100F-B124-46B7-94A1-A46956E0A307"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F354582-DE01-47DD-929D-B501E8EB5B46"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4DBC7AE-A1A8-401A-9345-BB0D2918876C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:512081E4-B6CF-4E36-B991-10F09074D3A4"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68B6CECD-1F24-4727-B937-3D423B617296">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68B6CECD-1F24-4727-B937-3D423B617296"/>
    <domeo:uuid>68B6CECD-1F24-4727-B937-3D423B617296</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-04-05 16:22:50 -0400</pav:createdOn>
    <ao:suffix>6,</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C96F5648-835D-48CE-B56B-D4B6189369D6">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C96F5648-835D-48CE-B56B-D4B6189369D6"/>
    <ao:exact>The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>C96F5648-835D-48CE-B56B-D4B6189369D6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-05 14:20:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6A419A6-B4F0-4F0A-B706-3B241717BA9E">
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEA0830-ACA8-40DD-8D9F-78F87866EE0C</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A524395-D3F0-418A-8DBD-D4B470A69417"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F69F59C5-45E1-414D-8043-4CC914956AA4"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E173CFF-7AAD-48C8-9F3E-CFABD85C4AD5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF4C86C0-5930-466F-9514-287D558A207E"/>
    <pav:lastSavedOn>2014-03-13 04:28:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:09AB535D-F27D-405E-A10A-9E1298C5E715</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2E9E5F9-FF4C-4A70-8318-560F190CBC36"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5356A51A-122A-4E8E-B96D-7D85DC3E3AEA"/>
    <pav:createdOn>2014-03-13 04:06:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B1472FE-09F5-46BF-84F7-07F5E801036E">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7B2733E-8102-4490-A2DE-08845682375B">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:05242102-A177-47F2-AF99-897858A48917">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAC7144D-83A3-4BC7-BA03-F1BEC846458A">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0C80D29-6020-4593-B721-8D44A21693D0">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67CFB9CB-FD5B-4134-A50F-35E212088286">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04E5CF0F-8728-4B7C-98FD-2CD37F1C7F2B">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>This will need to be discussed. </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C10D838B-FD6A-4CB1-883A-8996C7D76046">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C10D838B-FD6A-4CB1-883A-8996C7D76046"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Phenotyping and genotyping methods are commercially available. The most common non-functional alleles associated with reduced levels of TPMT activity are </ao:suffix>
    <ao:exact>It is recommended that consideration be given to either genotype or phenotype patients for TPMT.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-31 10:32:15 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4ADCD079-2F7C-4A13-AF93-09BEC50EB85F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4651603-DDAF-415C-B87C-F2E172EC6820">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60DBA1F1-8C76-4F8C-9E4A-A4A09F0BFEE1">
    <ao:exact>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above.</ao:exact>
    <domeo:uuid>60DBA1F1-8C76-4F8C-9E4A-A4A09F0BFEE1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-04-05 14:12:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60DBA1F1-8C76-4F8C-9E4A-A4A09F0BFEE1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patients CYP2C19 genotype. </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDC6D3CE-8360-41F1-AC01-ADCAB96DBE01">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2805EA8C-EF36-4F17-A3DE-0D65B57A2D91">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E57FFBDF-5B83-4A8E-B0FF-EAF9A92CF5D8">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B8FAA54-48A6-4B88-A9A5-5D1373EB3B83">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96435AEC-7FC7-476B-8A38-A7462924508D">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5EDB7F4-DCB6-4225-9C67-19232653963B">
    <rdfs:label>PHARMACOKINETICS (43682-4)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8B38C2C-60A1-4BB9-A29B-91AB3B1103AC">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A5FA49C-7A7C-4C31-A2CB-18FD6E93C717">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:40551475-996A-4ABF-A6A4-136400388D2E">
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2471E7F-FECD-4817-BF9E-1D554E5FEDBD">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED">
    <ao:body rdf:resource="urn:linkedspls:uuid:34F7A071-6983-40CD-B22D-108DA2488667"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-31 09:10:10 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:97A00FDB-1B7E-4BA6-B531-7DA063BAC30B"/>
    <pav:lineageUri>urn:domeoserver:annotation:5C114E05-B901-4854-ADFC-7481FF0A4FDA</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C751B6F1-6EDE-4C87-A5FE-1A6E0D3D4C92"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1EF0B4A4-3F75-4AB9-8AA1-84A028AD5EE7"/>
    <pav:lastSavedOn>2014-03-31 09:10:25 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC44848F-712F-4F1C-BAFD-94EEC65ED24D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A85EF876-AF0D-4316-82E4-390553A6DEBD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf5d285f1395e4e91bc2de94ca49d5c0c">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AAB10463-4594-41C7-8967-D01D6D1D6676">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F211EFB-8429-4BE7-8E97-2DC2313E9DBE">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF5181A8-730E-48BB-9435-15F38AE3D7C5">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:88CEE075-27A4-45CF-9AD6-7D8200984247">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Phenytoin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5034D1E8-1E2C-4493-90F2-D662231FF9CF">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F753BE50-C871-456B-8398-1CB493CA2C50">
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F753BE50-C871-456B-8398-1CB493CA2C50"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.</ao:exact>
    <pav:createdOn>2014-04-05 16:17:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F753BE50-C871-456B-8398-1CB493CA2C50</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AA95853-6352-4A19-AE15-6A6509370B0A">
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:0E921441-E10D-4841-BC87-04997D35DA17</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-04-05 16:22:57 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C9AE6E5-8D63-4782-A826-95A817B04A80"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D8D2153D-C927-4810-A9B8-5868EB64D705"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF5BD2DF-A230-4457-84BA-3BD31B498F42"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF70E34B-5763-441B-9F74-831B54FD6A75"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <pav:createdOn>2014-04-05 16:08:22 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:68B6CECD-1F24-4727-B937-3D423B617296"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96459EB0-915A-4FFF-ACCE-4EBA8EEA516A">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>low-or-absent-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nde21f8155cec49cd93dc31d53a73c955">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFDA1212-D9CD-482F-9553-0B68581B090C">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>DOSAGE AND ADMINISTRATION (34068-7)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N57a61d86f3954c1bb64df4fbe2bc00f3">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BFFAC07-01A5-4D15-9B29-27CC35619E56">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0BFFAC07-01A5-4D15-9B29-27CC35619E56"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:exact>TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 10:29:51 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08A6A966-51CF-4992-BC36-3C12B4E8EC7A">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E51D6570-58A4-4650-B5E1-E1D4463384B7">
    <ao:prefix>Hemolysis:</ao:prefix>
    <domeo:uuid>E51D6570-58A4-4650-B5E1-E1D4463384B7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-08 10:48:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E51D6570-58A4-4650-B5E1-E1D4463384B7"/>
    <ao:suffix> Immediately and permanently discontinue Elitek if hemolysis occurs. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek therapy (</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <ao:exact> Do not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4B5F9D6-6190-4D39-A50E-B39CD7193832">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA4519DC-727B-4A71-AFAE-85DE63C6BE8D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7CB636F-0374-4648-9C14-E151AB0B6507">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96E4CB7E-0FA4-484B-9FF5-B62030E81FCC">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DDEE7195-B373-41DA-9360-816DBE73CFFB"/>
    <pav:createdOn>2014-03-31 09:09:18 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E08C847-80F4-4998-AA08-71AE4C51F44B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA184D35-B996-4FF0-922B-6B732D552E7C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:4792249C-8AEE-47E7-BDDB-5D43DC4DB5E4</pav:lineageUri>
    <pav:lastSavedOn>2014-03-31 09:10:25 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0FFCDB3-7874-48E5-99F9-2E81E91B47AF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F8D1B18-EB03-4CA0-94D9-8576A215322A">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Use specific</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5FED7CB-8323-4BDC-BD71-E1C16F06B46F">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F54C376-30A1-41D7-8621-445FDA308DB9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77763CA5-72B3-4FD1-8566-6302D1BB2E6F">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00321</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Amitriptyline</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:033D1863-DEEF-4F8F-8743-867CCE695424">
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-31 08:59:45 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:684DEB11-4F24-438A-9FEB-1A6BAA9E2767">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A572B29E-DA06-4D69-9DBD-1D5AA92BBB2C">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdfs:label>Recommend</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0862483-2AC9-4C81-9DC2-BDBBAC721E69">
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BFB99BF-9A88-40DD-8810-1E0A1E7A6D0A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:ED0170B2-B4E0-4B2B-B614-54F18F28590F</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AC93DEDB-7C87-4168-8104-9E2959E8F017</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:10FCC8D9-8DEB-49C0-8FFE-CC0378BC383D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F91D0EF-2A93-43B1-AE98-431E75007AFD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D1F9B53-86F9-40A1-A403-4A70C4379678"/>
    <pav:createdOn>2014-04-05 15:18:06 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-04-05 15:18:09 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:CD345D13-0B97-4476-B792-51AA96654F0F</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE50DAC7-B31A-403F-BB04-748BC8292D20"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9DF0573F-1E06-4F3F-8818-9CA8BAAB5223"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:508FAE65-0963-4DF7-9CCD-11FAFAEDDD84">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1665415C-50E8-4DEC-8A24-3A0E50710FC5">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38A49BE9-743E-4568-A7D3-2B9CBECD8F52">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Noncompliant</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B1D41D3-765D-4219-97FB-CD526A2262F8">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:99E94AA2-89EE-4CC7-BC1E-9022C163738B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F696731F-DD89-46F8-A2A7-7E01184A366D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2D71524C-C891-419F-BFCF-DD418673C531</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:CEF29BBA-E19C-4061-89FB-884D3898EA68"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-05 16:18:26 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-04-05 16:18:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C9DDA46-72CB-41F2-8F6B-9B06E851D824">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Phenytoin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EB23E7A-2869-485D-965A-820F1D704C25">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>sitivity reaction, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a hypersensitivity reaction.</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact> If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-22 22:18:30 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E112DEF-DB5E-4B6C-917E-5838F9434D76">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>BOXED WARNING (34066-1)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:232541B6-1FA8-43DE-B45A-960569AFD4D2">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>CLINICAL STUDIES (34092-7)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75B5D7CF-A4B7-429C-977F-A0AE4401ED25">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E36349D-A55A-478F-B303-057062C970F8">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A08A96C-6C74-4E35-8BC1-AF29037EF9B7">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-05 12:33:39 -0400</pav:createdOn>
    <domeo:uuid>9A08A96C-6C74-4E35-8BC1-AF29037EF9B7</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>A retrospective genome-wide association analysis1,2 of 1671 subjects (1604 subjects from Study 4 [see Clinical Studies (14.1)] and 67 subjects from another clinical trial) was performed to identify human genetic contributions to anti-HCV treatment response in previously untreated HCV genotype 1 subjects. A single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B rs12979860) was associated with variable SVR rates. The rs12979860 genotype was categorized as CC, CT and TT. In the pooled analysis of Caucasian, African-American, and Hispanic subjects from these trials (n=1587), SVR rates by rs12979860 genotype were as follows: CC 66% vs. CT 30% vs. TT 22%. The genotype frequencies differed depending on racial/ethnic background, but the relationship of SVR to IL28B genotype was consistent across various racial/ethnic groups (see Table 13). Other variants near the IL28B gene (e.g., rs8099917 and rs8103142) have been identified; however, they have not been shown to independently influence SVR rates during treatment with pegylated interferon alpha therapies combined with ribavirin.1\nTable 13: SVR Rates by IL28B Genotype*\nPopulation	CC	CT	TT\n*\nThe SVR rates are the overall rates for subjects treated with PegIntron 1.0 mcg/kg/REBETOL, PegIntron 1.5 mcg/kg/REBETOL and Pegasys 180 mcg/Copegus according to self-reported race/ethnicity.\nCaucasian	69% (301/436)	33% (196/596)	27% (38/139)\nAfrican-American	48% (20/42)	15% (22/146)	13% (15/112)\nHispanic	56% (19/34)	38% (21/56)	27% (7/26)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A08A96C-6C74-4E35-8BC1-AF29037EF9B7"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PEGINTERFERON_ALFA-2B-0a8f3137-0e3a-4a60-a872-cb7d761b30e1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E917341D-315D-47DD-823A-B38F630BB493">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E917341D-315D-47DD-823A-B38F630BB493"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix> Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous)</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-31 10:33:56 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F54C758-D4E0-4429-966D-86A62BCB99DE">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2149C6EF-CB6E-4CBD-A1BE-17C5A03881D2">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31AEE449-5872-49E6-87A3-8034A2A4C06E">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D79C5BB-E112-4A3A-BDAB-DA2CED022D2C">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:231FB605-C0BA-4076-A03F-F60FA03C8005">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3BC4EB7-7B55-4A32-B1F3-F18E60EA2784">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdfs:label>WARNINGS (34071-1)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92A5DF92-D34E-422B-A682-9D87888F028C">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3012</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>DPYD</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D36A6837-4292-476E-B4E5-57120CAFD169">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <rdfs:label>G6PD</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-31 08:58:47 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele</ao:suffix>
    <ao:exact>CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n=1,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F355DB1-F2E0-4D1C-8E14-13AAB95AF32B">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0AE4805A-9064-4B43-9C66-7F8E47ECAB77">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:275D20C4-ABA0-49C9-8CA0-CE21B5A4C774">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AC52C4F-30F0-4DE2-8ACB-2AE73DBFFC8F">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A73443EF-AA27-4534-A1A3-5EBEBDDDBFD7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A73443EF-AA27-4534-A1A3-5EBEBDDDBFD7"/>
    <pav:createdOn>2014-04-05 14:09:05 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>A73443EF-AA27-4534-A1A3-5EBEBDDDBFD7</domeo:uuid>
    <ao:exact>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D29BBA81-587C-4066-A8FA-C57C38744BA3">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ACEB6342-E9BD-49A1-A32D-5853FA3C4FDC">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN. Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B* 1502 positive patients, when alternative therapies are otherwise equally acceptable.</ao:exact>
    <domeo:uuid>ACEB6342-E9BD-49A1-A32D-5853FA3C4FDC</domeo:uuid>
    <ao:prefix>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE]). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <pav:createdOn>2014-03-31 11:30:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ACEB6342-E9BD-49A1-A32D-5853FA3C4FDC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2010B203-56DB-4F65-9F71-89F69C107739">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0"/>
    <ao:exact> NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status</ao:exact>
    <ao:prefix>ZIAGEN is contraindicated in patients with previously demonstrated hypersensitivity to abacavir or any other component of the products.</ao:prefix>
    <pav:createdOn>2014-03-22 22:06:02 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6477100F-B124-46B7-94A1-A46956E0A307">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3FC1B95-BF74-48EA-BDD9-D5D59413425D">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A488585E-8C31-494A-82C0-A0192B649F4B">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B29A0DD-F4CA-40E4-A73D-50262CE8D533">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:648B76D4-14FF-42F7-A62D-19B52C07FAD0">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B6B7344-5691-4A81-8539-22F0C0A83EE0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-31 00:20:28 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9718231-5945-4B15-8C90-921DFE7E3D2C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2805EA8C-EF36-4F17-A3DE-0D65B57A2D91"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF1F2F52-A010-4F7B-A226-1B42DC211DD5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E4A83A6-A990-4861-BCF6-169897B6B8D9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 00:20:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04168134-D13A-48ED-B29A-33D10973411D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36466390-592B-408A-A206-8E537F60D10B">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:exact> Dosage reduction is recommended in patients with reduced TPMT activity.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36466390-592B-408A-A206-8E537F60D10B"/>
    <pav:createdOn>2014-03-31 10:36:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C23F3CF2-7C50-4437-9BD9-FC11F54CDF3E">
    <poc:MedicalCondition>HLA-B*1502 negative</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF1B0A87-0850-4C5E-9029-B7477BD432CD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <rdfs:label>Phenytoin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5356A51A-122A-4E8E-B96D-7D85DC3E3AEA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <ao:exact>In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5356A51A-122A-4E8E-B96D-7D85DC3E3AEA"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-13 04:11:59 -0400</pav:createdOn>
    <domeo:uuid>5356A51A-122A-4E8E-B96D-7D85DC3E3AEA</domeo:uuid>
    <ao:suffix> Citalopram 20 mg/day is the m</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7e93a99a0c5c4eed8d64bcb0e23a99ec">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:794627FA-8A1B-47EC-930C-89EAA96DCE8A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <rdfs:label>Do not start</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7EFE6C13-B696-4DA7-864B-D7641D424489">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*2, *3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6595EA04-1E7C-449E-BBE5-6569547FC2B8">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AFFDC03-AB18-40B8-A042-A4208215CC79">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFDBBDAE-1D40-4207-988F-1E8CEC5ADA04">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE588D93-C0EC-4E98-AC83-D151CAD07967">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00706460-7B8F-4A66-93D0-7F09DF19B730">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B5E4576-3B52-46ED-A373-960974ED6CC7">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <rdfs:label>Phenytoin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2F2E1BD-DA94-455B-BCE8-504DDB9CCA35">
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B029387A-6DF6-4791-81C8-640DDABE9E7C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B029387A-6DF6-4791-81C8-640DDABE9E7C"/>
    <ao:exact>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-04-05 16:10:45 -0400</pav:createdOn>
    <domeo:uuid>B029387A-6DF6-4791-81C8-640DDABE9E7C</domeo:uuid>
    <ao:prefix>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:294E3750-362F-4FE6-90F5-16F26618EB8C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>node positive breast cancer, estrogen receptor positive breast cancer, progesterone receptor positive breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C9688E86-8AE0-488E-BCCE-5552AF549D79">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:428A5C10-8C0C-42CC-BC78-1E3D27230F69">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:231714C1-0EDE-4AC4-BF14-1539518DE7EB">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CB3E759-D86B-4DF5-BCBA-D74920F266AD">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2CB3E759-D86B-4DF5-BCBA-D74920F266AD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>2CB3E759-D86B-4DF5-BCBA-D74920F266AD</domeo:uuid>
    <pav:createdOn>2014-04-05 15:39:50 -0400</pav:createdOn>
    <ao:prefix>ministered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events.</ao:prefix>
    <ao:exact> In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8C4ACC7-F6BD-4859-8787-7CA75B06C6B2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFBCF9E3-E6EB-44EB-9FA9-FA8288501BCA">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CF1DB3F-D571-4659-87C3-A8418E8E1024">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>ancestry with high risk for HLA-B*1502</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49EE63F5-AA50-43BB-9A16-C8EF5565FBA5">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37863929-E644-4CAF-A730-6DA1B4C8C31C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5206FF4-43D0-486E-AD37-1641571853D8">
    <pav:createdOn>2014-05-29 14:08:49 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F5206FF4-43D0-486E-AD37-1641571853D8"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:929876C3-7A0F-4C27-860D-6ECFBB206325">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*2, *3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D339484-75A7-4F61-986B-34254401FBDC">
    <rdfs:label>Do not start</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388">
    <ao:exact>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388"/>
    <pav:createdOn>2014-03-22 22:02:44 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8CA311B-6880-4B71-9C68-9253C95469D0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0396bf07dea3411e9af9d86aebbeae56">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D22F7B0A-E1F0-49FC-8E1A-95DE0F9B7B17">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:18C26EFF-090B-4295-9AC1-BB1A5010E96D">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6C5C6C1-0C96-4407-B7F9-14A2EEF7C651">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF1F2F52-A010-4F7B-A226-1B42DC211DD5">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0317AB6B-3211-41B4-A7A4-911502DE79E2">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CA30A28-B75A-4D14-87B5-8F1D73A58AF0">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C302DD1A-5312-4CBB-84A3-A9157160B0CD">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B5C15C4-69DB-4101-A97A-F5E71FE34E31">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4302688-2092-43B3-AA5A-F2E208E250B8">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B04A39F7-A9EE-4865-B7C3-458FB6246DED">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B969AF7-491B-4B0D-9C3C-CADF2A313CEB">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84C9C2FD-017F-43C7-AD66-35BE4F24C7CC">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6246790C-2A80-41B2-9416-D6EA8ECFB253">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33C47CF9-B746-4807-8239-B7A0034B5CA2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:33C47CF9-B746-4807-8239-B7A0034B5CA2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-04 18:35:49 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:suffix> (12.5) </ao:suffix>
    <ao:exact>Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6122C146-F947-43E6-A37B-054986F13726">
    <ao:prefix>PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed [see DRUG INTERACTIONS (7.1)]</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6122C146-F947-43E6-A37B-054986F13726"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <pav:createdOn>2014-03-31 09:32:37 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:240A151F-8525-41A6-94B0-89BF2D5B4B09">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78A1719D-0994-4541-ACAD-575FC841174F">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FCF11334-1046-42B4-A5C4-9FE4655BC1B7">
    <domeo:uuid>FCF11334-1046-42B4-A5C4-9FE4655BC1B7</domeo:uuid>
    <ao:suffix> Immediately and permanently discontinue Elitek in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek [</ao:suffix>
    <pav:createdOn>2014-08-08 10:51:30 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <ao:exact>Do not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FCF11334-1046-42B4-A5C4-9FE4655BC1B7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9B9E7CF-06A9-4A88-BB1C-FA61FD224758">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76CA930A-8FB7-4D0E-B8A0-16806DF17946">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdfs:label>Alternative Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B39A55ED-DE3F-41B7-AB3B-9296A2272AA8">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Noncompliant</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79B2D094-0174-4838-92F0-966F2EAA6D21">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A158D68-CC0D-4049-A37D-80094F766DF8">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:30590FDF-8852-4985-8AAF-0D446C7B20CB">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>For dose recommendation: I said "decrease from baseline" because they are recommending a decrease in the standard max dose rather than recommending a specific dose. It may be easier to convey if there was an option like "do not exceed x dose."</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DB8FA0B-465E-4FB6-885F-E8906A821B76">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D986E293-5E73-4523-95D3-9E70CA59FB2B">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C504F222-A2CF-4F52-B31C-954FE303DF26">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>G6PD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D53DDA2-4DC2-4C6F-9A6F-676B4E30032E">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>CLINICAL STUDIES (34092-7)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6535077F-E961-482C-8B57-F786CEC0E8B6">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:200827ED-2E77-4C34-9CA9-A49627058B17">
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63850B6C-3C0C-4460-B237-61B45B217657">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0697AC43-D2AD-49FB-AE5B-3618ED26027D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0697AC43-D2AD-49FB-AE5B-3618ED26027D"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>0697AC43-D2AD-49FB-AE5B-3618ED26027D</domeo:uuid>
    <pav:createdOn>2014-04-05 15:28:10 -0400</pav:createdOn>
    <ao:suffix> The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D690D50B-5476-446F-BC94-2ABF31A96DC6">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC44848F-712F-4F1C-BAFD-94EEC65ED24D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:417A9CCF-F2A9-4ADF-8677-F5EBEA736745">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:525A1A88-3E56-41E0-B8B0-F36EF85A756E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:ECE8AB57-BD07-4B4E-9773-4041C16C8293</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:163946C5-D2BE-4C9A-9484-8ECD726ECFD5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C271EF89-0BA7-4D1F-B08C-786C64D72A0F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:93EC19C9-FE86-456F-9737-C8F58AC581D3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-04-05 15:57:40 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:923E4D8E-3A80-4547-81B9-393003BDBC56</pav:lineageUri>
    <pav:createdOn>2014-04-05 15:57:18 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:D956BAE8-49DF-4A38-83D0-7D96397F914D</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3C573B81-5D57-4755-8DAA-D1B21F97D486">
    <poc:MedicalCondition>fatal dermatologic reactions</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC67D62E-76A8-484C-B632-32B086C0C237">
    <ao:exact>Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.</ao:exact>
    <domeo:uuid>DC67D62E-76A8-484C-B632-32B086C0C237</domeo:uuid>
    <pav:createdOn>2014-03-13 04:16:26 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC67D62E-76A8-484C-B632-32B086C0C237"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDC51AAD-92B0-4CA4-8F84-563B8F3DA6C2">
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:911FE15A-A1D1-45B8-80F8-B2A7A19AF0EC">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C1B08A1-538C-4FCC-9013-665F0B7A9D8F">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <rdfs:label>Capecitabine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C72D52E4-CD52-4DA5-9075-5F3A2EB7EC43">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E69519CE-CDB4-4ADE-9142-E9FF4BAFBE3D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47ABA217-9567-40AE-B181-951C9C73F456">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84CB3302-4893-423F-8351-EC515FEE5767">
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:20BDC0BB-49CD-4BF1-826C-42DC4D12B075">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91373757-CDC9-41DF-834E-F17713AEE49F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:524FA29B-279F-4873-ABB9-881E8E3FADC2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:524FA29B-279F-4873-ABB9-881E8E3FADC2"/>
    <ao:exact>Risk of death in ultra-rapid metabolizers: Conversion of codeine into its active metabolite, morphine, may occur more rapidly and completely resulting in higher than expected morphine levels and respiratory depression or death.</ao:exact>
    <ao:suffix> (5.1)</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-22 18:12:24 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD404436-B0A0-4A86-A4BF-0CBB25951730">
    <pav:createdOn>2014-03-31 10:42:14 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD404436-B0A0-4A86-A4BF-0CBB25951730"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK (SEE </ao:suffix>
    <ao:exact>HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16190606-ABD8-4160-99D0-3FC9526D8679">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>ytic reactions occurred within 24 days of the start of Elitek. Immediately and permanently discontinue Elitek administration in any patient developing hemolysis. Institute appropriate patient monitoring and support measures (e.g., transfusion support). </ao:prefix>
    <ao:exact>Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16190606-ABD8-4160-99D0-3FC9526D8679"/>
    <pav:createdOn>2014-08-08 10:57:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> [</ao:suffix>
    <domeo:uuid>16190606-ABD8-4160-99D0-3FC9526D8679</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84CDF7A6-6379-47FD-AE15-BDF59079AC5B">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50E89487-AEBD-4C92-8435-DA6E6DF542E7">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:50E89487-AEBD-4C92-8435-DA6E6DF542E7"/>
    <pav:createdOn>2014-05-29 14:12:32 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A1DEFF0-2B38-467C-8BDB-57D01AAB839D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <rdfs:label>Rasburicase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0AA45B3A-5961-4083-BEE0-F2EC6C600E93">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Possible issue with table annotation?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B1228DD-587C-440D-B53F-1CB7F91F977A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Rasburicase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E070E033-6FF0-4935-BFD9-7D3615D5B5A6">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A98FC90B-0172-4B94-8197-2D6E42E0C094">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B320883-7E40-4EE6-934D-64133E41A51F">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>This one is a little difficult, as the contraindication is mentioned in connection with the pgx, but it is contraindicated in these conditions regardless of cyp2d6</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF44CB0B-8D3B-4979-A4BF-84A8306DD07E">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>PHARMACOKINETICS (43682-4)</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B45A1161-E1F3-43A9-87F3-72B6694108A3">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E638CC1-F722-47BF-B15F-70520BF73577">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A9A0113-CA08-49FE-A7FE-E0A08C5601C9">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D650174-CEF0-4E26-9480-84F302FF2D61">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A811AD28-ECA2-4AD1-890F-F3AF8C07E145">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:19F33D58-FE1E-46C1-B076-70725190FF1F">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D5393BF6-CC07-48B0-A45C-CC5746C469C6">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>G6PD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007749</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2118E19-85E9-439B-A2BE-5001150AB7C2">
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82EDBD4A-D28C-4573-A121-F077D37550FD">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#NURSING MOTHERS (34080-2)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>NURSING MOTHERS (34080-2)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC497212-D269-4238-AA69-CFE2271A33C3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7511CC4-4C2A-4BF1-ABEB-7A7E224C66E0">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 14:04:21 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:903A0C27-C16B-4458-884A-B7E17AC3498A">
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB21A51C-F18D-4AA6-9FA2-596E554A26A0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F140206-4891-4319-B539-857B384767DF">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC48DCC3-79AE-45A9-B2F5-5F4D71A28BA7">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9B031F8-0FE1-467C-A320-1BEC8CFFB046">
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2DDD3BEC-4F61-45C8-B334-A382E94D6B8E">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8FA5770-5F24-4B37-B3C2-9F126A0C01E5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ADB4624B-180F-4FC8-93CB-70984538DBB3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Voriconazole</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00582</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:02D700A1-EB95-46CE-AFAD-9D741A4CF918">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:14BCF077-5B5D-4F5B-8368-DC46C36ED32D">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommended</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE825745-A408-46CC-A2DF-3EC188BFF1B7">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACAD1467-1EAA-4047-A039-2BD0A336E02C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>estrogen receptor positive breast cancer, estrogen receptor unknown breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:073BA57C-2916-4E35-9AF3-AA99E504958C">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:585DB1D6-47AF-45EC-B199-A38AE81D7FF2">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9FD9B2E4-A468-4445-A352-D37CBAD1BC3A">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF440220-03B7-4A3A-B485-7718DB5337E1">
    <poc:MedicalCondition>estrogen receptor positive breast cancer, estrogen receptor unknown breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:500D2BFA-D162-492A-84D8-7565B933C44A">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4A639E7-B5E1-41AD-BDEA-3D6F86DBFF7A">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE6A11BA-9F40-4FCC-AD6B-A61A5202A894">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D01FB849-1606-42D2-9C6F-02D76517DD5F">
    <ao:suffix>(SEE </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-31 10:43:17 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D01FB849-1606-42D2-9C6F-02D76517DD5F"/>
    <ao:exact>PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE6E5FC3-C3DC-4769-8F5E-F798B06D841D">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58D51FB7-6F1E-491E-8784-7B322766B0A4">
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85AB55BF-99C3-42CB-B17F-7BC782CA7B6D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hormone receptor positive breast cancer, hormone receptor unknown breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A411F30C-B738-4C16-9002-C2FDBBFF7D03">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A01999AD-BCED-4C44-AA67-75D0C46380C6">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F02AF8F9-61D2-4DAD-8522-4971DB7C4DD1">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC313370-013E-4D31-9C91-0639B09C70C0">
    <rdfs:label>Rasburicase</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:40AC27D0-6D44-444E-A3B8-CE5689AD915D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A66B4A39-E0C6-4822-83EB-94A40AAABE20">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95AE669C-DEBF-4988-AB1B-2E1481AA1261">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A41FEF50-F825-483B-A5B2-792BE459747E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na9191ddb5a6b46b38da84b79d6faaf9f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DDEE7195-B373-41DA-9360-816DBE73CFFB">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74AFE340-9F0B-44D6-B3FE-0DDE02300229">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79E7780C-E197-4433-BC48-27D6D8269513">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58E59978-E28B-4ADC-AB4A-815E87565940">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F7C5F16-ED8A-43AA-B057-CD1C38FA8BCA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34178809-00EF-47D7-8591-4F5BE26FF59A">
    <rdfs:label>Do not start</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:207BA609-3844-44A9-98B4-E6695EA86595">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B8B5B40-43F1-4AFF-BBE5-2D809EE85569">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A84C1F4-ACB2-4D98-B2F7-F5606AF22F3F">
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAB45A3E-C885-423C-8180-616EBB2B70D7">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:144D94CA-9F40-4777-95A3-126DC102C392">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D8D2153D-C927-4810-A9B8-5868EB64D705">
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D513D738-4472-4743-A187-3200479661B2">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F38969D3-27ED-472F-85C7-83C05232C92D">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdfs:label>Azathioprine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2FC0361E-34A6-4ABA-9BF0-68DEC792FC43">
    <rdfs:label>Ph Chromosome</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://www.fakeuri.com</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:484512E9-44DD-4E7D-9CB4-DA99B2BDD0FC">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:640E6CBB-2ECD-4B68-80C2-7FA279028E61">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A22AC452-44D3-45A4-A9E2-418CAAA413B3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>HLA-B*1502 positive Asian, other ethnicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34D31E31-C438-4861-84E8-E08DC610E12D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58308C5D-40B5-427A-AB8A-BA9B5B593ADB">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6943D8EC-25DB-4498-B7EB-229A9093F33B">
    <poc:MedicalCondition>adenoidectomy, tonsillectomy, pediatric</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C11F474C-5FE5-41F1-BF97-71793CD0C79E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F007A3E0-FB60-4CDA-9A07-BC6E3A3F95D1">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CONTRAINDICATIONS (34070-3)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>CONTRAINDICATIONS (34070-3)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E3E3B7C1-31DA-4515-A45D-0487C9D87BF8">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1161E82-9339-49AD-AAC4-F58471BF51EA">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B52DDA70-3E7C-4358-8558-ADAC22E0B522">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27027F5C-200C-4EC5-A1DF-38AF71320ECA">
    <rdfs:label>Active ingredient</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E1DE9EEC-D7E9-43DD-9614-254A64DA4566">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-31 11:25:15 -0400</pav:createdOn>
    <ao:exact> Carbamazepine Extended-Release Capsules should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E1DE9EEC-D7E9-43DD-9614-254A64DA4566"/>
    <ao:suffix>Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN </ao:suffix>
    <domeo:uuid>E1DE9EEC-D7E9-43DD-9614-254A64DA4566</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92E3917B-F049-41BF-B9E8-4177940118E0">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C57DECE4-94D2-4E66-B95D-0B92ED09F101">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4dc444063a974317acaa19185b635034">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A8CECC3-ADF7-4BF5-A7F9-53CA959E9EC5">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99E94AA2-89EE-4CC7-BC1E-9022C163738B">
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE3EF123-F169-4856-A367-0910456D1C13">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB66D283-6593-4F13-B316-171AA63A1E6A">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>South Asian, Indian</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD29CCDF-3F5C-4A5F-B055-6A7C5C5B8DE2">
    <poc:MedicalCondition>breastfeeding</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6727EEEC-0FA1-4F5D-A001-BF4BF5B6EBA0">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D50CE73F-31C8-4AAD-BF2E-EEDBE1F40F42">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11E0D331-7AD3-4D77-9754-5827D1F13665">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>homozygous non-function</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:889E70DD-660A-49E9-8EFE-6A2091ECBE3D">
    <ao:prefix>ing codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-03-22 18:10:00 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:889E70DD-660A-49E9-8EFE-6A2091ECBE3D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97B839E1-AC98-4EFF-B82A-4758C6D6FA67">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63CD03D5-538E-4158-8C99-312CA91D33CA">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FEFE02F-7BE5-4491-AC45-494E15972825">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:404E3A01-9ACB-447C-A78D-63217942AFDE">
    <rdfs:label>BOXED WARNING (34066-1)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C0D2D71-30BE-4C6F-9E76-83570D870A36">
    <rdfs:label>Peginterferon_alfa-2b</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00022</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E273AC2-D475-4307-B956-36A5EF1FD482">
    <domeo:uuid>6E273AC2-D475-4307-B956-36A5EF1FD482</domeo:uuid>
    <ao:exact> Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrels active metabolite.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-05 14:03:53 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E273AC2-D475-4307-B956-36A5EF1FD482"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A2389CB-84FE-4A5C-98A0-3CEBA6E43DD7">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84D9D2B1-F3B6-4D62-B457-CAF8EEB82D57">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1BD1263F-1D46-44FC-A11C-29A8F2B0B2FA">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34066-1) BOXED WARNING</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34066-1) BOXED WARNING</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:724637DE-1892-4854-AF72-E081712C9608">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06218F34-0177-4307-871A-29DDF8734A8C">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69654F1F-F8B9-43CE-87A1-63A39B364922">
    <poc:MedicalCondition>estrogen receptor poor breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2336D1A4-8B85-4B22-9E42-5C0D4CCF2690">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <ao:exact>For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-22 22:11:34 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA95EF6A-69CD-4E8E-B0AF-39CEB701AEC9">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Maraviroc</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4925ECB-8672-4676-BB41-B92BE271909E">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7218BA66-5AC4-49A0-88C4-BED2D225D29D">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6C4E4DC-F3D7-41CF-A7C2-1197BEF909D1">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>BOXED WARNING (34066-1)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD507E05-6BCF-49EE-A25A-B71210D9C9C6">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0238086F-B61A-4EA7-8488-FCC3838FDB57">
    <ao:exact>The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. </ao:exact>
    <ao:prefix> </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 10:20:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0238086F-B61A-4EA7-8488-FCC3838FDB57"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E81029A-B4F2-4E40-BEC8-C0DA8FF61D0B">
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4734F15E-5E9A-406B-8261-68A584AE0192">
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>BOXED WARNING (34066-1)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79886681-5236-48AE-96FC-450031C1FE2C">
    <poc:MedicalCondition>Stephens-Johnson syndrome, toxic epidermal necrolysis, Chinese ancestry</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15D8BCC3-9814-462C-A460-8C95DE79D543">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Proton Pump Inhibitors Avoid c</ao:suffix>
    <pav:createdOn>2014-04-05 13:57:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15D8BCC3-9814-462C-A460-8C95DE79D543"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>15D8BCC3-9814-462C-A460-8C95DE79D543</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5D3437A-86AF-4DFD-8D50-68FC52B89D04">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B66E5587-3003-49F2-95AB-8ED4901E5D99">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>bleeding risk</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A72F2706-DCC8-46D5-93ED-1CB1BEAC89B5">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E49CBEE-CB52-4586-94DB-B7BE7FEE31B3">
    <poc:MedicalCondition>node negative breast cancer, estrogen receptor positive breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A4274FC-E56A-4CF3-B0FF-E69ACB8124B2">
    <poc:MedicalCondition>over anticoagulation</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA180FC3-7F01-4E53-B1A1-8A0A0C1A181A">
    <poc:MedicalCondition>genotypes unknown</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5940DFA3-0716-4600-B609-84C37191F161">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:66710520-1FF6-45B8-BB01-D2C96ACD928C">
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF70E34B-5763-441B-9F74-831B54FD6A75">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF568213-74DA-4759-BEFD-27B2A9615A8D">
    <poc:MedicalCondition>Japanese, Korean</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C9AE6E5-8D63-4782-A826-95A817B04A80">
    <poc:MedicalCondition>asian, caucasian</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7F5105A-3886-4258-9032-560D597BDDD1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D15E0D1-9C28-416A-BD1F-7E1AEB24CAE5">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.0alpha-040">
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:version>2.0alpha</foafx:version>
    <foafx:build>040</foafx:build>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:homepage></foafx:homepage>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E3C7CAE-0309-46E4-BDC9-AD2A529B0C68">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C2E3803-33B9-4804-86ED-72E7EAA938FA">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>acute coronary syndrome, percutaneous coronary intervention</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:569FC6B8-F847-4E16-8DC6-2565BB94DAC8">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CC99684-CC25-4A65-B92D-19573F301798">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A65CDE07-A7B4-46CF-A0B5-2C3A69D3D796">
    <poc:MedicalCondition>recent blood transfusion</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FFDCD61D-7861-4B4F-AE17-4A15CD51BFA2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0FDB6D8-3B29-4169-B943-7B9136C0BE5F">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C271EF89-0BA7-4D1F-B08C-786C64D72A0F">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7FD460F-C987-4812-B8AA-8A86EA9D2598">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E3D25B8-C473-4C01-A52F-0E6E3FDDBEFD">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B4BFDF8-85C4-40F2-A42F-23B4B1176095">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CEDFE1C-AE4B-4114-B8EA-5BC9F86A43A8">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:888E1F10-7B19-406B-985C-7B49F664BAC8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C48398C-4677-4B8D-9AD5-2D2F27BACDD5">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdfs:label>Azathioprine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA0CC3C4-BB85-43B2-9E26-22491D1149A9">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A118BD1B-6912-410D-8C56-28BAFDA74348">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5E4B716-03DB-4B96-97E1-0692CCC51BA1">
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44AFA8EA-D5AA-493A-BEE4-FB63F29B3842">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA56D95F-F5FD-4A92-B8AB-0D7141F9DD42">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decreased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46A8E276-BD15-46EC-AB82-26BA60DCDA2A">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F3529E8-EC47-4F12-93B6-0C90DB27001C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE50DAC7-B31A-403F-BB04-748BC8292D20">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Maraviroc</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8A134D5-7E29-44BD-A95B-6E0675223571">
    <ao:suffix> Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrels active metabolite.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F8A134D5-7E29-44BD-A95B-6E0675223571"/>
    <domeo:uuid>F8A134D5-7E29-44BD-A95B-6E0675223571</domeo:uuid>
    <ao:exact>CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.</ao:exact>
    <pav:createdOn>2014-04-05 14:02:52 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4821B246-2A1E-468A-9599-A97AAA977C8A">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F2F6955-D5F0-4EA6-B928-9444BC14F6A9">
    <poc:MedicalCondition>non-Asian</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:91677CBE-0960-45DD-82D5-D6F7E8960A03">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:91677CBE-0960-45DD-82D5-D6F7E8960A03"/>
    <domeo:uuid>91677CBE-0960-45DD-82D5-D6F7E8960A03</domeo:uuid>
    <pav:createdOn>2014-08-04 19:48:38 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>XELODA is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0b288018d9624e598a5b7ab1ec79a182">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8746A5D-3C7C-4436-89ED-9F65C5B50AE0">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:222B5AC7-FAF6-4D08-8831-026C35001C30">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Not quite sure how to annotate this one. It's not talking about a specific variant</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46ACEFD6-B68B-4706-9724-666A000466DD">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Chinese ancestry, other anti-epileptic drugs associated with SJS/TEN</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C1EE3F2-8B30-438E-BCF0-903E5A1B07A4">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>breast feeding, nursing</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FE9FFAA-4E85-491C-B8CB-12AD2894769F">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6109457-C6B6-48D5-9ED4-CF1EE9C4CC17">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breastfeeding, nursing</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3697CCA7-3EDD-4F5E-A8C1-95621A186214">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CEF29BBA-E19C-4061-89FB-884D3898EA68">
    <poc:Comment>Chart does not display properly</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75B308C9-1DDE-449E-8E9E-9A1D909FC01B">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0C9BAA5-CE9B-433F-BC0C-0552964F164A">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36284728-D39E-4D0D-818B-103AE5464C1B">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53292FFE-31F2-4574-8E4D-5515E025353A">
    <rdfs:label>BOXED WARNING (34066-1)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F7F0EB3-F9C8-4AAE-BCD4-4A03CA215C14">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44CE23FF-1ACB-4636-9199-BC74D538CC29">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB4D099C-DAE0-44E6-9DED-57D52563F4BC">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>lactating</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE22753A-792C-4BF3-B52C-6071587AD3D9">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1694EBD6-F324-4F34-BF46-96811165F624">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17AE80BD-8220-46EA-8641-2EE1939DAEDA">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdfs:label>Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D1F9B53-86F9-40A1-A403-4A70C4379678">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF5332EA-A40B-4668-AF2A-6572169A6CFD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:549211CB-8AFF-415A-B1BD-09BC38B52755">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Abacavir naive</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23479765-E2D0-4F87-B129-EB38C21F3251">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AFDF697-A5A4-42EF-BE12-893415E6A1D6">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A3FE565-F624-4631-B7B9-ED12E84E6F92">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3CCED7A6-21A9-4D3F-8F4D-7F78B4D22EFC">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B970845-802E-4040-B226-6A4F84B3B6B3">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AEB2D80E-0E42-4F9D-8785-5C4D5A7639B9">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C553B1B6-192B-4B2C-A32D-72E7FBC6CC65">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CCB44E3B-1232-4E13-B6EF-4FAE9CE313C9">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2E9E5F9-FF4C-4A70-8318-560F190CBC36">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97A00FDB-1B7E-4BA6-B531-7DA063BAC30B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6818E0F-917B-415A-8423-5F2F4246E58F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>INDICATIONS AND USAGE (34067-9)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:110E324A-6920-4313-B80B-2414B6E63C92">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB1D64ED-6852-4F82-BF48-6711B335904D">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD149D7A-E9F0-440C-894B-8D7ABD8F1CEA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D932D2D-B0E1-42D0-A2E1-8D78B86A2FCF">
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42BFEABF-90BF-40F9-A2D6-ED9624EC3A04">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3012</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>DPYD</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F240620-91BE-4843-B33E-03E7959F89F9">
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCD381EE-901B-423A-AB9C-3DE76C7BF9E1">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D22B146B-D400-4905-ADDB-4FFC216CB489">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B9C0CF5-77BE-4351-8F4A-A03C7B56C33F">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF777739-AFDC-43F3-A8B4-F58883D3836C">
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4DBC7AE-A1A8-401A-9345-BB0D2918876C">
    <poc:MedicalCondition>previously tolerated abacavir</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC9275BB-8C69-41D3-B188-020A00419CAF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD256387-6739-48CA-A137-E3FBCFE0276D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DEB6B49-CDBC-428D-90A7-C95573351E17">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86C9129B-429C-46BA-BE2F-C6BC0ECD5371">
    <poc:MedicalCondition>Chinese ancestry, Stephens-Johnson syndrome, toxic epidermal necrolysis, any ethnicity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C19D1E6-4AC6-4752-869C-72A7C1CD4A47">
    <rdfs:label>Imatinib</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:30165D55-F0C3-495F-B740-02B137587144">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A880675-91C7-47AA-ADC7-D8E10E68AE4A">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDADF29B-ED0B-4CFB-A561-C1C48DAF8568">
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>DOSAGE AND ADMINISTRATION (34068-7)</rdfs:label>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B44F6619-C144-4D12-B575-BA96FED0BC7B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74B44044-2B72-4A73-A53D-DE7DBB4FBE1C">
    <rdfs:label>Not Important</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92D4A343-08E7-4448-A01D-A251DBEB233A">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4668FD1-0217-4075-9EA8-765FA07E8A9C">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FF427BD-C1B1-4D0C-BDFF-8CADC74AD460">
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>DOSAGE AND ADMINISTRATION (34068-7)</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D9E1DEE9-99F7-4AF0-952F-E05CF5631AE7">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A67F2809-2631-458A-895E-EF6D2A274649">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6926D7F6-0DBB-42DA-9D4B-AC61BC569818">
    <ao:prefix>An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding. Initial Dosage </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n\nClinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n\nGenetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6926D7F6-0DBB-42DA-9D4B-AC61BC569818"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-31 00:32:48 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80614695-DC56-44C3-B7EA-AB7E56B69546">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2011113-168F-413E-A516-232113392669">
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31707A99-58BE-45A2-8CF1-E07C41D243DC">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B75599F3-C241-4E70-8315-2EB60B3F2748">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1251D584-05EA-4CF8-80FC-10E3FEDB7270">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2C281AE-12B5-4CA9-8DEC-B53BBBA62366">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:homepage></foafx:homepage>
    <foafx:version>2.1alpha</foafx:version>
    <foafx:build>050</foafx:build>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9227B8AA-2E85-48E3-BCA0-F0C6EB543ED7">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9392de071d0e4fea8d352ef4196810f2">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9949892E-EB19-49D8-A737-FAF19F57740B">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E035B94B-194E-4AF0-9111-8C1C23B403CE">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A516DDD-4828-4B59-B4AF-626A4955BF4D">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8063FB58-0C19-4F4D-87DC-7AFA705FCE00">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:05557F68-5447-47D6-909A-0405158D7AB0">
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:961BA50E-515C-49B1-9E13-9A89032FBDD0">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdfs:label>Recommend</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB944467-7A08-46EB-8806-930A83CC44C9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DDADBAC-F1DA-4567-BB8D-FAF0090BDE7C">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:031D63F5-2F31-4483-8E84-9813522A2A07">
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:331B19A5-A857-4FEB-BD96-9730D10BC729">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D487312C-26D1-49CD-A7C0-B5ED285FF3FB">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E296F083-C6F9-4F83-B284-2E730777F02A">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:429FAE35-1F2E-49B3-8C8F-435F1C92F106">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>QT Prolongation</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DD15EA9-B9D8-497C-8F97-E7FFF0811BAF">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE10C1A9-AA47-4CBA-B514-90670EDD6BCF">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15E88ACA-8339-49D6-8E7D-2735AEA84E01">
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CCCC01C4-A92F-4944-A245-4FE4E2DC339D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8FA1C920-FFA6-4D34-AD90-D74FA680DF16">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBA969DE-1978-4391-A338-E793E7F5F06C">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA938CDA-3F80-4691-AA39-EEA9047C64AD">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA6DAA60-CEEE-483A-94BD-35641DCBE220">
    <ao:exact>Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek </ao:exact>
    <ao:prefix> Immediately and permanently discontinue Elitek in patients developing hemolysis. </ao:prefix>
    <domeo:uuid>CA6DAA60-CEEE-483A-94BD-35641DCBE220</domeo:uuid>
    <ao:suffix>[</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CA6DAA60-CEEE-483A-94BD-35641DCBE220"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <pav:createdOn>2014-08-08 10:52:11 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F9CF447-9D4F-4E5C-9689-2FDCB70C37A1">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8FB07F0-0211-45FC-B75C-FC0ED5802AAD">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60EB6CDE-6DBA-4D2D-9A39-84EE445B5FAA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39A0192C-7300-49A9-84EB-6C78A91C2510">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#NURSING MOTHERS (34080-2)</poc:productLabelSection>
    <sio:SIO_000111>NURSING MOTHERS (34080-2)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97D03A6D-0E7E-4379-84F2-E1C39FE5D581">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E35458E-5CDA-46AC-9775-514F2615A569">
    <ncit:Alleles>rs12979860 C&gt;T</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F1294AA-1E74-402F-9AED-0611A4B739AB">
    <poc:MedicalCondition>hypersensitivity, hla-b*5701 negative</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:70EB5D28-37B1-4D35-87F6-6830D8F2028C">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:946CCAEA-86B4-4DF7-BEBC-FDBE635A40E4">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81E1502F-383B-4344-B8EE-9E11279AF395">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Do not start</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8472DF2-885B-471C-B394-64841BCBEFCB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>estrogen receptor positive tumor</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E6FC1D1E-F8C3-4C88-BD3E-144FCCB95879">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdfs:label>Recommended</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA0A95C1-EEC6-42D7-90A0-41E65CD09812">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34F7A071-6983-40CD-B22D-108DA2488667">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3705BEB-6268-4FDB-A31F-0C593030101E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Liver disease</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B3FBA15-03F1-4FEE-9A6F-995B333D2B36">
    <ao:exact>Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.\nThe use of HLA-B*1502 genotyping has important limitations and must never substitute for appropriate clinical vigilance and patient management.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-07 12:46:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>3B3FBA15-03F1-4FEE-9A6F-995B333D2B36</domeo:uuid>
    <ao:suffix> The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring have not been studied</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3B3FBA15-03F1-4FEE-9A6F-995B333D2B36"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:586F4664-AA85-4036-86AE-C71007BEED1D">
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C819DC9-698D-4ABD-AE1B-95BA9238755B">
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB39F2CB-5442-4479-A939-6FDB899B3B62">
    <rdfs:label>Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37501176-3685-49F3-BC85-966B644473FF">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>intermediate-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:392C0811-F5EB-432A-90A8-6ADE9CF407BB">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>homozygous</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55819029-EACE-49D3-9A09-5DA751DA0CDE">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-decreased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an decreased risk of toxicity.</dct:description>
    <rdfs:label>Decreased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D22D3EE5-70D2-4E6B-98C6-A6D895D3172C">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1788F15A-B6DA-4423-A477-031F211E89F0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F4243FF-5048-4CF6-AFD9-11E2927F8F35">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Clozapine</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C784F374-FD0D-4D58-A395-967BCF50D373">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:512081E4-B6CF-4E36-B991-10F09074D3A4">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15CFACDA-93A0-4CF4-81F6-D807D5C1DDD5">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C9E8E94-0F78-4F71-ABB4-FDEA73577724">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Aripiprazole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8542DCD4-98AF-4508-A038-FFFE27F30205">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45E07643-7CD1-4A77-8272-0241073F3336">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4D9C262-7169-4552-95F8-1DC215AEE0EF">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Factor V Leiden</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:289239D5-3976-472F-9914-D5F5369EE441">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Hypersensitivity cannot be ruled out, HLA-B*5701 Negative</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:277A1FAA-CC1D-4B3E-85F9-8CCD51FC4929">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:083FA2D6-1C04-4B80-8630-FD99166A73EA">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61075185-39E7-4D6C-983B-843944A0649C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA0F134C-C2D3-4E23-AC59-D8499F4D1688">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>BOXED WARNING (34066-1)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91588194-37E0-42F4-B20F-F937A8704976">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>G6PD</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F334D04-6941-417C-B265-6F322B84AC4F">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Not a recommendation for a dose, just a statement that it is not known. </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8AE4545-2A2F-4FA9-AEA1-0F3A085FD0C8">
    <ao:exact>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance (Table 1).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8AE4545-2A2F-4FA9-AEA1-0F3A085FD0C8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>2</ao:suffix>
    <pav:createdOn>2014-04-05 15:57:37 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>C8AE4545-2A2F-4FA9-AEA1-0F3A085FD0C8</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58EFF7E3-78B6-4587-A089-7F58793F2EBF">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5960AF4E-EAA5-455B-9835-632815B2CF37">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>G6PD</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007749</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8511084F-F493-4148-8C31-16FDEA7C26C9">
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:89EF8354-538E-4D1E-8113-DA4B2C6DCDE5">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:187C74D5-58D7-4466-B5FD-47486A2199CC">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93A68F9D-E824-4EDA-A0D3-30BA1EE9E2CE">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FA6D6EF-BA00-42D2-8690-515DF2623380">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>This is technically referring to wild type drug interaction, so it may not need to be annotated. </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B5CDA5D-9A96-4645-BAED-6DC38A7DBB59">
    <poc:Comment>Heterozygote extensive metabolizer referes to the *2/*1 genotype. Most would still define this as poor metabolizer. I don't think that this needs to be annotated twice. </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FEBA183F-845F-4961-A518-20B74CE0EDBC">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>tonsillectomy, adenoidectomy, post-operative</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3668EBC9-213F-40B4-B79E-E760C14351FE">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8407F7CB-A711-4DBB-BF88-93BD1283B015">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9BFF2041-88B4-49AB-BD54-EFCBF740049A">
    <rdfs:label>Rasburicase</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F86084C3-9B07-43EE-A3DA-7A9BE7729213">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ACAEA188-F33B-4EF8-B4D8-744200091CA7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ACAEA188-F33B-4EF8-B4D8-744200091CA7"/>
    <domeo:uuid>ACAEA188-F33B-4EF8-B4D8-744200091CA7</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>on, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50. </ao:prefix>
    <pav:createdOn>2014-04-05 15:32:58 -0400</pav:createdOn>
    <ao:exact>One additional randomized study (NATO) demonstrated improved disease-free survival for tamoxifen compared to no adjuvant therapy following total mastectomy and axillary dissection in postmenopausal women with axillary node-negative breast cancer. In this study, the benefits of tamoxifen appeared to be independent of estrogen receptor status.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AEB202EC-C200-402F-B2DD-E41CC9351D9D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:308C686D-59C9-4C6B-BEB2-B9157C1C47F8">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:507CE4C6-4117-4ECB-9271-639925D6D3F7">
    <poc:MedicalCondition>heterozygous</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0FFCDB3-7874-48E5-99F9-2E81E91B47AF">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DEDFB9A-D108-4F65-BF83-1DB8E7491065">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PEDIATRIC USE (34081-0)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PEDIATRIC USE (34081-0)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB4F592B-C531-4655-A925-49465B929C5E">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-negative</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D7FD036-EB64-4C5A-B838-B9A9C1CF132B">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2b63a27472284332b4b2f3903fc5c0f0">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N47e92b592bb94acb8e8825e3cbe3faef">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA9A6EB1-B1BC-4FE6-99BB-502901A16ADA">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>INDICATIONS AND USAGE (34067-9)</rdfs:label>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55BBBF50-6FB3-404D-A12B-AB8A409E5B36">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>less severe hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9078D6CE-D692-4144-8366-17E60EAD0973">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6DB437A-60FD-4998-97F4-9BA04097046A">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94569D13-A994-40FA-BDCF-C0391FE365FD">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>unknown hla-b*5701 status</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8AB88976-04C8-482C-B348-379DD3FEA061">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>asian ancestry</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32885D72-6EC1-450C-97CD-5635EE42A329">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>This one may need to be tweaked. Talking about active metabolite and active drug. </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF75BAC3-9B1E-4E6C-9666-F407F87B964F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>previously tolerated abacavir</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6197856-D7DC-4524-90AF-D1E78B927C1F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC17395A-7D36-45CC-BFB3-4271FD68383B">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B01A89BD-BD22-407A-B260-89223E106531">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C61F89D-783E-4303-8058-D5AB9C43C44E">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25F3A5BA-0A71-49F5-A250-1863F45FE3A9">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39C15605-1B1F-4541-A2EF-CCDCFEB8DAB2">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E631D057-E51B-45DB-BFB7-AC3BD397D24E">
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Do not start</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D9689F2-4FA1-42BC-AF7A-85B246D98E51">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#http://fakeuri.org/Telaprevir</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1084982E-C983-483C-A085-E7347F911842">
    <poc:MedicalCondition>breastfeeding, nursing</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:05D0DCC4-6CFC-4B68-8371-508F96CC8EDF">
    <poc:MedicalCondition>over anticoagulation</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0E52ED2A-ACCC-40D5-B641-BCCC55EFB1A4">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#NURSING MOTHERS (34080-2)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>NURSING MOTHERS (34080-2)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1588e9c10a094ad390c00bf62827ce6f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N76b4bb14f5394f7bbd3ca867b70ac4af">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D25BD49F-3406-4D9E-AFF6-06E7D37A86F1">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33B2C016-C14E-453B-A5CE-4FB7B680ACD2">
    <poc:MedicalCondition>abnormal CBC, no response to dose reduction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
</rdf:RDF>
